Hercules Capital, Inc. Form 10-Q for the quarterly period ended June 30, 2020

Summary

Quarterly report on Form 10-Q of Hercules Capital, Inc. for the quarterly period ended June 30, 2020. The registrant is a Maryland company with principal offices in Palo Alto, California, and its Common Shares, 5.25% Notes due 2025 and 6.25% Notes due 2033 trade on the New York Stock Exchange under HTGC, HCXZ and HCXY. It is marked a large accelerated filer. The report also includes a schedule of control and affiliate investments, listing Total Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.), and the signature page. Scott Bluestein, President, Chief Executive Officer and Chief Investment Officer, and Seth H. Meyer, Chief Financial Officer and Chief Accounting Officer, signed on July 30, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" htgc-10q_20200630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended June 30, 2020

OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 814-00702

HERCULES CAPITAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Maryland | 74-3113410
(State or Jurisdiction of Incorporation or Organization) | (IRS Employer Identification Number)
400 Hamilton Ave., Suite 310 Palo Alto, California (Address of Principal Executive Offices) | 94301 (Zip Code)

(650) 289-3060

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Shares, par value $0.001 per share | HTGC | New York Stock Exchange
5.25% Notes due 2025 | HCXZ | New York Stock Exchange
6.25% Notes due 2033 | HCXY | New York Stock Exchange

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ | Accelerated filer | ☐
Non-accelerated filer | ☐ | Smaller reporting company | ☐
Emerging growth company | ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

On July 27, 2020, there were 114,229,759 shares outstanding of the Registrant’s common stock, $0.001 par value.

HERCULES CAPITAL, INC.

FORM 10-Q TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION | 3
Item 1. | Consolidated Financial Statements | 3
Consolidated Statements of Assets and Liabilities as of June 30, 2020 and December 31, 2019 (unaudited) | 3
Consolidated Statements of Operations for the three and six months ended June 30, 2020 and 2019 (unaudited) | 5
Consolidated Statements of Changes in Net Assets for the three and six months ended June 30, 2020 and 2019 (unaudited) | 6
Consolidated Statements of Cash Flows for the six months ended June 30, 2020 and 2019 (unaudited) | 8
Consolidated Schedule of Investments as of June 30, 2020 (unaudited) | 10
Consolidated Schedule of Investments as of December 31, 2019 (unaudited) | 21
Notes to Consolidated Financial Statements (unaudited) | 31
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 65
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 83
Item 4. | Controls and Procedures | 84
PART II. OTHER INFORMATION | 85
Item 1. | Legal Proceedings | 85
Item 1A. | Risk Factors | 85
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 87
Item 3. | Defaults Upon Senior Securities | 87
Item 4. | Mine Safety Disclosures | 87
Item 5. | Other Information | 87
Item 6. | Exhibits and Financial Statement Schedules | 88
SIGNATURES | 91

2

PART I: FINANCIAL INFORMATION

In this Quarterly Report, the “Company,” “Hercules,” “we,” “us” and “our” refer to Hercules Capital, Inc. and its wholly owned subsidiaries and its affiliated securitization trusts, unless the context otherwise requires.

ITE M 1. | CONSOLIDATED FINANCIAL STATEMENTS

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES

(unaudited)

(in thousands, except per share data)

June 30, 2020 | December 31, 2019
Assets
Investments:
Non-control/Non-affiliate investments (cost of $2,347,547 and $2,248,524, respectively) | $ | 2,297,180 | $ | 2,232,972
Control investments (cost of $65,227 and $65,333, respectively) | 54,431 | 59,746
Affiliate investments (cost of $88,584 and $88,175, respectively) | 11,910 | 21,808
Total investments in securities, at value (cost of $2,501,357 and $2,402,032, respectively) | 2,363,521 | 2,314,526
Cash and cash equivalents | 35,884 | 64,393
Restricted cash | 33,599 | 50,603
Interest receivable | 19,458 | 20,207
Right of use asset | 10,492 | 11,659
Other assets | 5,547 | 580
Total assets | $ | 2,468,501 | $ | 2,461,968
Liabilities
Accounts payable and accrued liabilities | $ | 29,162 | $ | 30,306
Operating lease liability | 10,178 | 11,538
SBA Debentures, net (principal of $110,250 and $149,000, respectively) (1) | 109,808 | 148,165
2022 Notes, net (principal of $150,000 and $150,000, respectively) (1) | 148,776 | 148,514
July 2024 Notes, net (principal of $105,000 and $105,000, respectively) (1) | 103,795 | 103,685
February 2025 Notes, net (principal of $50,000 and $0, respectively) (1) | 49,465 | —
2025 Notes, net (principal of $75,000 and $75,000, respectively) (1) | 73,161 | 72,970
June 2025 Notes, net (principal of $70,000 and $0, respectively) (1) | 69,217 | —
2033 Notes, net (principal of $40,000 and $40,000, respectively) (1) | 38,555 | 38,501
2027 Asset-Backed Notes, net (principal of $200,000 and $200,000, respectively) (1) | 197,448 | 197,312
2028 Asset-Backed Notes, net (principal of $250,000 and $250,000, respectively) (1) | 247,511 | 247,395
2022 Convertible Notes, net (principal of $230,000 and $230,000, respectively) (1) | 227,395 | 226,614
Credit Facilities | — | 103,919
Total liabilities | $ | 1,304,471 | $ | 1,328,919
Net assets consist of:
Common stock, par value | 115 | 108
Capital in excess of par value | 1,223,263 | 1,145,106
Total distributable earnings (loss) | (59,348 | ) | (12,165 | )
Total net assets | $ | 1,164,030 | $ | 1,133,049
Total liabilities and net assets | $ | 2,468,501 | $ | 2,461,968
Shares of common stock outstanding ($0.001 par value and 200,000,000 authorized) | 114,230 | 107,364
Net asset value per share | $ | 10.19 | $ | 10.55
(1) | The Company’s SBA debentures, 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, 2025 Notes, 2033 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, and 2022 Convertible Notes, as each term is defined herein, are presented net of the associated debt issuance costs for each instrument. See “Note 4 – Borrowings”.

See notes to consolidated financial statements

3

The following table presents the assets and liabilities of our consolidated securitization trusts for the 2027 Asset-Backed Notes and the 2028 Asset-Backed Notes (see Note 4), which are variable interest entities, or VIEs. The assets of our securitization VIEs can only be used to settle obligations of our consolidated securitization VIEs, these liabilities are only the obligations of our consolidated securitization VIEs, and the creditors (or beneficial interest holders) do not have recourse to our general credit. These assets and liabilities are included in the Consolidated Statements of Assets and Liabilities above.

(Dollars in thousands) | June 30, 2020 | December 31, 2019
Assets
Restricted Cash | 33,599 | $ | 50,603
2027 Asset-Backed Notes, investments in securities, at value (cost of $297,358 and $283,891, respectively) | 296,249 | 283,658
2028 Asset-Backed Notes, investments in securities, at value (cost of $352,401 and $347,295, respectively) | 351,871 | 347,929
Total assets | $ | 681,719 | $ | 682,190
Liabilities
2027 Asset-Backed Notes, net (principal of $200,000 and $200,000, respectively) (1) | $ | 197,448 | $ | 197,312
2028 Asset-Backed Notes, net (principal of $250,000 and $250,000, respectively) (1) | 247,511 | 247,395
Total liabilities | $ | 444,959 | $ | 444,707
(1) | The Company’s 2027 Asset-Backed Notes and the 2028 Asset-Backed Notes are presented net of the associated debt issuance costs. See “Note 4 – Borrowings”.

See notes to consolidated financial statements

4

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share data)

Three Months Ended June 30, | Six Months Ended June 30,
2020 | 2019 | 2020 | 2019
Investment income:
Interest income
Non-control/Non-affiliate investments | $ | 62,667 | $ | 59,932 | $ | 128,005 | $ | 113,872
Control investments | 731 | 1,040 | 1,377 | 2,064
Affiliate investments | 157 | 738 | 377 | 1,247
Total interest income | 63,555 | 61,710 | 129,759 | 117,183
Fee income
Commitment, facility and loan fee income
Non-control/Non-affiliate investments | 3,511 | 5,028 | 7,707 | 7,478
Control investments | 5 | 4 | 10 | 8
Affiliate investments | — | 72 | — | 160
Total commitment, facility and loan fee income | 3,516 | 5,104 | 7,717 | 7,646
One-time fee income
Non-control/Non-affiliate investments | 897 | 2,450 | 4,111 | 3,230
Total one-time fee income | 897 | 2,450 | 4,111 | 3,230
Total fee income | 4,413 | 7,554 | 11,828 | 10,876
Total investment income | 67,968 | 69,264 | 141,587 | 128,059
Operating expenses:
Interest | 15,076 | 13,515 | 29,608 | 26,070
Loan fees | 1,650 | 1,646 | 3,444 | 4,655
General and administrative
Legal expenses | 991 | 1,963 | 1,890 | 2,626
Tax expenses | 899 | 593 | 2,034 | 891
Other expenses | 3,973 | 3,239 | 7,998 | 6,431
Total general and administrative | 5,863 | 5,795 | 11,922 | 9,948
Employee compensation
Compensation and benefits | 7,180 | 9,190 | 15,394 | 15,813
Stock-based compensation | 2,515 | 3,851 | 4,955 | 7,273
Total employee compensation | 9,695 | 13,041 | 20,349 | 23,086
Total operating expenses | 32,284 | 33,997 | 65,323 | 63,759
Net investment income | 35,684 | 35,267 | 76,264 | 64,300
Net realized gain (loss) on investments
Non-control/Non-affiliate investments | 141 | 4,271 | 7,108 | 8,826
Total net realized gain (loss) on investments | 141 | 4,271 | 7,108 | 8,826
Net change in unrealized appreciation (depreciation) on investments
Non-control/Non-affiliate investments | 23,613 | 9,794 | (34,816 | ) | 41,884
Control investments | 2,642 | 808 | (5,209 | ) | (2,068 | )
Affiliate investments | (315 | ) | (2,009 | ) | (10,305 | ) | (3,226 | )
Total net unrealized appreciation (depreciation) on investments | 25,940 | 8,593 | (50,330 | ) | 36,590
Total net realized and unrealized gain (loss) | 26,081 | 12,864 | (43,222 | ) | 45,416
Net increase (decrease) in net assets resulting from operations | $ | 61,765 | $ | 48,131 | $ | 33,042 | $ | 109,716
Net investment income before investment gains and losses per common share:
Basic | $ | 0.32 | $ | 0.36 | $ | 0.69 | $ | 0.66
Change in net assets resulting from operations per common share:
Basic | $ | 0.55 | $ | 0.49 | $ | 0.29 | $ | 1.13
Diluted | $ | 0.55 | $ | 0.49 | $ | 0.29 | $ | 1.12
Weighted average shares outstanding
Basic | 111,558 | 98,223 | 110,256 | 97,226
Diluted | 111,729 | 98,737 | 110,504 | 97,630
Distributions paid per common share:
Basic | $ | 0.32 | $ | 0.33 | $ | 0.72 | $ | 0.64

See notes to consolidated financial statements

5

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

(unaudited)

(dollars and shares in thousands)

Capital in | Distributable
Common Stock | excess | Earnings | Net
For the Three Months Ended June 30, 2020 | Shares | Par Value | of par value | (loss) | Assets
Balance at March 31, 2020 | 110,601 | $ | 111 | $ | 1,182,080 | $ | (85,111 | ) | $ | 1,097,080
Net increase (decrease) in net assets resulting from operations | — | — | — | 61,765 | 61,765
Public offering, net of offering expenses | 3,525 | 4 | 38,696 | — | 38,700
Issuance of common stock under restricted stock plan | 52 | — | — | — | —
Retired shares for restricted stock vesting | (10 | ) | — | (282 | ) | — | (282 | )
Distributions reinvested in common stock | 62 | — | 643 | — | 643
Distributions | — | — | — | (36,002 | ) | (36,002 | )
Stock-based compensation (1) | — | — | 2,126 | — | 2,126
Balance at June 30, 2020 | 114,230 | $ | 115 | $ | 1,223,263 | $ | (59,348 | ) | $ | 1,164,030
For the Six Months Ended June 30, 2020
Balance at December 31, 2019 | 107,364 | $ | 108 | $ | 1,145,106 | $ | (12,165 | ) | $ | 1,133,049
Net increase (decrease) in net assets resulting from operations | — | — | — | 33,042 | 33,042
Public offering, net of offering expenses | 5,966 | 6 | 73,656 | — | 73,662
Issuance of common stock due to stock option exercises | 29 | — | 362 | — | 362
Retired shares from net issuance | (24 | ) | — | (376 | ) | — | (376 | )
Issuance of common stock under restricted stock plan | 801 | 1 | (1 | ) | — | —
Retired shares for restricted stock vesting | (27 | ) | — | (1,162 | ) | — | (1,162 | )
Distributions reinvested in common stock | 121 | — | 1,470 | — | 1,470
Distributions | — | — | — | (80,225 | ) | (80,225 | )
Stock-based compensation (1) | — | — | 4,208 | — | 4,208
Balance at June 30, 2020 | 114,230 | $ | 115 | $ | 1,223,263 | $ | (59,348 | ) | $ | 1,164,030
(1) | Stock-based compensation includes $23 and $44 of restricted stock and option expense related to director compensation for the three and six months ended June 30, 2020.

See notes to consolidated financial statements

6

Capital in | Distributable
Common Stock | excess | Earnings | Treasury | Net
For the Three Months Ended June 30, 2019 | Shares | Par Value | of par value | (loss) (2) | Stock | Assets
Balance at March 31, 2019 | 96,543 | $ | 96 | $ | 1,051,427 | $ | (61,174 | ) | $ | — | $ | 990,349
Net increase (decrease) in net assets resulting from operations | — | — | — | 48,131 | — | 48,131
Public offering, net of offering expenses | 7,700 | 8 | 95,436 | — | — | 95,444
Issuance of common stock due to stock option exercises | 1 | — | 7 | — | — | 7
Retired shares from net issuance | (1 | ) | — | (7 | ) | — | — | (7 | )
Issuance of common stock under restricted stock plan | 10 | — | — | — | — | —
Retirement of common stock under repurchase plan | — | — | — | — | — | —
Retired shares for restricted stock vesting | (13 | ) | — | (196 | ) | — | — | (196 | )
Distributions reinvested in common stock | 42 | — | 557 | — | — | 557
Distributions | — | — | — | (32,151 | ) | — | (32,151 | )
Stock-based compensation (1) | — | — | 2,550 | — | — | 2,550
Balance at June 30, 2019 | 104,282 | $ | 104 | $ | 1,149,774 | $ | (45,194 | ) | $ | — | $ | 1,104,684
For the Six Months Ended June 30, 2019
Balance at December 31, 2018 | 96,501 | $ | 96 | $ | 1,052,269 | $ | (92,859 | ) | $ | (4,062 | ) | $ | 955,444
Net increase (decrease) in net assets resulting from operations | — | — | — | 109,716 | — | 109,716
Public offering, net of offering expenses | 7,700 | 8 | 95,415 | — | — | 95,423
Issuance of common stock due to stock option exercises | 14 | — | 161 | — | — | 161
Retired shares from net issuance | (12 | ) | — | (166 | ) | — | — | (166 | )
Issuance of common stock under restricted stock plan | 58 | — | — | — | — | —
Retirement of common stock under repurchase plan | — | — | (4,062 | ) | — | 4,062 | —
Retired shares for restricted stock vesting | (68 | ) | — | (887 | ) | — | — | (887 | )
Distributions reinvested in common stock | 89 | — | 1,189 | — | — | 1,189
Issuance of Convertible Notes | — | — | — | — | — | —
Distributions | — | — | — | (62,051 | ) | — | (62,051 | )
Stock-based compensation (1) | — | — | 5,855 | — | — | 5,855
Balance at June 30, 2019 | 104,282 | $ | 104 | $ | 1,149,774 | $ | (45,194 | ) | $ | — | $ | 1,104,684
(1) | Stock-based compensation includes $24 and $31 of restricted stock and option expense related to director compensation for the three and six months ended June 30, 2019.
(2) | Certain prior year numbers have been adjusted to conform with the SEC final rules on disclosure updates and simplification effective November 5, 2018. See Note 11.

See notes to consolidated financial statements

7

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)

For the Six Months Ended June 30,
2020 | 2019
Cash flows from operating activities:
Net increase (decrease) in net assets resulting from operations | $ | 33,042 | $ | 109,716
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchase of investments | (365,890 | ) | (607,847 | )
Principal and fee payments received on investments | 269,234 | 267,654
Proceeds from the sale of investments | 19,802 | 21,264
Net unrealized depreciation (appreciation) on investments | 50,330 | (36,590 | )
Net realized loss (gain) on investments | (7,108 | ) | (8,826 | )
Accretion of paid-in-kind principal | (4,230 | ) | (4,310 | )
Accretion of loan discounts | (2,345 | ) | (1,510 | )
Accretion of loan discount on convertible notes | 336 | 336
Accretion of loan exit fees | (12,692 | ) | (11,253 | )
Change in deferred loan origination revenue | 3,664 | 10,787
Unearned fees related to unfunded commitments | (688 | ) | 1,898
Amortization of debt fees and issuance costs | 2,489 | 3,956
Depreciation | 222 | 101
Stock-based compensation and amortization of restricted stock grants (1) | 4,208 | 5,855
Change in operating assets and liabilities:
Interest and fees receivable | 749 | (1,247 | )
Prepaid expenses and other assets | (1,387 | ) | (11,453 | )
Accounts payable | (16 | ) | (191 | )
Accrued liabilities | (2,488 | ) | 10,136
Net cash provided by (used in) operating activities | (12,768 | ) | (251,524 | )
Cash flows from investing activities:
Purchases of capital equipment | (67 | ) | (241 | )
Net cash provided by (used in) investing activities | (67 | ) | (241 | )
Cash flows from financing activities:
Issuance of common stock, net | 73,662 | 95,379
Retirement of employee shares | (1,178 | ) | (850 | )
Distributions paid | (78,755 | ) | (60,862 | )
Issuance of 2028 Asset-Backed Notes | — | 250,000
Issuance of February 2025 Notes | 50,000 | —
Issuance of June 2025 Notes | 70,000
Repayments of 2024 Notes | — | (83,510 | )
Repayments of Long-Term SBA Debentures | (38,750 | ) | —
Borrowings of credit facilities | 325,288 | 405,192
Repayments of credit facilities | (429,207 | ) | (364,727 | )
Cash paid for debt issuance costs | (1,419 | ) | (3,117 | )
Fees paid for credit facilities and debentures | (2,319 | ) | (2,997 | )
Net cash provided by (used in) financing activities | (32,678 | ) | 234,508
Net increase (decrease) in cash, cash equivalents, and restricted cash | (45,513 | ) | (17,257 | )
Cash, cash equivalents, and restricted cash at beginning of period | 114,996 | 45,857
Cash, cash equivalents, and restricted cash at end of period | $ | 69,483 | $ | 28,600
Supplemental disclosures of cash flow information and non-cash investing and financing activities:
Distributions reinvested | 1,470 | 1,189
(1) | Stock-based compensation includes $44 and $31 of restricted stock and option expense related to director compensation for the six months ended June 30, 2020 and 2019, respectively.

See notes to consolidated financial statements

8

The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Assets and Liabilities that sum to the total of the same such amounts in the Consolidated Statements of Cash Flows:

For the Six Months Ended June 30,
(Dollars in thousands) | 2020 | 2019
Cash and cash equivalents | $ | 35,884 | $ | 13,261
Restricted cash | 33,599 | 15,339
Total cash, cash equivalents, and restricted cash presented in the Consolidated Statements of Cash Flows | $ | 69,483 | $ | 28,600

See “Note 2 – Summary of Significant Accounting Policies” for a description of restricted cash and cash equivalents.

See notes to consolidated financial statements

9

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Maturity Date | Interest Rate and Floor (2) | Principal Amount | Cost (3) | Value (4)
Debt investments
Communications & Networking
1-5 Years Maturity
Cytracom Holdings LLC (11)(17)(18) | Communications & Networking | Senior Secured | February 2025 | Interest rate 3-month LIBOR + 9.25% or Floor rate of 10.25% | $ | 7,000 | $ | 6,801 | $ | 6,801
Subtotal: 1-5 Years Maturity | 6,801 | 6,801
Subtotal: Communications & Networking (0.58%)* | 6,801 | 6,801
Diversified Financial Services
1-5 Years Maturity
Gibraltar Business Capital, LLC (7) | Diversified Financial Services | Unsecured | March 2023 | Interest rate FIXED 14.50% | $ | 15,000 | 14,808 | 14,808
Subtotal: 1-5 Years Maturity | 14,808 | 14,808
Subtotal: Diversified Financial Services (1.27%)* | 14,808 | 14,808
Drug Delivery
1-5 Years Maturity
Antares Pharma Inc. (10)(11)(15)(17) | Drug Delivery | Senior Secured | July 2022 | Interest rate PRIME + 4.50% or Floor rate of 4.50%, 4.14% Exit Fee | $ | 40,000 | 40,858 | 40,267
Subtotal: 1-5 Years Maturity | 40,858 | 40,267
Subtotal: Drug Delivery (3.46%)* | 40,858 | 40,267
Drug Discovery & Development
Under 1 Year Maturity
Genocea Biosciences, Inc. (11) | Drug Discovery & Development | Senior Secured | May 2021 | Interest rate PRIME + 3.00% or Floor rate of 8.00%, 13.43% Exit Fee | $ | 12,922 | 13,690 | 13,682
Metuchen Pharmaceuticals LLC | Drug Discovery & Development | Senior Secured | April 2021 | Interest rate PRIME + 7.25% or Floor rate of 11.50%, 3.05% Exit Fee | $ | 9,691 | 10,684 | 10,609
Stealth Bio Therapeutics Corp. (5)(10)(11) | Drug Discovery & Development | Senior Secured | January 2021 | Interest rate PRIME + 5.50% or Floor rate of 9.50%, 6.68% Exit Fee | $ | 10,489 | 11,726 | 11,726
Subtotal: Under 1 Year Maturity | 36,100 | 36,017
1-5 Years Maturity
Acacia Pharma Inc. (5)(10)(11) | Drug Discovery & Development | Senior Secured | January 2022 | Interest rate PRIME + 4.50% or Floor rate of 9.25%, 3.95% Exit Fee | $ | 7,779 | 8,008 | 7,961
Albireo Pharma, Inc. (5)(10)(17) | Drug Discovery & Development | Senior Secured | January 2024 | Interest rate PRIME + 5.90% or Floor rate of 9.15%, 6.95% Exit Fee | $ | 10,000 | 9,851 | 9,851
Aldeyra Therapeutics, Inc. (11) | Drug Discovery & Development | Senior Secured | October 2023 | Interest rate PRIME + 3.10% or Floor rate of 9.10%, 6.95% Exit Fee | $ | 15,000 | 15,152 | 15,098
Applied Genetic Technologies Corporation | Drug Discovery & Development | Senior Secured | December 2023 | Interest rate PRIME + 6.50% or Floor rate of 9.75%, 6.95% Exit Fee | $ | 10,000 | 9,881 | 9,881
Aveo Pharmaceuticals, Inc. (11) | Drug Discovery & Development | Senior Secured | July 2021 | Interest rate PRIME + 4.70% or Floor rate of 9.45%, 5.40% Exit Fee | $ | 5,667 | 6,063 | 6,034
Drug Discovery & Development | Senior Secured | July 2021 | Interest rate PRIME + 4.70% or Floor rate of 9.45%, 3.00% Exit Fee | $ | 5,667 | 5,966 | 6,001
Total Aveo Pharmaceuticals, Inc. | $ | 11,334 | 12,029 | 12,035
BridgeBio Pharma LLC (12)(13)(16) | Drug Discovery & Development | Senior Secured | November 2023 | Interest rate PRIME + 3.85% or Floor rate of 8.75%, 6.35% Exit Fee | $ | 35,000 | 35,951 | 36,137
Drug Discovery & Development | Senior Secured | November 2023 | Interest rate PRIME + 2.85% or Floor rate of 8.60%, 5.75% Exit Fee | $ | 20,000 | 20,418 | 20,524
Drug Discovery & Development | Senior Secured | November 2023 | Interest rate PRIME + 3.10% or Floor rate of 8.85%, 5.75% Exit Fee | $ | 20,000 | 20,250 | 20,346
Total BridgeBio Pharma LLC | $ | 75,000 | 76,619 | 77,007
Chemocentryx, Inc. (10)(11)(15)(17) | Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 3.30% or Floor rate of 8.05%, 6.25% Exit Fee | $ | 20,000 | 20,499 | 20,699
Drug Discovery & Development | Senior Secured | February 2024 | Interest rate PRIME + 3.25% or Floor rate of 8.50%, 7.15% Exit Fee | $ | 5,000 | 4,982 | 4,982
Total Chemocentryx, Inc. | $ | 25,000 | 25,481 | 25,681
Codiak Biosciences, Inc. (11)(17) | Drug Discovery & Development | Senior Secured | October 2024 | Interest rate PRIME + 3.75% or Floor rate of 9.00%, 5.50% Exit Fee | $ | 10,000 | 10,025 | 9,990
Constellation Pharmaceuticals, Inc. (12) | Drug Discovery & Development | Senior Secured | April 2023 | Interest rate PRIME + 2.55% or Floor rate of 8.55%, 6.35% Exit Fee | $ | 30,000 | 30,482 | 30,945
Dermavant Sciences Ltd. (5)(10)(13) | Drug Discovery & Development | Senior Secured | June 2022 | Interest rate PRIME + 4.45% or Floor rate of 9.95%, 6.95% Exit Fee | $ | 20,000 | 20,395 | 20,418
Eidos Therapeutics, Inc. (10)(13)(17) | Drug Discovery & Development | Senior Secured | October 2023 | Interest rate PRIME + 3.25% or Floor rate of 8.50%, 5.95% Exit Fee | $ | 8,750 | 8,814 | 8,885
G1 Therapeutics, Inc. (10)(17) | Drug Discovery & Development | Senior Secured | June 2024 | Interest rate PRIME + 6.40% or Floor rate of 9.65%, 6.95% Exit Fee | $ | 20,000 | 19,829 | 19,829
Integral Health Holdings, LLC (17) | Drug Discovery & Development | Senior Secured | May 2024 | Interest rate PRIME + 6.45% or Floor rate of 9.70%, 3.85% Exit Fee | $ | 5,000 | 4,863 | 4,863
Kaleido Biosciences, Inc. (13) | Drug Discovery & Development | Senior Secured | January 2024 | Interest rate PRIME + 6.10% or Floor rate of 9.35%, 7.55% Exit Fee | $ | 22,500 | 22,610 | 22,529
Mesoblast (5)(10)(11)(13) | Drug Discovery & Development | Senior Secured | March 2022 | Interest rate PRIME + 4.95% or Floor rate of 9.70%, 6.95% Exit Fee | $ | 50,000 | 52,222 | 52,295

See notes to consolidated financial statements

10

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Motif BioSciences Inc. (5)(8)(10) | Drug Discovery & Development | Senior Secured | September 2021 | Interest rate PRIME + 5.50% or Floor rate of 10.00%, 2.87% Exit Fee | $ | 6,738 | 6,732 | -
Nabriva Therapeutics (5)(10) | Drug Discovery & Development | Senior Secured | June 2023 | Interest rate PRIME + 4.30% or Floor rate of 9.80%, 9.95% Exit Fee | $ | 5,000 | 5,130 | 5,141
Paratek Pharmaceuticals, Inc. (11)(13)(15)(16) | Drug Discovery & Development | Senior Secured | September 2021 | Interest rate PRIME + 2.75% or Floor rate of 8.50%, 4.13% Exit Fee | $ | 60,000 | 62,247 | 62,282
Drug Discovery & Development | Senior Secured | August 2022 | Interest rate PRIME + 2.10% or Floor rate of 7.85%, 6.95% Exit Fee | $ | 10,000 | 10,359 | 10,379
Total Paratek Pharmaceuticals, Inc. | $ | 70,000 | 72,606 | 72,661
Replimune Group, Inc. (5)(10)(11) | Drug Discovery & Development | Senior Secured | August 2023 | Interest rate PRIME + 2.75% or Floor rate of 8.75%, 4.95% Exit Fee | $ | 10,000 | 10,051 | 10,063
Seres Therapeutics, Inc. (11) | Drug Discovery & Development | Senior Secured | November 2023 | Interest rate PRIME + 4.40% or Floor rate of 9.65%, 4.85% Exit Fee | $ | 25,000 | 25,014 | 25,266
Syndax Pharmaceutics Inc. (13) | Drug Discovery & Development | Senior Secured | September 2023 | Interest rate PRIME + 5.10% or Floor rate of 9.85%, 4.99% Exit Fee | $ | 20,000 | 20,023 | 20,023
TG Therapeutics, Inc. (10)(13) | Drug Discovery & Development | Senior Secured | March 2022 | Interest rate PRIME + 4.75% or Floor rate of 10.25%, 3.25% Exit Fee | $ | 30,000 | 30,061 | 30,390
Tricida, Inc. (11)(13)(15)(16) | Drug Discovery & Development | Senior Secured | April 2023 | Interest rate PRIME + 2.35% or Floor rate of 8.35%, 11.04% Exit Fee | $ | 75,000 | 76,578 | 77,296
uniQure B.V. (5)(10)(11) | Drug Discovery & Development | Senior Secured | June 2023 | Interest rate PRIME + 3.35% or Floor rate of 8.85%, 7.72% Exit Fee | $ | 35,000 | 35,381 | 36,129
Verastem, Inc. (11) | Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 5,000 | 5,078 | 5,123
Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 5,000 | 5,094 | 5,139
Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 5,000 | 5,126 | 5,131
Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 10,000 | 10,164 | 10,254
Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 10,000 | 10,139 | 10,228
Total Verastem, Inc. | $ | 35,000 | 35,601 | 35,875
X4 Pharmaceuticals, Inc. (11) | Drug Discovery & Development | Senior Secured | July 2023 | Interest rate PRIME + 3.75% or Floor rate of 8.75%, 7.18% Exit Fee | $ | 25,000 | 25,317 | 25,410
Yumanity Therapeutics, Inc. (11) | Drug Discovery & Development | Senior Secured | January 2024 | Interest rate PRIME + 4.00% or Floor rate of 8.75%, 7.25% Exit Fee | $ | 15,000 | 14,899 | 14,864
Subtotal: 1-5 Years Maturity | 683,654 | 680,386
Subtotal: Drug Discovery & Development (61.55%)* | 719,754 | 716,403
Electronics & Computer Hardware
Under 1 Year Maturity
Glo AB (5)(8)(10)(13)(14) | Electronics & Computer Hardware | Senior Secured | February 2021 | Interest rate PRIME + 6.20% or Floor rate of 10.45%, PIK Interest 1.75%, 5.03% Exit Fee | $ | 5,011 | 5,525 | 3,267
Subtotal: Under 1 Year Maturity | 5,525 | 3,267
Subtotal: Electronics & Computer Hardware (0.28%)* | 5,525 | 3,267
Healthcare Services, Other
1-5 Years Maturity
Oak Street Health (11)(13)(16) | Healthcare Services, Other | Senior Secured | December 2022 | Interest rate PRIME + 5.00% or Floor rate of 9.75%, 5.95% Exit Fee | $ | 80,000 | 81,973 | 82,453
The CM Group LLC (17) | Healthcare Services, Other | Senior Secured | June 2024 | Interest rate 1-month LIBOR + 8.35% or Floor rate of 9.35% | $ | 10,381 | 10,236 | 9,777
Velocity Clinical Research, Inc. (13)(18) | Healthcare Services, Other | Senior Secured | November 2024 | Interest rate 1-month LIBOR + 9.08% or Floor rate of 10.08% | $ | 7,443 | 7,193 | 7,315
Healthcare Services, Other | Senior Secured | November 2024 | Interest rate 1-month LIBOR + 9.08% or Floor rate of 10.08% | $ | 750 | 750 | 742
Healthcare Services, Other | Senior Secured | November 2024 | Interest rate 1-month LIBOR + 9.08% or Floor rate of 10.08% | $ | 1,980 | 1,910 | 1,949
Healthcare Services, Other | Senior Secured | November 2024 | Interest rate 1-month LIBOR + 9.08% or Floor rate of 10.08% | $ | 452 | 426 | 435
Total Velocity Clinical Research, Inc. | $ | 10,625 | 10,279 | 10,441
Subtotal: 1-5 Years Maturity | 102,488 | 102,671
Subtotal: Healthcare Services, Other (8.82%)* | 102,488 | 102,671
Information Services
1-5 Years Maturity
Planet Labs, Inc. (11) | Information Services | Senior Secured | June 2022 | Interest rate PRIME + 5.50% or Floor rate of 11.00%, 3.00% Exit Fee | $ | 25,000 | 24,647 | 24,593
Sapphire Digital, Inc. (p.k.a. MDX Medical, Inc.) (14)(15)(19) | Information Services | Senior Secured | December 2021 | Interest rate PRIME + 6.25% or Floor rate of 9.50%, PIK Interest 1.70%, 2.80% Exit Fee | $ | 15,689 | 15,956 | 15,929

See notes to consolidated financial statements

11

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Yipit, LLC (11)(17)(18) | Information Services | Senior Secured | May 2024 | Interest rate 1-month LIBOR + 8.88% or Floor rate of 9.88% | $ | 12,000 | 11,754 | 11,773
Subtotal: 1-5 Years Maturity | 52,357 | 52,295
Subtotal: Information Services (4.49%)* | 52,357 | 52,295
Internet Consumer & Business Services
Under 1 Year Maturity
Greenphire, Inc. (17) | Internet Consumer & Business Services | Senior Secured | January 2021 | Interest rate 3-month LIBOR + 8.00% or Floor rate of 9.00% | $ | 1,254 | 1,254 | 1,254
Internet Consumer & Business Services | Senior Secured | January 2021 | Interest rate PRIME + 3.75% or Floor rate of 8.75% | $ | 1,800 | 1,800 | 1,800
Total Greenphire, Inc. | $ | 3,054 | 3,054 | 3,054
Snagajob.com, Inc. (13) | Internet Consumer & Business Services | Senior Secured | June 2021 | Interest rate PRIME + 6.90% or Floor rate of 10.15%, 2.55% Exit Fee | $ | 43,005 | 43,900 | 43,382
Internet Consumer & Business Services | Senior Secured | June 2021 | Interest rate PRIME + 7.80% or Floor rate of 11.05%, 2.55% Exit Fee | $ | 5,173 | 5,256 | 5,194
Total Snagajob.com, Inc. | $ | 48,178 | 49,156 | 48,576
Tectura Corporation (7)(8)(14) | Internet Consumer & Business Services | Senior Secured | March 2021 | PIK Interest 5.00% | $ | 10,680 | 240 | -
Internet Consumer & Business Services | Senior Secured | March 2021 | Interest rate FIXED 8.25% | $ | 8,250 | 8,250 | 7,803
Internet Consumer & Business Services | Senior Secured | March 2021 | PIK Interest 5.00% | $ | 13,023 | 13,023 | -
Total Tectura Corporation | $ | 31,953 | 21,513 | 7,803
Subtotal: Under 1 Year Maturity | 73,723 | 59,433
1-5 Years Maturity
AppDirect, Inc. (11)(19) | Internet Consumer & Business Services | Senior Secured | January 2022 | Interest rate PRIME + 5.70% or Floor rate of 9.95%, 3.45% Exit Fee | $ | 20,000 | 20,413 | 20,187
Arctic Wolf Networks, Inc. (13)(19) | Internet Consumer & Business Services | Senior Secured | April 2023 | Interest rate 3-month LIBOR + 7.75% or Floor rate of 10.10%, 7.55% Exit Fee | $ | 30,000 | 30,621 | 30,403
Contentful, Inc. (5)(10)(11)(14) | Internet Consumer & Business Services | Senior Secured | July 2022 | Interest rate PRIME + 2.95% or Floor rate of 7.95%, PIK Interest 1.25%, 3.55% Exit Fee | $ | 3,818 | 3,848 | 3,830
ePayPolicy Holdings, LLC (11)(17) | Internet Consumer & Business Services | Senior Secured | December 2024 | Interest rate 3-month LIBOR + 9.00% or Floor rate of 10.00% | $ | 8,000 | 7,778 | 7,938
EverFi, Inc. (13)(14)(16) | Internet Consumer & Business Services | Senior Secured | May 2022 | Interest rate PRIME + 3.90% or Floor rate of 9.15%, PIK Interest 2.30% | $ | 83,104 | 82,861 | 82,286
Houzz, Inc. (13)(14) | Internet Consumer & Business Services | Senior Secured | November 2022 | Interest rate PRIME + 3.20% or Floor rate of 8.45%, PIK Interest 2.50%, 4.50% Exit Fee | $ | 50,755 | 50,770 | 50,384
Intent (p.k.a. Intent Media, Inc.) (12) | Internet Consumer & Business Services | Senior Secured | September 2021 | Interest rate PRIME + 5.13% or Floor rate of 10.13%, 2.00% Exit Fee | $ | 5,200 | 5,244 | 4,351
Internet Consumer & Business Services | Senior Secured | September 2021 | PIK Interest 10.13% | $ | 5,000 | 4,976 | 4,128
Total Intent (p.k.a. Intent Media, Inc.) | $ | 10,200 | 10,220 | 8,479
Nextroll, Inc. (14)(17)(19) | Internet Consumer & Business Services | Senior Secured | June 2022 | Interest rate PRIME + 3.85% or Floor rate of 9.35%, PIK Interest 2.95%, 3.50% Exit Fee | $ | 20,610 | 20,746 | 20,700
Patron Technology (8)(18) | Internet Consumer & Business Services | Senior Secured | June 2024 | Interest rate 3-month LIBOR + 8.30% or Floor rate of 9.30% | $ | 32,433 | 31,589 | 8,723
Internet Consumer & Business Services | Senior Secured | June 2024 | Interest rate 3-month LIBOR + 8.30% or Floor rate of 9.30% | $ | 2,492 | 2,492 | 689
Internet Consumer & Business Services | Senior Secured | June 2024 | Interest rate 3-month LIBOR + 8.30% or Floor rate of 9.30% | $ | 6,727 | 6,537 | 1,798
Total Patron Technology | $ | 41,652 | 40,618 | 11,210
Postmates, Inc. (19) | Internet Consumer & Business Services | Senior Secured | September 2022 | Interest rate PRIME + 3.85% or Floor rate of 8.85%, 8.05% Exit Fee | $ | 20,000 | 20,619 | 20,619
SeatGeek, Inc. (14)(16) | Internet Consumer & Business Services | Senior Secured | June 2023 | Interest rate PRIME + 5.00% or Floor rate of 10.50%, PIK Interest 0.50% | $ | 60,148 | 58,943 | 57,223
Skyword, Inc. (14) | Internet Consumer & Business Services | Senior Secured | September 2023 | Interest rate PRIME + 3.88% or Floor rate of 9.38%, PIK Interest 1.25%, 4.00% Exit Fee | $ | 12,118 | 12,088 | 11,941
Thumbtack, Inc. (13)(14) | Internet Consumer & Business Services | Senior Secured | September 2023 | Interest rate PRIME + 3.45% or Floor rate of 8.95%, PIK Interest 1.50%, 3.95% Exit Fee | $ | 25,040 | 24,680 | 24,681
Varsity Tutors LLC (13)(14) | Internet Consumer & Business Services | Senior Secured | August 2023 | Interest rate PRIME + 5.25% or Floor rate of 10.75%, PIK Interest 0.55%, 3.00% Exit Fee | $ | 39,155 | 39,092 | 39,325
Wheels Up Partners LLC (11) | Internet Consumer & Business Services | Senior Secured | July 2022 | Interest rate 3-month LIBOR + 8.55% or Floor rate of 9.55% | $ | 15,475 | 15,399 | 15,181

See notes to consolidated financial statements

12

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Xometry, Inc. (13) | Internet Consumer & Business Services | Senior Secured | May 2022 | Interest rate PRIME + 3.95% or Floor rate of 8.70%, 6.25% Exit Fee | $ | 15,000 | 15,469 | 15,585
Subtotal: 1-5 Years Maturity | 454,165 | 419,972
Subtotal: Internet Consumer & Business Services (41.18%)* | 527,888 | 479,405
Media/Content/Info
1-5 Years Maturity
Bustle (14)(15) | Media/Content/Info | Senior Secured | June 2023 | Interest rate PRIME + 4.35% or Floor rate of 9.35%, PIK Interest 1.95%, 4.34% Exit Fee | $ | 20,837 | 20,958 | 20,846
Subtotal: 1-5 Years Maturity | 20,958 | 20,846
Subtotal: Media/Content/Info (1.79%)* | 20,958 | 20,846
Medical Devices & Equipment
Under 1 Year Maturity
Intuity Medical, Inc. (11)(15) | Medical Devices & Equipment | Senior Secured | June 2021 | Interest rate PRIME + 5.00% or Floor rate of 9.25%, 6.95% Exit Fee | $ | 11,217 | 12,185 | 12,161
Sebacia, Inc. (11)(15) | Medical Devices & Equipment | Senior Secured | January 2021 | Interest rate PRIME + 4.35% or Floor rate of 8.85%, 6.05% Exit Fee | $ | 11,000 | 11,607 | 11,547
Subtotal: Under 1 Year Maturity | 23,792 | 23,708
1-5 Years Maturity
Flowonix Medical Incorporated (11)(14) | Medical Devices & Equipment | Senior Secured | October 2021 | Interest rate PRIME + 4.25% or Floor rate of 9.25%, 7.95% Exit Fee | $ | 7,561 | 8,317 | 8,295
Optiscan Biomedical, Corp. (6)(9) | Medical Devices & Equipment | Convertible Debt | July 2021 | Interest rate FIXED 8.00% | $ | 408 | 408 | 407
Quanterix Corporation (11) | Medical Devices & Equipment | Senior Secured | October 2021 | Interest rate PRIME + 2.75% or Floor rate of 8.00%, 0.96% Exit Fee | $ | 7,688 | 7,705 | 7,623
Subtotal: 1-5 Years Maturity | 16,430 | 16,325
Subtotal: Medical Devices & Equipment (3.44%)* | 40,222 | 40,033
Semiconductors
Under 1 Year Maturity
Achronix Semiconductor Corporation | Semiconductors | Senior Secured | December 2020 | Interest rate PRIME + 5.50% or Floor rate of 10.25%, 5.50% Exit Fee | $ | 25,000 | 25,155 | 25,155
Subtotal: Under 1 Year Maturity | 25,155 | 25,155
Subtotal: Semiconductors (2.16%)* | 25,155 | 25,155
Software
Under 1 Year Maturity
Pollen, Inc. (15) | Software | Senior Secured | October 2020 | Interest rate PRIME + 4.25% or Floor rate of 8.50%, 5.95% Exit Fee | $ | 7,000 | 7,390 | 7,390
Subtotal: Under 1 Year Maturity | 7,390 | 7,390
1-5 Years Maturity
3GTMS, LLC. (11)(17)(18) | Software | Senior Secured | February 2025 | Interest rate 3-month LIBOR + 9.28% or Floor rate of 10.28% | $ | 10,000 | 9,739 | 9,739
Abrigo (18) | Software | Senior Secured | March 2023 | Interest rate 3-month LIBOR + 7.88% or Floor rate of 8.88% | $ | 38,954 | 38,395 | 37,964
Software | Senior Secured | March 2023 | Interest rate 3-month LIBOR + 5.92% or Floor rate of 6.92% | $ | 2,350 | 2,302 | 2,271
Total Abrigo | $ | 41,304 | 40,697 | 40,235
Businessolver.com, Inc. (11)(16)(17) | Software | Senior Secured | May 2023 | Interest rate 6-month LIBOR + 7.50% or Floor rate of 8.50% | $ | 58,650 | 57,891 | 57,891
Software | Senior Secured | May 2023 | Interest rate 6-month LIBOR + 7.50% or Floor rate of 8.50% | $ | 7,650 | 7,510 | 7,510
Total Businessolver.com, Inc. | $ | 66,300 | 65,401 | 65,401
Clarabridge, Inc. (12)(13)(14)(17) | Software | Senior Secured | May 2024 | Interest rate PRIME + 5.30% or Floor rate of 8.55%, PIK Interest 2.25% | $ | 55,189 | 54,666 | 54,835
Cloud 9 Software (13) | Software | Senior Secured | April 2024 | Interest rate 3-month LIBOR + 8.20% or Floor rate of 9.20% | $ | 10,000 | 9,849 | 9,313
Cloudian, Inc. (11) | Software | Senior Secured | November 2022 | Interest rate PRIME + 3.25% or Floor rate of 8.25%, 9.75% Exit Fee | $ | 15,000 | 15,605 | 15,169
Couchbase, Inc. (11)(15)(19) | Software | Senior Secured | June 2024 | Interest rate PRIME + 5.25% or Floor rate of 10.75%, 3.75% Exit Fee | $ | 25,000 | 25,094 | 25,082
Dashlane, Inc. (11)(14)(17)(19) | Software | Senior Secured | April 2022 | Interest rate PRIME + 4.05% or Floor rate of 8.55%, PIK Interest 1.10%, 8.50% Exit Fee | $ | 10,237 | 10,628 | 10,496
Software | Senior Secured | March 2023 | Interest rate PRIME + 4.05% or Floor rate of 8.55%, PIK Interest 1.10%, 4.95% Exit Fee | $ | 10,138 | 10,081 | 9,876
Total Dashlane, Inc. | $ | 20,375 | 20,709 | 20,372
Delphix Corp. (13)(16)(19) | Software | Senior Secured | February 2023 | Interest rate PRIME + 5.50% or Floor rate of 10.25%, 5.00% Exit Fee | $ | 60,000 | 59,111 | 58,386
Envisage Technologies, LLC (18) | Software | Senior Secured | March 2025 | Interest rate 3-month LIBOR + 9.00% or Floor rate of 10.00% | $ | 9,750 | 9,503 | 9,503
Evernote Corporation (11)(14)(15)(19) | Software | Senior Secured | July 2021 | Interest rate PRIME + 5.45% or Floor rate of 8.95% | $ | 5,549 | 5,519 | 5,484

See notes to consolidated financial statements

13

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Software | Senior Secured | July 2021 | Interest rate PRIME + 6.00% or Floor rate of 9.50%, PIK Interest 1.25% | $ | 4,152 | 4,114 | 4,088
Software | Senior Secured | July 2022 | Interest rate PRIME + 6.00% or Floor rate of 9.50%, PIK Interest 1.25% | $ | 5,110 | 5,064 | 5,006
Total Evernote Corporation | $ | 14,811 | 14,697 | 14,578
FreedomPay, Inc. (19) | Software | Senior Secured | June 2023 | Interest rate PRIME + 7.70% or Floor rate of 10.95%, 3.55% Exit Fee | $ | 10,000 | 9,888 | 9,888
Ikon Science Limited (5)(10)(17)(18) | Software | Senior Secured | October 2024 | Interest rate 3-month LIBOR + 9.00% or Floor rate of 10.00% | $ | 7,000 | 6,715 | 6,634
Insurance Technologies Corporation (11)(18) | Software | Senior Secured | January 2025 | Interest rate 3-month LIBOR + 8.27% or Floor rate of 9.27% | $ | 17,000 | 16,558 | 16,334
Jolt Software, Inc. (14) | Software | Senior Secured | October 2022 | Interest rate PRIME + 3.00% or Floor rate of 8.50%, PIK Interest 1.75%, 4.50% Exit Fee | $ | 7,571 | 7,593 | 7,584
Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.) (11)(18) | Software | Senior Secured | July 2023 | Interest rate 6-month LIBOR + 10.15% or Floor rate of 11.15% | $ | 8,740 | 8,485 | 8,240
Khoros (p.k.a Lithium Technologies) (11)(17) | Software | Senior Secured | October 2022 | Interest rate 6-month LIBOR + 8.00% or Floor rate of 9.00% | $ | 12,000 | 11,862 | 11,812
Software | Senior Secured | October 2022 | Interest rate 6-month LIBOR + 8.00% or Floor rate of 9.00% | $ | 43,000 | 42,356 | 42,185
Software | Senior Secured | October 2022 | Interest rate 6-month LIBOR + 8.00% or Floor rate of 9.00% | $ | 1,811 | 1,811 | 1,802
Total Khoros (p.k.a Lithium Technologies) | $ | 56,811 | 56,029 | 55,799
Lightbend, Inc. (14)(15) | Software | Senior Secured | February 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.25%, PIK Interest 2.00%, 3.00% Exit Fee | $ | 15,982 | 16,082 | 15,996
memsql, Inc. (14)(17) | Software | Senior Secured | May 2023 | Interest rate PRIME + 4.70% or Floor rate of 7.95%, PIK Interest 0.75%, 3.95% Exit Fee | $ | 5,001 | 4,954 | 4,954
Mobile Solutions Services (17)(18) | Software | Senior Secured | October 2024 | Interest rate 6-month LIBOR + 8.80% or Floor rate of 9.80% | $ | 5,500 | 5,344 | 5,218
Nuvolo Technologies Corporation (19) | Software | Senior Secured | October 2022 | Interest rate PRIME + 6.25% or Floor rate of 11.75% | $ | 15,000 | 14,828 | 14,746
OrthoFi, Inc. (13)(18) | Software | Senior Secured | April 2024 | Interest rate 6-month LIBOR + 8.28% or Floor rate of 9.28% | $ | 17,853 | 17,459 | 16,808
Software | Senior Secured | April 2024 | Interest rate 6-month LIBOR + 8.28% or Floor rate of 9.28% | $ | 1,667 | 1,667 | 1,667
Total OrthoFi, Inc. | $ | 19,520 | 19,126 | 18,475
Regent Education (14) | Software | Senior Secured | January 2022 | Interest rate FIXED 10.00%, PIK Interest 2.00%, 7.94% Exit Fee | $ | 3,187 | 3,265 | 3,058
Reltio, Inc. (17)(19) | Software | Senior Secured | July 2023 | Interest rate PRIME + 5.70% or Floor rate of 8.95%, PIK Interest 1.70%, 4.95% Exit Fee | $ | 10,000 | 9,747 | 9,747
Salsa Labs, Inc. (11) | Software | Senior Secured | April 2023 | Interest rate 3-month LIBOR + 8.15% or Floor rate of 9.15% | $ | 6,000 | 5,926 | 5,810
Software | Senior Secured | April 2023 | Interest rate 3-month LIBOR + 8.15% or Floor rate of 9.15% | $ | 500 | 500 | 495
Total Salsa Labs, Inc. | $ | 6,500 | 6,426 | 6,305
Tact.ai Technologies, Inc. (11)(14) | Software | Senior Secured | February 2023 | Interest rate PRIME + 4.00% or Floor rate of 8.75%, PIK Interest 2.00%, 5.50% Exit Fee | $ | 5,030 | 4,829 | 4,715
ThreatConnect, Inc. (13)(18) | Software | Senior Secured | May 2024 | Interest rate 3-month LIBOR + 8.26% or Floor rate of 9.26% | $ | 4,500 | 4,378 | 4,347
Software | Senior Secured | May 2024 | Interest rate 3-month LIBOR + 8.26% or Floor rate of 9.26% | $ | 1,800 | 1,800 | 1,800
Total ThreatConnect, Inc. | $ | 6,300 | 6,178 | 6,147
Vela Trading Technologies (11)(18) | Software | Senior Secured | July 2022 | Interest rate 3-month LIBOR + 9.50% or Floor rate of 10.50% | $ | 18,595 | 18,291 | 17,938
ZeroFox, Inc. (13) | Software | Senior Secured | January 2023 | Interest rate PRIME + 4.75% or Floor rate of 10.25%, 3.00% Exit Fee | $ | 20,000 | 19,951 | 19,905
ZocDoc (11)(19) | Software | Senior Secured | August 2021 | Interest rate PRIME + 6.20% or Floor rate of 10.95%, 2.00% Exit Fee | $ | 30,000 | 30,372 | 30,511
Subtotal: 1-5 Years Maturity | 589,732 | 584,807
Greater than 5 Years Maturity
Campaign Monitor Limited (11)(17)(19) | Software | Senior Secured | November 2025 | Interest rate 6-month LIBOR + 8.50% or Floor rate of 9.50% | $ | 29,333 | 28,719 | 28,206
Software | Senior Secured | November 2025 | Interest rate 1-month LIBOR + 8.50% or Floor rate of 9.50% | $ | 688 | 672 | 665
Total Campaign Monitor Limited | $ | 30,021 | 29,391 | 28,871
Imperva, Inc. (19) | Software | Senior Secured | January 2027 | Interest rate 3-month LIBOR + 7.75% or Floor rate of 8.75% | $ | 20,000 | 19,817 | 19,099

See notes to consolidated financial statements

14

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Subtotal: Greater than 5 Years Maturity | 49,208 | 47,970
Subtotal: Software (55.00%)* | 646,330 | 640,167
Sustainable and Renewable Technology
Under 1 Year Maturity
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) (6)(8)(14) | Sustainable and Renewable Technology | Senior Secured | December 2020 | Interest rate FIXED 6.48%, PIK Interest 6.48%, 6.67% Exit Fee | $ | 10,000 | 10,775 | 9,408
Sustainable and Renewable Technology | Senior Secured | December 2020 | PIK Interest 10.00% | $ | 683 | 683 | -
Sustainable and Renewable Technology | Senior Secured | December 2020 | Interest rate FIXED 8.85%, PIK Interest 8.85% | $ | 1,492 | 1,492 | 1,492
Total Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) | $ | 12,175 | 12,950 | 10,900
Proterra, Inc. (14)(19) | Sustainable and Renewable Technology | Senior Secured | May 2021 | Interest rate PRIME + 5.05% or Floor rate of 10.55%, PIK Interest 1.75% | $ | 10,191 | 10,165 | 10,164
Subtotal: Under 1 Year Maturity | 23,115 | 21,064
1-5 Years Maturity
Impossible Foods, Inc. (12)(13) | Sustainable and Renewable Technology | Senior Secured | July 2022 | Interest rate PRIME + 3.95% or Floor rate of 8.95%, 9.00% Exit Fee | $ | 50,000 | 52,660 | 53,170
Subtotal: 1-5 Years Maturity | 52,660 | 53,170
Subtotal: Sustainable and Renewable Technology (6.38%)* | 75,775 | 74,234
Total: Debt Investments (190.40%)* | 2,278,919 | 2,216,352

See notes to consolidated financial statements

15

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
Equity Investments
Communications & Networking
Peerless Network Holdings, Inc. | Communications & Networking | Equity | Preferred Series A | 1,135,000 | $ | 1,230 | $ | 2,868
Subtotal: Communications & Networking (0.25%)* | 1,230 | 2,868
Consumer & Business Products
Intelligent Beauty, Inc. | Consumer & Business Products | Equity | Preferred Series B | 111,156 | $ | 230 | $ | 601
Subtotal: Consumer & Business Products (0.05%)* | 230 | 601
Diversified Financial Services
Gibraltar Business Capital, LLC (7) | Diversified Financial Services | Equity | Common Stock | 830,000 | 1,884 | 2,141
Diversified Financial Services | Equity | Preferred Series A | 10,602,752 | 26,122 | 29,679
Total Gibraltar Business Capital, LLC | 11,432,752 | 28,006 | 31,820
Subtotal: Diversified Financial Services (2.73%)* | 28,006 | 31,820
Drug Delivery
AcelRx Pharmaceuticals, Inc. (4) | Drug Delivery | Equity | Common Stock | 176,730 | 1,329 | 214
BioQ Pharma Incorporated (15) | Drug Delivery | Equity | Preferred Series D | 165,000 | 500 | 757
Kaleo, Inc. | Drug Delivery | Equity | Preferred Series B | 82,500 | 1,007 | 2,904
Neos Therapeutics, Inc. (4)(15) | Drug Delivery | Equity | Common Stock | 125,000 | 1,500 | 86
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) (4) | Drug Delivery | Equity | Common Stock | 2,498 | 309 | 5
Subtotal: Drug Delivery (0.34%)* | 4,645 | 3,966
Drug Discovery & Development
Aveo Pharmaceuticals, Inc. (4)(15) | Drug Discovery & Development | Equity | Common Stock | 190,175 | 1,714 | 979
Axovant Gene Therapies Ltd. (p.k.a. Axovant Sciences Ltd.) (4)(5)(10) | Drug Discovery & Development | Equity | Common Stock | 16,228 | 1,269 | 46
BridgeBio Pharma LLC (4)(16) | Drug Discovery & Development | Equity | Common Stock | 203,579 | 2,000 | 6,639
Cerecor, Inc. (4) | Drug Discovery & Development | Equity | Common Stock | 119,087 | 1,000 | 310
Chemocentryx, Inc. (4)(10)(15) | Drug Discovery & Development | Equity | Common Stock | 17,241 | 1,000 | 992
Concert Pharmaceuticals, Inc. (4)(10) | Drug Discovery & Development | Equity | Common Stock | 70,796 | 1,367 | 704
Dare Biosciences, Inc. (4) | Drug Discovery & Development | Equity | Common Stock | 13,550 | 1,000 | 13
Dynavax Technologies (4)(10) | Drug Discovery & Development | Equity | Common Stock | 20,000 | 550 | 177
Eidos Therapeutics, Inc. (4)(10) | Drug Discovery & Development | Equity | Common Stock | 15,000 | 255 | 715
Genocea Biosciences, Inc. (4) | Drug Discovery & Development | Equity | Common Stock | 27,932 | 2,000 | 64
Paratek Pharmaceuticals, Inc. (4)(16) | Drug Discovery & Development | Equity | Common Stock | 76,362 | 2,744 | 399
Rocket Pharmaceuticals, Ltd. (4) | Drug Discovery & Development | Equity | Common Stock | 944 | 1,500 | 20
Savara, Inc. (4)(15) | Drug Discovery & Development | Equity | Common Stock | 11,119 | 203 | 28
uniQure B.V. (4)(5)(10) | Drug Discovery & Development | Equity | Common Stock | 17,175 | 332 | 774
X4 Pharmaceuticals, Inc. (4) | Drug Discovery & Development | Equity | Common Stock | 83,334 | 641 | 777
Subtotal: Drug Discovery & Development (1.09%)* | 17,575 | 12,637
Healthcare Services, Other
23andMe, Inc. | Healthcare Services, Other | Equity | Common Stock | 360,000 | 5,094 | 6,651
Chromadex Corporation (4) | Healthcare Services, Other | Equity | Common Stock | 44,264 | 157 | 203
Subtotal: Healthcare Services, Other (0.59%)* | 5,251 | 6,854
Internet Consumer & Business Services
Blurb, Inc. | Internet Consumer & Business Services | Equity | Preferred Series B | 220,653 | 175 | —
Contentful, Inc. (5)(10) | Internet Consumer & Business Services | Equity | Preferred Series D | 217 | 500 | 775
Countable Corporation (p.k.a. Brigade Group, Inc.) | Internet Consumer & Business Services | Equity | Common Stock | 9,023 | 93 | —
DoorDash, Inc. | Internet Consumer & Business Services | Equity | Common Stock | 105,000 | 6,051 | 18,412
Fastly, Inc. (4) | Internet Consumer & Business Services | Equity | Common Stock | 6,238 | 8 | 531
Lyft, Inc. (4) | Internet Consumer & Business Services | Equity | Common Stock | 200,738 | 10,487 | 6,627
Nextdoor.com, Inc. | Internet Consumer & Business Services | Equity | Common Stock | 328,190 | 4,854 | 7,188
OfferUp, Inc. | Internet Consumer & Business Services | Equity | Preferred Series A | 286,080 | 1,663 | 1,555
Internet Consumer & Business Services | Equity | Preferred Series A-1 | 108,710 | 632 | 591
Total OfferUp, Inc. | 394,790 | 2,295 | 2,146
Oportun (4) | Internet Consumer & Business Services | Equity | Common Stock | 48,365 | 577 | 650
Tectura Corporation (7) | Internet Consumer & Business Services | Equity | Common Stock | 414,994,863 | 900 | —
Internet Consumer & Business Services | Equity | Preferred Series BB | 1,000,000 | — | —
Total Tectura Corporation | 415,994,863 | 900 | —
Subtotal: Internet Consumer & Business Services (3.12%)* | 25,940 | 36,329

See notes to consolidated financial statements

16

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
Medical Devices & Equipment
Flowonix Medical Incorporated | Medical Devices & Equipment | Equity | Preferred Series AA | 221,893 | 1,500 | —
Gelesis, Inc. | Medical Devices & Equipment | Equity | Common Stock | 227,013 | — | 605
Medical Devices & Equipment | Equity | Preferred Series A-1 | 191,210 | 425 | 529
Medical Devices & Equipment | Equity | Preferred Series A-2 | 191,626 | 500 | 519
Total Gelesis, Inc. | 609,849 | 925 | 1,653
Medrobotics Corporation (15) | Medical Devices & Equipment | Equity | Preferred Series E | 136,798 | 250 | —
Medical Devices & Equipment | Equity | Preferred Series F | 73,971 | 155 | —
Medical Devices & Equipment | Equity | Preferred Series G | 163,934 | 500 | —
Total Medrobotics Corporation | 374,703 | 905 | —
Optiscan Biomedical, Corp. (6) | Medical Devices & Equipment | Equity | Preferred Series B | 61,855 | 3,000 | 3
Medical Devices & Equipment | Equity | Preferred Series C | 19,273 | 655 | 1
Medical Devices & Equipment | Equity | Preferred Series D | 551,038 | 5,257 | 50
Medical Devices & Equipment | Equity | Preferred Series E | 507,103 | 4,240 | 548
Total Optiscan Biomedical, Corp. | 1,139,269 | 13,152 | 602
Outset Medical, Inc. | Medical Devices & Equipment | Equity | Preferred Series B | 232,061 | 527 | 471
ViewRay, Inc. (4)(15) | Medical Devices & Equipment | Equity | Common Stock | 36,457 | 333 | 83
Subtotal: Medical Devices & Equipment (0.24%)* | 17,342 | 2,809
Software
CapLinked, Inc. | Software | Equity | Preferred Series A-3 | 53,614 | 51 | 70
Docker, Inc. | Software | Equity | Common Stock | 20,000 | 4,284 | 26
Druva Holdings, Inc. (p.k.a. Druva, Inc.) | Software | Equity | Preferred Series 2 | 458,841 | 1,000 | 3,083
Software | Equity | Preferred Series 3 | 93,620 | 300 | 664
Total Druva Holdings, Inc. (p.k.a. Druva, Inc.) | 552,461 | 1,300 | 3,747
HighRoads, Inc. | Software | Equity | Common Stock | 190 | 307 | —
Palantir Technologies | Software | Equity | Preferred Series D | 9,535 | 47 | 63
Software | Equity | Preferred Series E | 1,749,089 | 10,489 | 11,498
Software | Equity | Preferred Series G | 326,797 | 2,211 | 2,149
Total Palantir Technologies | 2,085,421 | 12,747 | 13,710
Sprinklr, Inc. | Software | Equity | Common Stock | 700,000 | 3,749 | 4,194
Subtotal: Software (1.87%)* | 22,438 | 21,747
Surgical Devices
Gynesonics, Inc. (15) | Surgical Devices | Equity | Preferred Series B | 219,298 | 250 | 9
Surgical Devices | Equity | Preferred Series C | 656,538 | 282 | 27
Surgical Devices | Equity | Preferred Series D | 1,991,157 | 712 | 88
Surgical Devices | Equity | Preferred Series E | 2,786,367 | 429 | 141
Surgical Devices | Equity | Preferred Series F | 1,523,693 | 118 | 140
Surgical Devices | Equity | Preferred Series F-1 | 2,418,125 | 150 | 196
Total Gynesonics, Inc. | 9,595,178 | 1,941 | 601
TransMedics Group, Inc. (p.k.a Transmedics, Inc.) (4) | Surgical Devices | Equity | Common Stock | 162,617 | 2,550 | 2,914
Subtotal: Surgical Devices (0.30%)* | 4,491 | 3,515
Sustainable and Renewable Technology
Impossible Foods, Inc. | Sustainable and Renewable Technology | Equity | Preferred Series E-1 | 188,611 | 2,000 | 2,282
Modumetal, Inc. | Sustainable and Renewable Technology | Equity | Preferred Series A-1 | 103,584 | 500 | 6
Proterra, Inc. | Sustainable and Renewable Technology | Equity | Preferred Series 5 | 99,280 | 500 | 259
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) (6) | Sustainable and Renewable Technology | Equity | Common Stock | 488 | 61,502 | —
Subtotal: Sustainable and Renewable Technology (0.22%)* | 64,502 | 2,547
Total: Equity Investments (10.80%)* | 191,650 | 125,693
Warrant Investments
Communications & Networking
Peerless Network Holdings, Inc. | Communications & Networking | Warrant | Common Stock | 3,328 | — | 5
Spring Mobile Solutions, Inc. | Communications & Networking | Warrant | Common Stock | 2,834,375 | 418 | —
Subtotal: Communications & Networking (0.00%)* | 418 | 5
Consumer & Business Products
Gadget Guard (15) | Consumer & Business Products | Warrant | Common Stock | 1,662,441 | 228 | —
The Neat Company | Consumer & Business Products | Warrant | Common Stock | 54,054 | 365 | —
Whoop, Inc. | Consumer & Business Products | Warrant | Preferred Series C | 68,627 | 18 | 42
Subtotal: Consumer & Business Products (0.00%)* | 611 | 42
Drug Delivery
Aerami Therapeutics (p.k.a. Dance Biopharm, Inc.) (15) | Drug Delivery | Warrant | Common Stock | 110,882 | 74 | —
BioQ Pharma Incorporated | Drug Delivery | Warrant | Common Stock | 459,183 | 1 | 1,100

See notes to consolidated financial statements

17

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
Neos Therapeutics, Inc. (4)(15) | Drug Delivery | Warrant | Common Stock | 70,833 | 285 | —
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) (4) | Drug Delivery | Warrant | Common Stock | 3,929 | 390 | —
Subtotal: Drug Delivery (0.09%)* | 750 | 1,100
Drug Discovery & Development
Acacia Pharma Inc. (4)(5)(10) | Drug Discovery & Development | Warrant | Common Stock | 201,330 | 304 | 263
ADMA Biologics, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 89,750 | 295 | 22
Albireo Pharma, Inc. (4)(5)(10) | Drug Discovery & Development | Warrant | Common Stock | 5,310 | 61 | 58
Brickell Biotech, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 9,005 | 119 | —
Cerecor, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 22,328 | 70 | 1
Concert Pharmaceuticals, Inc. (4)(10)(15) | Drug Discovery & Development | Warrant | Common Stock | 61,273 | 178 | 107
CytRx Corporation (4)(15) | Drug Discovery & Development | Warrant | Common Stock | 105,694 | 160 | —
Dermavant Sciences Ltd. (5)(10) | Drug Discovery & Development | Warrant | Common Stock | 223,642 | 101 | 361
Evofem Biosciences, Inc. (4)(15) | Drug Discovery & Development | Warrant | Common Stock | 7,806 | 266 | 5
Genocea Biosciences, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 41,176 | 165 | 16
Integral Health Holdings, LLC | Drug Discovery & Development | Warrant | Common Stock | 50,000 | 117 | 119
Motif BioSciences Inc. (4)(5)(10) | Drug Discovery & Development | Warrant | Common Stock | 121,337,041 | 282 | —
Myovant Sciences, Ltd. (4)(5)(10) | Drug Discovery & Development | Warrant | Common Stock | 73,710 | 460 | 713
Ology Bioservices, Inc. (15) | Drug Discovery & Development | Warrant | Common Stock | 171,389 | 838 | —
Paratek Pharmaceuticals, Inc. (4)(15)(16) | Drug Discovery & Development | Warrant | Common Stock | 94,841 | 204 | 46
Sorrento Therapeutics, Inc. (4)(10) | Drug Discovery & Development | Warrant | Common Stock | 306,748 | 889 | 827
Stealth Bio Therapeutics Corp. (4)(5)(10) | Drug Discovery & Development | Warrant | Common Stock | 500,000 | 158 | 360
TG Therapeutics, Inc. (4)(10) | Drug Discovery & Development | Warrant | Common Stock | 147,058 | 563 | 1,807
Tricida, Inc. (4)(15)(16) | Drug Discovery & Development | Warrant | Common Stock | 138,269 | 1,143 | 1,684
Urovant Sciences, Ltd. (4)(5)(10) | Drug Discovery & Development | Warrant | Common Stock | 99,777 | 383 | 374
X4 Pharmaceuticals, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 108,334 | 673 | 246
Yumanity Therapeutics, Inc. | Drug Discovery & Development | Warrant | Class B Preferred Units | 73,110 | 110 | 160
Subtotal: Drug Discovery & Development (0.62%)* | 7,539 | 7,169
Electronics & Computer Hardware
908 Devices, Inc. (15) | Electronics & Computer Hardware | Warrant | Preferred Series D | 79,856 | 101 | 42
Subtotal: Electronics & Computer Hardware (0.00%)* | 101 | 42
Information Services
INMOBI Inc. (5)(10) | Information Services | Warrant | Common Stock | 65,587 | 82 | —
NetBase Solutions, Inc. | Information Services | Warrant | Preferred Series 1 | 60,000 | 356 | 328
Planet Labs, Inc. | Information Services | Warrant | Common Stock | 357,752 | 615 | 178
RichRelevance, Inc. | Information Services | Warrant | Preferred Series E | 112,612 | 98 | —
Sapphire Digital, Inc. (p.k.a. MDX Medical, Inc.) (15) | Information Services | Warrant | Common Stock | 2,812,500 | 283 | 407
Subtotal: Information Services (0.08%)* | 1,434 | 913
Internet Consumer & Business Services
Aria Systems, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series G | 231,535 | 73 | —
Blurb, Inc. (15) | Internet Consumer & Business Services | Warrant | Preferred Series C | 234,280 | 636 | —
Cloudpay, Inc. (5)(10) | Internet Consumer & Business Services | Warrant | Preferred Series B | 6,763 | 54 | 11
Contentful, Inc. (5)(10) | Internet Consumer & Business Services | Warrant | Preferred Series C | 82 | 1 | 153
First Insight, Inc. (15) | Internet Consumer & Business Services | Warrant | Preferred Series B | 75,917 | 96 | 125
Houzz, Inc. | Internet Consumer & Business Services | Warrant | Common Stock | 529,661 | 20 | 17
Intent (p.k.a. Intent Media, Inc.) | Internet Consumer & Business Services | Warrant | Common Stock | 140,077 | 168 | —
Interactions Corporation | Internet Consumer & Business Services | Warrant | Preferred Series G-3 | 68,187 | 204 | 464
Just Fabulous, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series B | 206,184 | 1,102 | 1,547
Lendio, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series D | 127,032 | 39 | 29
LogicSource | Internet Consumer & Business Services | Warrant | Preferred Series C | 79,625 | 30 | 91
Postmates, Inc. | Internet Consumer & Business Services | Warrant | Common Stock | 189,865 | 317 | 565
RumbleON, Inc. (4) | Internet Consumer & Business Services | Warrant | Common Stock | 5,139 | 87 | 2
SeatGeek, Inc. (16) | Internet Consumer & Business Services | Warrant | Common Stock | 1,379,761 | 842 | 1,309
ShareThis, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series C | 493,502 | 547 | —

See notes to consolidated financial statements

18

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
Skyword, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series B | 444,444 | 83 | 23
Snagajob.com, Inc. | Internet Consumer & Business Services | Warrant | Common Stock | 600,000 | 16 | 28
Internet Consumer & Business Services | Warrant | Preferred Series A | 1,800,000 | 782 | 23
Internet Consumer & Business Services | Warrant | Preferred Series B | 1,211,537 | 62 | 9
Total Snagajob.com, Inc. | 3,611,537 | 860 | 60
Tapjoy, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series D | 748,670 | 316 | 3
The Faction Group LLC | Internet Consumer & Business Services | Warrant | Preferred Series AA | 8,076 | 234 | 554
Thumbtack, Inc. | Internet Consumer & Business Services | Warrant | Common Stock | 190,953 | 553 | 264
Xometry, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series B | 87,784 | 47 | 213
Subtotal: Internet Consumer & Business Services (0.47%)* | 6,309 | 5,430
Media/Content/Info
Napster | Media/Content/Info | Warrant | Common Stock | 715,755 | 384 | —
WP Technology, Inc. (Wattpad, Inc.) (5)(10) | Media/Content/Info | Warrant | Common Stock | 255,818 | 4 | —
Zoom Media Group, Inc. | Media/Content/Info | Warrant | Preferred Series A | 1,204 | 348 | —
Subtotal: Media/Content/Info (0.00%)* | 736 | —
Medical Devices & Equipment
Aspire Bariatrics, Inc. (15) | Medical Devices & Equipment | Warrant | Preferred Series B-1 | 112,858 | 455 | —
Flowonix Medical Incorporated | Medical Devices & Equipment | Warrant | Preferred Series AA | 155,325 | 362 | —
Medical Devices & Equipment | Warrant | Preferred Series BB | 725,806 | 351 | —
Total Flowonix Medical Incorporated | 881,131 | 713 | —
Gelesis, Inc. | Medical Devices & Equipment | Warrant | Preferred Series A-1 | 74,784 | 78 | 158
InspireMD, Inc. (4)(5)(10) | Medical Devices & Equipment | Warrant | Common Stock | 23 | 0 | —
Intuity Medical, Inc. (15) | Medical Devices & Equipment | Warrant | Preferred Series 5 | 1,819,078 | 294 | 274
Medrobotics Corporation (15) | Medical Devices & Equipment | Warrant | Preferred Series E | 455,539 | 370 | —
NinePoint Medical, Inc. | Medical Devices & Equipment | Warrant | Preferred Series A-1 | 587,840 | 170 | —
Optiscan Biomedical, Corp. (6) | Medical Devices & Equipment | Warrant | Preferred Series E | 74,424 | 572 | 1
Outset Medical, Inc. | Medical Devices & Equipment | Warrant | Preferred Series A | 500,000 | 402 | 175
Sebacia, Inc. | Medical Devices & Equipment | Warrant | Preferred Series D | 778,301 | 133 | 1
SonaCare Medical, LLC | Medical Devices & Equipment | Warrant | Preferred Series A | 6,464 | 188 | —
Tela Bio, Inc. (4) | Medical Devices & Equipment | Warrant | Common Stock | 15,712 | 61 | 10
Subtotal: Medical Devices & Equipment (0.05%)* | 3,436 | 619
Semiconductors
Achronix Semiconductor Corporation | Semiconductors | Warrant | Preferred Series C | 360,000 | 160 | 21
Semiconductors | Warrant | Preferred Series D-2 | 750,000 | 99 | 302
Total Achronix Semiconductor Corporation | 1,110,000 | 259 | 323
Subtotal: Semiconductors (0.03%)* | 259 | 323
Software
Actifio, Inc. | Software | Warrant | Common Stock | 73,584 | 249 | 74
Software | Warrant | Preferred Series F | 31,673 | 343 | 71
Total Actifio, Inc. | 105,257 | 592 | 145
BryterCX, Inc. (p.k.a. Clickfox, Inc.) (15) | Software | Warrant | Preferred Series B | 492,877 | 152 | —
Software | Warrant | Preferred Series C | 592,019 | 730 | —
Software | Warrant | Preferred Series C-A | 2,218,214 | 231 | —
Total BryterCX, Inc. (p.k.a. ClickFox, Inc.) | 3,303,110 | 1,113 | —
Cloudian, Inc. | Software | Warrant | Common Stock | 477,454 | 71 | 36
Couchbase, Inc. | Software | Warrant | Common Stock | 263,377 | 462 | 864
Dashlane, Inc. | Software | Warrant | Common Stock | 346,747 | 303 | 229
Delphix Corp. (16) | Software | Warrant | Common Stock | 718,898 | 1,594 | 1,251
DNAnexus, Inc. | Software | Warrant | Preferred Series C | 909,091 | 97 | 78
Evernote Corporation | Software | Warrant | Common Stock | 62,500 | 106 | 44
Fuze, Inc. (15) | Software | Warrant | Preferred Series F | 256,158 | 89 | —
Lightbend, Inc. (15) | Software | Warrant | Preferred Series C-1 | 854,787 | 130 | 88
memsql, Inc. | Software | Warrant | Preferred Series D | 312,596 | 103 | 123
Message Systems, Inc. (15) | Software | Warrant | Preferred Series C | 503,718 | 334 | 527
Nuvolo Technologies Corporation | Software | Warrant | Common Stock | 30,000 | 43 | 65

See notes to consolidated financial statements

19

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

June 30, 2020

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
OneLogin, I nc. (15) | Software | Warrant | Common Stock | 381,620 | 305 | 646
Poplicus, Inc. | Software | Warrant | Common Stock | 132,168 | — | —
RapidMiner, Inc. | Software | Warrant | Preferred Series C-1 | 4,982 | 24 | 25
Reltio, Inc. | Software | Warrant | Common Stock | 69,120 | 215 | 215
SignPost, Inc. | Software | Warrant | Series Junior 1 Preferred | 474,019 | 314 | —
Tact.ai Technologies, Inc. | Software | Warrant | Common Stock | 1,041,667 | 206 | 108
ZeroFox, Inc. | Software | Warrant | Common Stock | 162,087 | 43 | 42
Software | Warrant | Preferred Series C-1 | 486,263 | 57 | 125
Total ZeroFox, Inc. | 648,350 | 100 | 167
Subtotal: Software (0.40%)* | 6,201 | 4,611
Specialty Pharmaceuticals
Alimera Sciences, Inc. (4) | Specialty Pharmaceuticals | Warrant | Common Stock | 114,513 | 861 | 38
Subtotal: Specialty Pharmaceuticals (0.00%)* | 861 | 38
Surgical Devices
Gynesonics, Inc. (15) | Surgical Devices | Warrant | Preferred Series C | 151,123 | 67 | 6
Surgical Devices | Warrant | Preferred Series D | 1,575,965 | 320 | 22
Total Gynesonics, Inc. | 1,727,088 | 387 | 28
TransMedics Group, Inc. (p.k.a Transmedics, Inc.) (4) | Surgical Devices | Warrant | Common Stock | 64,441 | 139 | 413
Subtotal: Surgical Devices (0.04%)* | 526 | 441
Sustainable and Renewable Technology
Agrivida, Inc. | Sustainable and Renewable Technology | Warrant | Preferred Series D | 471,327 | 120 | —
Calera, Inc. | Sustainable and Renewable Technology | Warrant | Preferred Series C | 44,529 | 513 | —
Fulcrum Bioenergy, Inc. | Sustainable and Renewable Technology | Warrant | Preferred Series C-1 | 280,897 | 274 | 467
Kinestral Technologies, Inc. | Sustainable and Renewable Technology | Warrant | Preferred Series A | 325,000 | 155 | 160
Sustainable and Renewable Technology | Warrant | Preferred Series B | 131,883 | 63 | 54
Total Kinestral Technologies, Inc. | 456,883 | 218 | 214
NantEnergy, Inc. (p.k.a. Fluidic, Inc.) | Sustainable and Renewable Technology | Warrant | Preferred Series D | 61,804 | 102 | —
Polyera Corporation (15) | Sustainable and Renewable Technology | Warrant | Preferred Series C | 311,609 | 338 | —
Proterra, Inc. | Sustainable and Renewable Technology | Warrant | Common Stock | 36,630 | 1 | 2
Sustainable and Renewable Technology | Warrant | Preferred Series 4 | 477,517 | 41 | 60
Total Proterra, Inc. | 514,147 | 42 | 62
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) (6) | Sustainable and Renewable Technology | Warrant | Class A Units | 1 | — | —
Subtotal: Sustainable and Renewable Technology (0.06%)* | 1,607 | 743
Total: Warrant Investments (1.84%)* | $ | 30,788 | $ | 21,476
Total: Investments in Securities (203.05%)* | $ | 2,501,357 | $ | 2,363,521
* | Value as a percent of net assets
(1) | Preferred and common stock, warrants, and equity interests are generally non-income producing.
(2) | Interest rate PRIME represents 3.25% at June 30, 2020. 1-month LIBOR, 3-month LIBOR and 12-month LIBOR represent 0.16%, 0.30% and 0.55%, respectively, at June 30, 2020.
(3) | Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $69.9 million, $187.2 million and $117.4 million, respectively. The tax cost of investments is $2.5 billion.
(4) | Except for warrants in 25 publicly traded companies and common stock in 24 publicly traded companies, all investments are restricted at June 30, 2020 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s board of directors (the “Board of Directors”). No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
(5) | Non-U.S. company or the company’s principal place of business is outside the United States.
(6) | Affiliate investment as defined under the Investment Company Act of 1940, as amended, (the “1940 Act”) in which Hercules owns at least 5% but generally less than 25% of the company’s voting securities.
(7) | Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.
(8) | Debt is on non-accrual status at June 30, 2020, and is therefore considered non-income producing. Note that at June 30, 2020, only the PIK, or payment-in-kind, portion is on non-accrual for the Company’s debt investment in Solar Spectrum Holdings LLC (p.k.a. Sungevity Inc.), Tectura Corporation, and Glo AB.
(9) | Denotes that all or a portion of the debt investment is convertible debt.
(10) | Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.
(11) | Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitization (as defined in Note 4).
(12) | Denotes that all or a portion of the debt investment is pledged as collateral under the Wells Facility (as defined in Note 4).
(13) | Denotes that all or a portion of the debt investment is pledged as collateral under the Union Bank Facility (as defined in Note 4).
(14) | Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.
(15) | Denotes that all or a portion of the investment in this portfolio company is held by Hercules Technology III, L.P., or HT III, the Company’s wholly owned small business investment company, or SBIC, subsidiary.
(16) | Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total assets at June 30, 2020.
(17) | Denotes that there is an unfunded contractual commitment available at the request of this portfolio company at June 30, 2020. Refer to Note 10.
(18) | Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition.
(19) | Denotes second lien senior secured debt.

See notes to consolidated financial statements

20

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Maturity Date | Interest Rate and Floor (2) | Principal Amount | Cost (3) | Value (4)
Debt Investments
Biotechnology Tools
Under 1 Year Maturity
Exicure, Inc. (11) | Biotechnology Tools | Senior Secured | March 2020 | Interest rate PRIME + 6.45% or Floor rate of 9.95%, 5.52% Exit Fee | $ | 4,999 | $ | 5,067 | $ | 5,067
Subtotal: Under 1 Year Maturity | 5,067 | 5,067
Subtotal: Biotechnology Tools (0.45%)* | 5,067 | 5,067
Diversified Financial Services
1-5 Years Maturity
Gibraltar Business Capital, LLC (7) | Diversified Financial Services | Unsecured | March 2023 | Interest rate FIXED 14.50% | $ | 15,000 | 14,780 | 14,780
Pico Quantitative Trading LLC (18) | Diversified Financial Services | Senior Secured | June 2024 | Interest rate 1-month LIBOR + 8.60% or Floor rate of 9.60% | $ | 30,000 | 29,556 | 28,773
Subtotal: 1-5 Years Maturity | 44,336 | 43,553
Subtotal: Diversified Financial Services (3.84%)* | 44,336 | 43,553
Drug Delivery
1-5 Years Maturity
Antares Pharma Inc. (10)(11)(15) | Drug Delivery | Senior Secured | July 2022 | Interest rate PRIME + 4.50% or Floor rate of 4.50%, 4.14% Exit Fee | $ | 40,000 | 40,626 | 40,773
Subtotal: 1-5 Years Maturity | 40,626 | 40,773
Subtotal: Drug Delivery (3.60%)* | 40,626 | 40,773
Drug Discovery & Development
Under 1 Year Maturity
Metuchen Pharmaceuticals LLC (14) | Drug Discovery & Development | Senior Secured | October 2020 | Interest rate PRIME + 7.25% or Floor rate of 10.75%, PIK Interest 1.35%, 2.25% Exit Fee | $ | 12,775 | 13,730 | 13,731
Subtotal: Under 1 Year Maturity | 13,730 | 13,731
1-5 Years Maturity
Acacia Pharma Inc. (5)(10)(11) | Drug Discovery & Development | Senior Secured | January 2022 | Interest rate PRIME + 4.50% or Floor rate of 9.25%, 3.95% Exit Fee | $ | 10,000 | 10,115 | 10,043
Aldeyra Therapeutics, Inc | Drug Discovery & Development | Senior Secured | October 2023 | Interest rate PRIME + 3.10% or Floor rate of 9.10%, 6.95% Exit Fee | $ | 15,000 | 14,969 | 14,969
Aveo Pharmaceuticals, Inc. (11) | Drug Discovery & Development | Senior Secured | July 2021 | Interest rate PRIME + 4.70% or Floor rate of 9.45%, 5.40% Exit Fee | $ | 8,084 | 8,404 | 8,340
Drug Discovery & Development | Senior Secured | July 2021 | Interest rate PRIME + 4.70% or Floor rate of 9.45%, 3.00% Exit Fee | $ | 8,084 | 8,280 | 8,274
Total Aveo Pharmaceuticals, Inc. | $ | 16,168 | 16,684 | 16,614
Axovant Gene Therapies Ltd. (p.k.a. Axovant Sciences Ltd.) (5)(10)(11) | Drug Discovery & Development | Senior Secured | March 2021 | Interest rate PRIME + 6.80% or Floor rate of 11.55% | $ | 15,731 | 15,608 | 15,608
BridgeBio Pharma LLC (12)(13)(16) | Drug Discovery & Development | Senior Secured | January 2023 | Interest rate PRIME + 3.85% or Floor rate of 8.85%, 6.35% Exit Fee | $ | 35,000 | 35,684 | 35,721
Drug Discovery & Development | Senior Secured | January 2023 | Interest rate PRIME + 2.85% or Floor rate of 8.60%, 5.75% Exit Fee | $ | 20,000 | 20,264 | 20,495
Drug Discovery & Development | Senior Secured | January 2023 | Interest rate PRIME + 3.10% or Floor rate of 9.10%, 5.75% Exit Fee | $ | 20,000 | 20,062 | 20,284
Total BridgeBio Pharma LLC | $ | 75,000 | 76,010 | 76,500
Chemocentryx, Inc. (10)(15) | Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 3.30% or Floor rate of 8.05%, 6.25% Exit Fee | $ | 20,000 | 20,306 | 20,501
Codiak Biosciences, Inc. (11)(17) | Drug Discovery & Development | Senior Secured | October 2024 | Interest rate PRIME + 3.75% or Floor rate of 9.00%, 5.50% Exit Fee | $ | 10,000 | 9,955 | 9,955
Constellation Pharmaceuticals, Inc. (12)(17) | Drug Discovery & Development | Senior Secured | April 2023 | Interest rate PRIME + 2.55% or Floor rate of 8.55%, 6.35% Exit Fee | $ | 30,000 | 30,139 | 30,636
Dermavant Sciences Ltd. (5)(10)(13) | Drug Discovery & Development | Senior Secured | June 2022 | Interest rate PRIME + 4.45% or Floor rate of 9.95%, 6.95% Exit Fee | $ | 20,000 | 20,085 | 20,113
Eidos Therapeutics, Inc. (10)(17) | Drug Discovery & Development | Senior Secured | October 2023 | Interest rate PRIME + 3.25% or Floor rate of 8.50%, 5.95% Exit Fee | $ | 8,750 | 8,728 | 8,728
Genocea Biosciences, Inc. (11) | Drug Discovery & Development | Senior Secured | May 2021 | Interest rate PRIME + 3.00% or Floor rate of 8.00%, 13.43% Exit Fee | $ | 12,922 | 13,502 | 13,542
Kaleido Biosciences, Inc. | Drug Discovery & Development | Senior Secured | January 2024 | Interest rate PRIME + 4.20% or Floor rate of 8.95%, 7.55% Exit Fee | $ | 22,500 | 22,372 | 22,373
Mesoblast (5)(10)(11) | Drug Discovery & Development | Senior Secured | March 2022 | Interest rate PRIME + 4.95% or Floor rate of 9.45%, 6.95% Exit Fee | $ | 50,000 | 51,552 | 51,547
Motif BioSciences Inc. (5)(8)(10) | Drug Discovery & Development | Senior Secured | September 2021 | Interest rate PRIME + 5.50% or Floor rate of 10.00%, 2.87% Exit Fee | $ | 6,738 | 6,732 | —
Nabriva Therapeutics (5)(10) | Drug Discovery & Development | Senior Secured | June 2023 | Interest rate PRIME + 4.30% or Floor rate of 9.80%, 6.95% Exit Fee | $ | 35,000 | 35,259 | 35,536
Paratek Pharmaceuticals, Inc. (11)(15)(16) | Drug Discovery & Development | Senior Secured | September 2021 | Interest rate PRIME + 2.75% or Floor rate of 8.50%, 4.13% Exit Fee | $ | 60,000 | 61,905 | 62,131
Drug Discovery & Development | Senior Secured | August 2022 | Interest rate PRIME + 2.10% or Floor rate of 7.85%, 6.95% Exit Fee | $ | 10,000 | 10,241 | 10,295

See notes to consolidated financial statements

21

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Maturity Date | Interest Rate and Floor (2) | Principal Amount | Cost (3) | Value (4)
Total Paratek Pharmaceuticals, Inc. | $ | 70,000 | 72,146 | 72,426
Replimune Group, Inc. (5)(10)(11) | Drug Discovery & Development | Senior Secured | August 2023 | Interest rate PRIME + 2.75% or Floor rate of 8.75%, 4.95% Exit Fee | $ | 10,000 | $ | 9,974 | $ | 9,974
Seres Therapeutics, Inc. (11) | Drug Discovery & Development | Senior Secured | November 2023 | Interest rate PRIME + 4.40% or Floor rate of 9.65%, 4.85% Exit Fee | $ | 25,000 | 24,804 | 24,804
Stealth Bio Therapeutics Corp. (5)(10)(11) | Drug Discovery & Development | Senior Secured | January 2021 | Interest rate PRIME + 5.50% or Floor rate of 9.50%, 6.68% Exit Fee | $ | 16,509 | 17,502 | 17,501
TG Therapeutics, Inc. (10)(13) | Drug Discovery & Development | Senior Secured | March 2022 | Interest rate PRIME + 4.75% or Floor rate of 10.25%, 3.25% Exit Fee | $ | 30,000 | 29,726 | 29,849
Tricida, Inc. (11)(15)(16)(17) | Drug Discovery & Development | Senior Secured | April 2023 | Interest rate PRIME + 2.35% or Floor rate of 8.35%, 11.92% Exit Fee | $ | 60,000 | 60,442 | 61,193
uniQure B.V. (5)(10)(11) | Drug Discovery & Development | Senior Secured | June 2023 | Interest rate PRIME + 3.35% or Floor rate of 8.85%, 7.72% Exit Fee | $ | 35,000 | 36,090 | 36,419
Urovant Sciences, Ltd. (5)(10)(13) | Drug Discovery & Development | Senior Secured | March 2023 | Interest rate PRIME + 4.65% or Floor rate of 10.15%, 4.25% Exit Fee | $ | 45,000 | 44,622 | 44,622
Verastem, Inc. (11) | Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 5,000 | 5,028 | 5,073
Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 5,000 | 5,048 | 5,094
Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 5,000 | 5,060 | 5,083
Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 10,000 | 10,066 | 10,157
Drug Discovery & Development | Senior Secured | December 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee | $ | 10,000 | 10,035 | 10,125
Total Verastem, Inc. | $ | 35,000 | 35,237 | 35,532
X4 Pharmaceuticals, Inc. (11)(17) | Drug Discovery & Development | Senior Secured | July 2023 | Interest rate PRIME + 2.75% or Floor rate of 8.75%, 7.98% Exit Fee | $ | 20,000 | 20,088 | 20,165
Yumanity Therapeutics, Inc. | Drug Discovery & Development | Senior Secured | January 2024 | Interest rate PRIME + 4.00% or Floor rate of 8.75%, 5.25% Exit Fee | $ | 15,000 | 14,732 | 14,732
Subtotal: 1-5 Years Maturity | 717,379 | 713,882
Subtotal: Drug Discovery & Development (64.22%)* | 731,109 | 727,613
Electronics & Computer Hardware
1-5 Years Maturity
Glo AB (5)(10)(13)(14) | Electronics & Computer Hardware | Senior Secured | February 2021 | Interest rate PRIME + 6.20% or Floor rate of 10.45%, PIK Interest 1.75%, 5.03% Exit Fee | $ | 8,215 | 8,730 | 4,410
Subtotal: 1-5 Years Maturity | 8,730 | 4,410
Subtotal: Electronics & Computer Hardware (0.39%)* | 8,730 | 4,410
Healthcare Services, Other
1-5 Years Maturity
Oak Street Health (11)(16) | Healthcare Services, Other | Senior Secured | June 2022 | Interest rate PRIME + 5.00% or Floor rate of 9.75%, 5.95% Exit Fee | $ | 80,000 | 81,190 | 81,270
The CM Group LLC (17) | Healthcare Services, Other | Senior Secured | June 2024 | Interest rate 1-month LIBOR + 8.35% or Floor rate of 9.35% | $ | 9,429 | 9,268 | 9,114
Velocity Clinical Research, Inc. (18) | Healthcare Services, Other | Senior Secured | November 2024 | Interest rate 3-month LIBOR + 9.08% or Floor rate of 10.08% | $ | 7,500 | 7,226 | 7,226
Subtotal: 1-5 Years Maturity | 97,684 | 97,610
Subtotal: Healthcare Services, Other (8.61%)* | 97,684 | 97,610
Information Services
1-5 Years Maturity
Planet Labs, Inc. (11) | Information Services | Senior Secured | June 2022 | Interest rate PRIME + 5.50% or Floor rate of 11.00%, 3.00% Exit Fee | $ | 20,000 | 19,526 | 19,583
Sapphire Digital, Inc. (p.k.a. MDX Medical, Inc.) (14)(15)(19) | Information Services | Senior Secured | June 2021 | Interest rate PRIME + 2.75% or Floor rate of 9.50%, PIK Interest 1.70%, 2.80% Exit Fee | $ | 15,554 | 15,647 | 15,682
Yipit, LLC (17)(18) | Information Services | Senior Secured | May 2024 | Interest rate 3-month LIBOR + 7.99% or Floor rate of 8.99% | $ | 10,625 | 10,415 | 10,272
Subtotal: 1-5 Years Maturity | 45,588 | 45,537
Subtotal: Information Services (4.02%)* | 45,588 | 45,537
Internet Consumer & Business Services
Under 1 Year Maturity
Snagajob.com, Inc. (13)(14) | Internet Consumer & Business Services | Senior Secured | August 2020 | Interest rate PRIME + 5.15% or Floor rate of 9.15%, PIK Interest 1.95%, 2.55% Exit Fee | $ | 42,676 | 43,344 | 43,344
Internet Consumer & Business Services | Senior Secured | August 2020 | Interest rate PRIME + 5.65% or Floor rate of 10.65%, PIK Interest 1.95%, 2.55% Exit Fee | $ | 5,134 | 5,127 | 5,127
Total Snagajob.com, Inc. | $ | 47,810 | 48,471 | 48,471
Subtotal: Under 1 Year Maturity | 48,471 | 48,471

See notes to consolidated financial statements

22

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Maturity Date | Interest Rate and Floor (2) | Principal Amount | Cost (3) | Value (4)
1-5 Years Maturity
AppDirect, Inc. (11)(19) | Internet Consumer & Business Services | Senior Secured | January 2022 | Interest rate PRIME + 5.70% or Floor rate of 9.95%, 3.45% Exit Fee | $ | 20,000 | $ | 20,288 | $ | 20,239
Arctic Wolf Networks, Inc. (13)(19) | Internet Consumer & Business Services | Senior Secured | April 2023 | Interest rate 3-month LIBOR + 7.75% or Floor rate of 10.10%, 7.55% Exit Fee | $ | 30,000 | 30,214 | 30,280
Cloudpay, Inc. (5)(10)(11) | Internet Consumer & Business Services | Senior Secured | April 2022 | Interest rate PRIME + 4.05% or Floor rate of 8.55%, 6.95% Exit Fee | $ | 15,000 | 15,304 | 15,169
Contentful, Inc. (5)(10)(11)(14) | Internet Consumer & Business Services | Senior Secured | July 2022 | Interest rate PRIME + 2.95% or Floor rate of 7.95%, PIK Interest 1.25%, 3.55% Exit Fee | $ | 3,794 | 3,793 | 3,786
ePayPolicy Holdings, LLC (17) | Internet Consumer & Business Services | Senior Secured | December 2024 | Interest rate 3-month LIBOR + 9.00% or Floor rate of 10.00% | $ | 8,000 | 7,758 | 7,758
EverFi, Inc. (11)(14)(16) | Internet Consumer & Business Services | Senior Secured | May 2022 | Interest rate PRIME + 3.90% or Floor rate of 9.15%, PIK Interest 2.30% | $ | 72,208 | 71,905 | 72,277
Greenphire, Inc. | Internet Consumer & Business Services | Senior Secured | January 2021 | Interest rate 3-month LIBOR + 8.00% or Floor rate of 9.00% | $ | 1,612 | 1,612 | 1,610
Internet Consumer & Business Services | Senior Secured | January 2021 | Interest rate PRIME + 3.75% or Floor rate of 8.75% | $ | 2,000 | 2,000 | 2,000
Total Greenphire, Inc. | $ | 3,612 | 3,612 | 3,610
Houzz, Inc. (14) | Internet Consumer & Business Services | Senior Secured | November 2022 | Interest rate PRIME + 3.20% or Floor rate of 8.45%, PIK Interest 2.50%, 4.50% Exit Fee | $ | 50,115 | 49,720 | 49,720
Intent (p.k.a. Intent Media, Inc.) (12) | Internet Consumer & Business Services | Senior Secured | September 2021 | Interest rate PRIME + 5.13% or Floor rate of 10.13%, 2.00% Exit Fee | $ | 15,200 | 15,141 | 15,034
Lendio, Inc. (11)(19) | Internet Consumer & Business Services | Senior Secured | April 2023 | Interest rate PRIME + 4.45% or Floor rate of 9.95%, 5.25% Exit Fee | $ | 5,000 | 4,985 | 4,999
Nextroll, Inc. (14)(19) | Internet Consumer & Business Services | Senior Secured | June 2022 | Interest rate PRIME + 3.85% or Floor rate of 9.35%, PIK Interest 2.95%, 3.50% Exit Fee | $ | 20,303 | 20,268 | 20,459
Patron Technology (18) | Internet Consumer & Business Services | Senior Secured | June 2024 | Interest rate 3-month LIBOR + 8.30% or Floor rate of 9.30% | $ | 35,750 | 34,776 | 35,400
Internet Consumer & Business Services | Senior Secured | June 2024 | Interest rate 3-month LIBOR + 8.30% or Floor rate of 9.30% | $ | 1,500 | 1,500 | 1,500
Total Patron Technology | $ | 37,250 | 36,276 | 36,900
Postmates, Inc. (19) | Internet Consumer & Business Services | Senior Secured | September 2022 | Interest rate PRIME + 3.85% or Floor rate of 8.85%, 8.05% Exit Fee | $ | 20,000 | 20,313 | 20,274
SeatGeek, Inc. (14)(17) | Internet Consumer & Business Services | Senior Secured | June 2023 | Interest rate PRIME + 5.00% or Floor rate of 10.50%, PIK Interest 0.50% | $ | 23,043 | 22,382 | 22,471
Skyword, Inc. (14) | Internet Consumer & Business Services | Senior Secured | September 2023 | Interest rate PRIME + 3.88% or Floor rate of 9.38%, PIK Interest 1.25%, 2.75% Exit Fee | $ | 12,042 | 11,886 | 11,886
Tectura Corporation (7)(8)(9)(14) | Internet Consumer & Business Services | Senior Secured | June 2021 | Interest rate FIXED 6.00%, PIK Interest 3.00% | $ | 21,407 | 21,407 | 9,586
Internet Consumer & Business Services | Senior Secured | June 2021 | PIK Interest 8.00% | $ | 10,680 | 240 | —
Total Tectura Corporation | $ | 32,087 | 21,647 | 9,586
Varsity Tutors LLC (14) | Internet Consumer & Business Services | Senior Secured | August 2023 | Interest rate PRIME + 5.25% or Floor rate of 10.75%, PIK Interest 0.55%, 3.00% Exit Fee | $ | 35,052 | 34,822 | 34,822
Wheels Up Partners LLC (11) | Internet Consumer & Business Services | Senior Secured | July 2022 | Interest rate 3-month LIBOR + 8.55% or Floor rate of 9.55% | $ | 17,129 | 17,026 | 16,988
Xometry, Inc. (13)(19) | Internet Consumer & Business Services | Senior Secured | November 2021 | Interest rate PRIME + 3.95% or Floor rate of 8.45%, 7.09% Exit Fee | $ | 11,000 | 11,345 | 11,401
Subtotal: 1-5 Years Maturity | 418,685 | 407,659
Subtotal: Internet Consumer & Business Services (40.26%)* | 467,156 | 456,130
Media/Content/Info
1-5 Years Maturity
Bustle (14)(15) | Media/Content/Info | Senior Secured | June 2023 | Interest rate PRIME + 4.35% or Floor rate of 9.35%, PIK Interest 1.95%, 4.34% Exit Fee | $ | 20,632 | 20,647 | 20,786
Subtotal: 1-5 Years Maturity | 20,647 | 20,786
Subtotal: Media/Content/Info (1.83%)* | 20,647 | 20,786
Medical Devices & Equipment
1-5 Years Maturity
Flowonix Medical Incorporated (11) | Medical Devices & Equipment | Senior Secured | October 2021 | Interest rate PRIME + 4.00% or Floor rate of 9.00%, 7.95% Exit Fee | $ | 7,561 | 8,178 | 8,158
Intuity Medical, Inc. (11)(15) | Medical Devices & Equipment | Senior Secured | June 2021 | Interest rate PRIME + 5.00% or Floor rate of 9.25%, 6.95% Exit Fee | $ | 14,188 | 14,906 | 14,810
Quanterix Corporation (11) | Medical Devices & Equipment | Senior Secured | October 2021 | Interest rate PRIME + 2.75% or Floor rate of 8.00%, 0.96% Exit Fee | $ | 7,688 | 7,683 | 7,728

See notes to consolidated financial statements

23

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Maturity Date | Interest Rate and Floor (2) | Principal Amount | Cost (3) | Value (4)
Rapid Micro Biosystems, Inc. (11)(15) | Medical Devices & Equipment | Senior Secured | April 2022 | Interest rate PRIME + 5.15% or Floor rate of 9.65%, 7.25% Exit Fee | $ | 18,000 | 18,586 | 18,454
Sebacia, Inc. (11)(15) | Medical Devices & Equipment | Senior Secured | January 2021 | Interest rate PRIME + 4.35% or Floor rate of 8.85%, 6.05% Exit Fee | $ | 11,000 | $ | 11,503 | $ | 11,426
Subtotal: 1-5 Years Maturity | 60,856 | 60,576
Subtotal: Medical Devices & Equipment (5.35%)* | 60,856 | 60,576
Semiconductors
1-5 Years Maturity
Elenion Technologies Corporation (13)(14) | Semiconductors | Senior Secured | February 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.75%, PIK Interest 2.25%, 5.00% Exit Fee | $ | 10,187 | 10,316 | 10,316
Subtotal: 1-5 Years Maturity | 10,316 | 10,316
Subtotal: Semiconductors (0.91%)* | 10,316 | 10,316
Software
Under 1 Year Maturity
Delphix Corp. (19) | Software | Senior Secured | September 2020 | Interest rate PRIME + 5.25% or Floor rate of 10.25%, 7.00% Exit Fee | $ | 10,000 | 9,878 | 9,878
Evernote Corporation (11)(14)(15)(19) | Software | Senior Secured | October 2020 | Interest rate PRIME + 5.45% or Floor rate of 8.95% | $ | 5,549 | 5,494 | 5,494
Lightbend, Inc. (14)(15) | Software | Senior Secured | June 2020 | Interest rate PRIME + 4.25% or Floor rate of 9.25%, PIK Interest 2.00%, 12.95% Exit Fee | $ | 2,026 | 2,026 | 2,026
Pollen, Inc. (15) | Software | Senior Secured | October 2020 | Interest rate PRIME + 4.25% or Floor rate of 8.50%, 5.95% Exit Fee | $ | 7,000 | 7,339 | 7,339
Subtotal: Under 1 Year Maturity | 24,737 | 24,737
1-5 Years Maturity
Abrigo (18) | Software | Senior Secured | March 2023 | Interest rate 3-month LIBOR + 7.88% or Floor rate of 8.88% | $ | 39,303 | 38,649 | 38,826
Software | Senior Secured | March 2023 | Interest rate 3-month LIBOR + 5.92% or Floor rate of 6.92% | $ | 2,362 | 2,304 | 2,304
Total Abrigo | $ | 41,665 | 40,953 | 41,130
Businessolver.com, Inc. (11)(16) | Software | Senior Secured | May 2023 | Interest rate 3-month LIBOR + 7.50% or Floor rate of 8.50% | $ | 58,650 | 57,776 | 57,760
Software | Senior Secured | May 2023 | Interest rate 3-month LIBOR + 7.50% or Floor rate of 8.50% and Interest rate PRIME + 6.5% or Floor rate of 8.50% | $ | 2,550 | 2,550 | 2,550
Total Businessolver.com, Inc. | $ | 61,200 | 60,326 | 60,310
Clarabridge, Inc. (12)(13)(14)(17) | Software | Senior Secured | April 2022 | Interest rate PRIME + 4.80% or Floor rate of 8.55%, PIK Interest 2.25% | $ | 48,268 | 47,907 | 48,006
Cloud 9 Software (13)(17) | Software | Senior Secured | April 2024 | Interest rate 3-month LIBOR + 8.20% or Floor rate of 9.20% | $ | 9,500 | 9,332 | 9,374
Cloudian, Inc. (11) | Software | Senior Secured | November 2022 | Interest rate PRIME + 3.25% or Floor rate of 8.25%, 9.75% Exit Fee | $ | 15,000 | 15,323 | 15,211
Couchbase, Inc. (11)(15)(19) | Software | Senior Secured | May 2023 | Interest rate PRIME + 5.25% or Floor rate of 10.75%, 3.75% Exit Fee | $ | 50,000 | 49,575 | 49,932
Dashlane, Inc. (11)(14)(17)(19) | Software | Senior Secured | April 2022 | Interest rate PRIME + 4.05% or Floor rate of 8.55%, PIK Interest 1.10%, 8.50% Exit Fee | $ | 10,180 | 10,457 | 10,481
Software | Senior Secured | March 2023 | Interest rate PRIME + 4.05% or Floor rate of 8.55%, PIK Interest 1.10%, 4.95% Exit Fee | $ | 10,081 | 9,920 | 9,899
Total Dashlane, Inc. | $ | 20,261 | 20,377 | 20,380
Evernote Corporation (11)(14)(15)(19) | Software | Senior Secured | July 2021 | Interest rate PRIME + 6.00% or Floor rate of 9.50%, PIK Interest 1.25% | $ | 4,126 | 4,055 | 4,038
Software | Senior Secured | July 2022 | Interest rate PRIME + 6.00% or Floor rate of 9.50%, PIK Interest 1.25% | $ | 5,077 | 5,012 | 5,065
Total Evernote Corporation | $ | 9,203 | 9,067 | 9,103
Ikon Science Limited (5)(10)(18) | Software | Senior Secured | October 2024 | Interest rate LIBOR + 9.00% or Floor rate of 10.00% | $ | 7,000 | 6,688 | 6,688
Insurance Technologies Corporation (11)(18) | Software | Senior Secured | March 2023 | Interest rate 3-month LIBOR + 7.90% or Floor rate of 8.90% | $ | 13,750 | 13,526 | 13,330
Jolt Software, Inc. (14) | Software | Senior Secured | October 2022 | Interest rate PRIME + 3.00% or Floor rate of 8.50%, PIK Interest 1.75%, 4.50% Exit Fee | $ | 5,017 | 5,004 | 5,004
Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.) (11)(18) | Software | Senior Secured | July 2023 | Interest rate 1-month LIBOR + 8.65% or Floor rate of 9.65% | $ | 8,785 | 8,589 | 8,531
Khoros (p.k.a Lithium Technologies) (11) | Software | Senior Secured | October 2022 | Interest rate 6-month LIBOR + 8.00% or Floor rate of 9.00% | $ | 12,000 | 11,835 | 11,825
Software | Senior Secured | October 2022 | Interest rate 6-month LIBOR + 8.00% or Floor rate of 9.00% | $ | 43,000 | 42,233 | 42,049
Total Khoros (p.k.a Lithium Technologies) | $ | 55,000 | 54,068 | 53,874

See notes to consolidated financial statements

24

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Maturity Date | Interest Rate and Floor (2) | Principal Amount | Cost (3) | Value (4)
Lastline, Inc. (19) | Software | Senior Secured | July 2022 | Interest rate PRIME + 5.45% or Floor rate of 10.95% | $ | 6,000 | 5,834 | 5,844
Lightbend, Inc. (14)(15) | Software | Senior Secured | February 2022 | Interest rate PRIME + 4.25% or Floor rate of 9.25%, PIK Interest 2.00%, 3.00% Exit Fee | $ | 16,509 | $ | 16,384 | $ | 16,333
Mobile Solutions Services (17)(18) | Software | Senior Secured | October 2024 | Interest rate 3-month LIBOR + 8.80% or Floor rate of 9.80% | $ | 5,500 | 5,329 | 5,329
Nuvolo Technologies Corporation (19) | Software | Senior Secured | October 2022 | Interest rate PRIME + 6.25% or Floor rate of 11.75% | $ | 13,000 | 12,815 | 12,877
OrthoFi, Inc. (13)(18) | Software | Senior Secured | April 2024 | Interest rate 3-month LIBOR + 8.28% or Floor rate of 9.28% | $ | 17,853 | 17,417 | 17,283
Quid, Inc. (11)(14)(15) | Software | Senior Secured | November 2022 | Interest rate PRIME + 4.45% or Floor rate of 9.95%, PIK Interest 2.25%, 3.61% Exit Fee | $ | 13,251 | 13,235 | 13,235
Regent Education (14) | Software | Senior Secured | January 2022 | Interest rate FIXED 10.00%, PIK Interest 2.00%, 7.94% Exit Fee | $ | 3,155 | 3,214 | 1,773
Salsa Labs, Inc. (11)(17) | Software | Senior Secured | April 2023 | Interest rate 3-month LIBOR + 8.15% or Floor rate of 9.15% | $ | 6,000 | 5,915 | 5,959
Software | Senior Secured | April 2023 | Interest rate 3-month LIBOR + 8.15% or Floor rate of 9.15% | $ | 150 | 150 | 151
Total Salsa Labs, Inc. | $ | 6,150 | 6,065 | 6,110
ThreatConnect, Inc. (13)(17)(18) | Software | Senior Secured | May 2024 | Interest rate 3-month LIBOR + 8.26% or Floor rate of 9.26% | $ | 4,500 | 4,365 | 4,387
Vela Trading Technologies (11)(18) | Software | Senior Secured | July 2022 | Interest rate 3-month LIBOR + 10.50% or Floor rate of 11.50% | $ | 19,095 | 18,721 | 18,721
ZeroFox, Inc. | Software | Senior Secured | January 2023 | Interest rate PRIME + 4.75% or Floor rate of 10.25%, 3.00% Exit Fee | $ | 15,000 | 14,927 | 14,948
ZocDoc (11)(19) | Software | Senior Secured | August 2021 | Interest rate PRIME + 6.20% or Floor rate of 10.95%, 2.00% Exit Fee | $ | 30,000 | 30,241 | 30,287
Subtotal: 1-5 Years Maturity | 489,282 | 488,000
Greater than 5 Years Maturity
Campaign Monitor Limited (11)(17)(19) | Software | Senior Secured | November 2025 | Interest rate 1-month LIBOR + 8.50% or Floor rate of 9.50% | $ | 29,333 | 28,676 | 28,511
Software | Senior Secured | November 2025 | Interest rate 1-month LIBOR + 8.50% or Floor rate of 9.50% | $ | 688 | 672 | 672
Total Campaign Monitor Limited | $ | 30,021 | 29,348 | 29,183
Imperva, Inc. (19) | Software | Senior Secured | January 2027 | Interest rate 3-month LIBOR + 7.75% or Floor rate of 8.75% | $ | 20,000 | 19,806 | 19,806
Subtotal: Greater than 5 Years Maturity | 49,154 | 48,989
Subtotal: Software (49.58%)* | 563,173 | 561,726
Sustainable and Renewable Technology
1-5 Years Maturity
Impossible Foods, Inc. (12)(13) | Sustainable and Renewable Technology | Senior Secured | January 2022 | Interest rate PRIME + 3.95% or Floor rate of 8.95%, 9.00% Exit Fee | $ | 50,000 | 51,843 | 51,780
Proterra, Inc. (11)(14)(19) | Sustainable and Renewable Technology | Senior Secured | May 2021 | Interest rate PRIME + 5.05% or Floor rate of 10.55%, PIK Interest 1.75% | $ | 10,101 | 10,059 | 10,100
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) (6)(8)(14)(19) | Sustainable and Renewable Technology | Senior Secured | December 2020 | Interest rate FIXED 6.73%, PIK Interest 6.73%, 6.67% Exit Fee | $ | 10,000 | 10,775 | 10,512
Sustainable and Renewable Technology | Senior Secured | December 2020 | PIK Interest 10.00% | $ | 683 | 683 | 664
Sustainable and Renewable Technology | Senior Secured | December 2020 | Interest rate FIXED 8.85%, PIK Interest 8.85% | $ | 1,492 | 1,492 | 1,439
Total Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) | $ | 12,175 | 12,950 | 12,615
Subtotal: 1-5 Years Maturity | 74,852 | 74,495
Subtotal: Sustainable and Renewable Technology (6.57%)* | 74,852 | 74,495
Total: Debt Investments (189.63%)* | 2,170,140 | 2,148,592

See notes to consolidated financial statements

25

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
Equity Investments
Communications & Networking
Peerless Network Holdings, Inc. | Communications & Networking | Equity | Preferred Series A | 1,135,000 | $ | 1,230 | $ | 3,955
Subtotal: Communications & Networking (0.35%)* | 1,230 | 3,955
Diversified Financial Services
Gibraltar Business Capital, LLC (7) | Diversified Financial Services | Equity | Common Stock | 830,000 | 1,884 | 2,380
Diversified Financial Services | Equity | Preferred Series A | 10,602,752 | 26,122 | 33,000
Total Gibraltar Business Capital, LLC | 11,432,752 | 28,006 | 35,380
Subtotal: Diversified Financial Services (3.11%)* | 28,006 | 35,380
Drug Delivery
AcelRx Pharmaceuticals, Inc. (4) | Drug Delivery | Equity | Common Stock | 176,730 | 1,329 | 373
BioQ Pharma Incorporated (15) | Drug Delivery | Equity | Preferred Series D | 165,000 | 500 | 768
Kaleo, Inc. | Drug Delivery | Equity | Preferred Series B | 82,500 | 1,007 | 3,067
Neos Therapeutics, Inc. (4)(15) | Drug Delivery | Equity | Common Stock | 125,000 | 1,500 | 189
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) (4) | Drug Delivery | Equity | Common Stock | 2,498 | 309 | 7
Subtotal: Drug Delivery (0.39%)* | 4,645 | 4,404
Drug Discovery & Development
Aveo Pharmaceuticals, Inc. (4)(15) | Drug Discovery & Development | Equity | Common Stock | 1,901,791 | 1,715 | 1,189
Axovant Gene Therapies Ltd. (p.k.a. Axovant Sciences Ltd.) (4)(5)(10) | Drug Discovery & Development | Equity | Common Stock | 16,228 | 1,269 | 83
BridgeBio Pharma LLC (4)(16) | Drug Discovery & Development | Equity | Common Stock | 203,579 | 2,000 | 7,135
Cerecor, Inc. (4) | Drug Discovery & Development | Equity | Common Stock | 119,087 | 1,000 | 642
Concert Pharmaceuticals, Inc. (4)(10) | Drug Discovery & Development | Equity | Common Stock | 70,796 | 1,367 | 653
Dare Biosciences, Inc. (4) | Drug Discovery & Development | Equity | Common Stock | 13,550 | 1,000 | 11
Dynavax Technologies (4)(10) | Drug Discovery & Development | Equity | Common Stock | 20,000 | 550 | 114
Eidos Therapeutics, Inc. (4)(10) | Drug Discovery & Development | Equity | Common Stock | 15,000 | 255 | 861
Genocea Biosciences, Inc. (4) | Drug Discovery & Development | Equity | Common Stock | 27,932 | 2,000 | 58
Insmed, Incorporated (4) | Drug Discovery & Development | Equity | Common Stock | 50,771 | 717 | 1,212
Melinta Therapeutics (4) | Drug Discovery & Development | Equity | Common Stock | 10,364 | 2,000 | 6
Paratek Pharmaceuticals, Inc. (4)(16) | Drug Discovery & Development | Equity | Common Stock | 76,362 | 2,744 | 307
Rocket Pharmaceuticals, Ltd. (4) | Drug Discovery & Development | Equity | Common Stock | 944 | 1,500 | 21
Savara, Inc. (4)(15) | Drug Discovery & Development | Equity | Common Stock | 11,119 | 203 | 50
uniQure B.V. (4)(5)(10) | Drug Discovery & Development | Equity | Common Stock | 17,175 | 332 | 1,231
X4 Pharmaceuticals, Inc. (4) | Drug Discovery & Development | Equity | Common Stock | 83,334 | 640 | 891
Subtotal: Drug Discovery & Development (1.28%)* | 19,292 | 14,464
Healthcare Services, Other
23andMe, Inc. | Healthcare Services, Other | Equity | Common Stock | 360,000 | 5,094 | 5,196
Chromadex Corporation (4) | Healthcare Services, Other | Equity | Common Stock | 44,264 | 157 | 191
Subtotal: Healthcare Services, Other (0.48%)* | 5,251 | 5,387
Information Services
DocuSign, Inc. (4) | Information Services | Equity | Common Stock | 251,000 | 3,871 | 13,795
Subtotal: Information Services (1.22%)* | 3,871 | 13,795
Internet Consumer & Business Services
Blurb, Inc. | Internet Consumer & Business Services | Equity | Preferred Series B | 220,653 | 175 | 46
Contentful, Inc. (5)(10) | Internet Consumer & Business Services | Equity | Preferred Series D | 217 | 500 | 443
Countable Corporation (p.k.a. Brigade Group, Inc.) | Internet Consumer & Business Services | Equity | Common Stock | 9,023 | 93 | —
DoorDash, Inc. | Internet Consumer & Business Services | Equity | Common Stock | 105,000 | 6,051 | 14,422
Lyft, Inc. (4) | Internet Consumer & Business Services | Equity | Common Stock | 200,738 | 10,487 | 8,636
Nextdoor.com, Inc. | Internet Consumer & Business Services | Equity | Common Stock | 328,190 | 4,854 | 6,692
OfferUp, Inc. | Internet Consumer & Business Services | Equity | Preferred Series A | 286,080 | 1,663 | 1,470
Internet Consumer & Business Services | Equity | Preferred Series A-1 | 108,710 | 632 | 559
Total OfferUp, Inc. | 394,790 | 2,295 | 2,029
Oportun (4) | Internet Consumer & Business Services | Equity | Common Stock | 37,393 | 500 | 890
Tectura Corporation (7) | Internet Consumer & Business Services | Equity | Common Stock | 414,994,863 | 900 | —
Internet Consumer & Business Services | Equity | Preferred Series BB | 1,000,000 | — | —
Total Tectura Corporation | 415,994,863 | 900 | —
Subtotal: Internet Consumer & Business Services (2.92%)* | 25,855 | 33,158
Medical Devices & Equipment
Flowonix Medical Incorporated | Medical Devices & Equipment | Equity | Preferred Series AA | 221,893 | 1,500 | —
Gelesis, Inc. | Medical Devices & Equipment | Equity | Common Stock | 227,013 | — | 679
Medical Devices & Equipment | Equity | Preferred Series A-1 | 191,210 | 425 | 598
Medical Devices & Equipment | Equity | Preferred Series A-2 | 191,626 | 500 | 584
Total Gelesis, Inc. | 609,849 | 925 | 1,861
Medrobotics Corporation (15) | Medical Devices & Equipment | Equity | Preferred Series E | 136,798 | 250 | —
Medical Devices & Equipment | Equity | Preferred Series F | 73,971 | 155 | —
Medical Devices & Equipment | Equity | Preferred Series G | 163,934 | 500 | —
Total Medrobotics Corporation | 374,703 | 905 | —

See notes to consolidated financial statements

26

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
Optiscan Biomedical, Corp. (6) | Medical Devices & Equipment | Equity | Preferred Series B | 61,855 | $ | 3,000 | $ | 463
Medical Devices & Equipment | Equity | Preferred Series C | 19,273 | 655 | 127
Medical Devices & Equipment | Equity | Preferred Series D | 551,038 | 5,257 | 3,784
Medical Devices & Equipment | Equity | Preferred Series E | 507,103 | 4,239 | 4,610
Total Optiscan Biomedical, Corp. | 1,139,269 | 13,151 | 8,984
Outset Medical, Inc. | Medical Devices & Equipment | Equity | Preferred Series B | 232,061 | 527 | 615
ViewRay, Inc. (4)(15) | Medical Devices & Equipment | Equity | Common Stock | 36,457 | 333 | 154
Subtotal: Medical Devices & Equipment (1.03%)* | 17,341 | 11,614
Software
CapLinked, Inc. | Software | Equity | Preferred Series A-3 | 53,614 | 51 | 95
Docker, Inc. | Software | Equity | Common Stock | 20,000 | 4,284 | 22
Druva Holdings, Inc. (p.k.a. Druva, Inc.) | Software | Equity | Preferred Series 2 | 458,841 | 1,000 | 1,883
Software | Equity | Preferred Series 3 | 93,620 | 300 | 432
Total Druva Holdings, Inc. (p.k.a. Druva, Inc.) | 552,461 | 1,300 | 2,315
HighRoads, Inc. | Software | Equity | Common Stock | 190 | 307 | —
Palantir Technologies | Software | Equity | Preferred Series D | 9,535 | 47 | 49
Software | Equity | Preferred Series E | 1,749,089 | 10,489 | 8,932
Software | Equity | Preferred Series G | 326,797 | 2,211 | 1,668
Total Palantir Technologies | 2,085,421 | 12,747 | 10,649
Sprinklr, Inc. | Software | Equity | Common Stock | 700,000 | 3,749 | 4,159
Subtotal: Software (1.52%)* | 22,438 | 17,240
Surgical Devices
Gynesonics, Inc. (15) | Surgical Devices | Equity | Preferred Series B | 219,298 | 250 | 7
Surgical Devices | Equity | Preferred Series C | 656,538 | 282 | 21
Surgical Devices | Equity | Preferred Series D | 1,991,157 | 712 | 70
Surgical Devices | Equity | Preferred Series E | 2,786,367 | 429 | 121
Surgical Devices | Equity | Preferred Series F | 1,523,693 | 118 | 148
Surgical Devices | Equity | Preferred Series F-1 | 2,418,125 | 150 | 201
Total Gynesonics, Inc. | 9,595,178 | 1,941 | 568
TransMedics Group, Inc. (p.k.a Transmedics, Inc.) (4) | Surgical Devices | Equity | Common Stock | 162,617 | 2,550 | 3,091
Subtotal: Surgical Devices (0.32%)* | 4,491 | 3,659
Sustainable and Renewable Technology
Impossible Foods, Inc. | Sustainable and Renewable Technology | Equity | Preferred Series E-1 | 188,611 | 2,000 | 1,496
Modumetal, Inc. | Sustainable and Renewable Technology | Equity | Preferred Series A-1 | 103,584 | 500 | 8
Proterra, Inc. | Sustainable and Renewable Technology | Equity | Preferred Series 5 | 99,280 | 500 | 493
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) (6) | Sustainable and Renewable Technology | Equity | Common Stock | 488 | 61,502 | —
Subtotal: Sustainable and Renewable Technology (0.18%)* | 64,502 | 1,997
Total: Equity Investments (12.80%)* | 196,922 | 145,053
Communications & Networking
Peerless Network Holdings, Inc. | Communications & Networking | Warrant | Common Stock | 3,328 | — | 7
Spring Mobile Solutions, Inc. | Communications & Networking | Warrant | Common Stock | 2,834,375 | 418 | —
Subtotal: Communications & Networking (0.00%)* | 418 | 7
Consumer & Business Products
Gadget Guard (15) | Consumer & Business Products | Warrant | Common Stock | 1,662,441 | 228 | —
Intelligent Beauty, Inc. | Consumer & Business Products | Warrant | Preferred Series B | 190,234 | 230 | 475
The Neat Company | Consumer & Business Products | Warrant | Common Stock | 54,054 | 365 | —
Whoop, Inc. | Consumer & Business Products | Warrant | Preferred Series C | 68,627 | 18 | 55
Subtotal: Consumer & Business Products (0.05%)* | 841 | 530
Drug Delivery
Aerami Therapeutics (p.k.a. Dance Biopharm, Inc.) (15) | Drug Delivery | Warrant | Common Stock | 110,882 | 74 | —
Agile Therapeutics, Inc. (4) | Drug Delivery | Warrant | Common Stock | 180,274 | 730 | 113
BioQ Pharma Incorporated | Drug Delivery | Warrant | Common Stock | 459,183 | 1 | 928
Neos Therapeutics, Inc. (4)(15) | Drug Delivery | Warrant | Common Stock | 70,833 | 285 | —
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) (4) | Drug Delivery | Warrant | Common Stock | 3,929 | 390 | —
Pulmatrix Inc. (4) | Drug Delivery | Warrant | Common Stock | 2,515 | 116 | —
ZP Opco, Inc. (4) | Drug Delivery | Warrant | Common Stock | 3,618 | 265 | —
Subtotal: Drug Delivery (0.09%)* | 1,861 | 1,041
Drug Discovery & Development
Acacia Pharma Inc. (4)(5)(10) | Drug Discovery & Development | Warrant | Common Stock | 201,330 | 304 | 109
ADMA Biologics, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 89,750 | 295 | 39
Brickell Biotech, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 9,005 | 119 | —
Cerecor, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 22,328 | 70 | 12
Concert Pharmaceuticals, Inc. (4)(10)(15) | Drug Discovery & Development | Warrant | Common Stock | 61,273 | 178 | 75

See notes to consolidated financial statements

27

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
CTI BioPharma Corp. (4) | Drug Discovery & Development | Warrant | Common Stock | 29,239 | $ | 165 | $ | —
CytRx Corporation (4)(15) | Drug Discovery & Development | Warrant | Common Stock | 105,694 | 160 | —
Dare Biosciences, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 17,190 | 369 | —
Dermavant Sciences Ltd. (5)(10) | Drug Discovery & Development | Warrant | Common Stock | 223,642 | 101 | 108
Dicerna Pharmaceuticals, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 200 | 28 | —
Evofem Biosciences, Inc. (4)(15) | Drug Discovery & Development | Warrant | Common Stock | 7,806 | 266 | 19
Genocea Biosciences, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 41,176 | 165 | 15
Immune Pharmaceuticals (4) | Drug Discovery & Development | Warrant | Common Stock | 10,742 | 164 | —
Melinta Therapeutics (4) | Drug Discovery & Development | Warrant | Common Stock | 8,109 | 625 | —
Motif BioSciences Inc. (4)(5)(10)(15) | Drug Discovery & Development | Warrant | Common Stock | 73,452 | 282 | —
Myovant Sciences, Ltd. (4)(5)(10) | Drug Discovery & Development | Warrant | Common Stock | 73,710 | 460 | 485
Ology Bioservices, Inc. (15) | Drug Discovery & Development | Warrant | Common Stock | 171,389 | 838 | —
Paratek Pharmaceuticals, Inc. (4)(15)(16) | Drug Discovery & Development | Warrant | Common Stock | 94,841 | 204 | 20
Sorrento Therapeutics, Inc. (4)(10) | Drug Discovery & Development | Warrant | Common Stock | 306,748 | 889 | 270
Stealth Bio Therapeutics Corp. (4)(5)(10) | Drug Discovery & Development | Warrant | American Depositary Shares | 41,667 | 158 | 2
TG Therapeutics, Inc. (4)(10) | Drug Discovery & Development | Warrant | Common Stock | 147,058 | 564 | 920
Tricida, Inc. (4)(15)(16) | Drug Discovery & Development | Warrant | Common Stock | 131,998 | 1,102 | 2,667
Urovant Sciences, Ltd. (4)(5)(10) | Drug Discovery & Development | Warrant | Common Stock | 99,777 | 383 | 715
X4 Pharmaceuticals, Inc. (4) | Drug Discovery & Development | Warrant | Common Stock | 108,334 | 673 | 302
XOMA Corporation (4)(10)(15) | Drug Discovery & Development | Warrant | Common Stock | 9,063 | 279 | 6
Yumanity Therapeutics, Inc. | Drug Discovery & Development | Warrant | Class B Preferred Units | 34,946 | 110 | 114
Subtotal: Drug Discovery & Development (0.51%)* | 8,951 | 5,878
Electronics & Computer Hardware
908 Devices, Inc. (15) | Electronics & Computer Hardware | Warrant | Preferred Series D | 79,856 | 101 | 52
Subtotal: Electronics & Computer Hardware (0.00%)* | 101 | 52
Information Services
InMobi Inc. (5)(10) | Information Services | Warrant | Common Stock | 65,587 | 82 | —
Netbase Solutions, Inc. | Information Services | Warrant | Preferred Series 1 | 60,000 | 356 | 416
Planet Labs, Inc. | Information Services | Warrant | Common Stock | 274,160 | 565 | 224
RichRelevance, Inc. | Information Services | Warrant | Preferred Series E | 112,612 | 98 | —
Sapphire Digital, Inc. (p.k.a. MDX Medical, Inc.) (15) | Information Services | Warrant | Common Stock | 2,812,500 | 283 | 122
Subtotal: Information Services (0.07%)* | 1,384 | 762
Internet Consumer & Business Services
Aria Systems, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series G | 231,535 | 73 | —
Blurb, Inc. (15) | Internet Consumer & Business Services | Warrant | Preferred Series C | 234,280 | 636 | 13
Cloudpay, Inc. (5)(10) | Internet Consumer & Business Services | Warrant | Preferred Series B | 6,763 | 54 | 18
Contentful, Inc. (5)(10) | Internet Consumer & Business Services | Warrant | Preferred Series C | 82 | 1 | 17
Fastly, Inc. (4) | Internet Consumer & Business Services | Warrant | Common Stock | 76,098 | 71 | 617
First Insight, Inc. (15) | Internet Consumer & Business Services | Warrant | Preferred Series B | 75,917 | 96 | 151
Houzz, Inc. | Internet Consumer & Business Services | Warrant | Common Stock | 529,661 | 20 | 14
Intent (p.k.a. Intent Media, Inc.) | Internet Consumer & Business Services | Warrant | Common Stock | 140,077 | 168 | 214
Interactions Corporation | Internet Consumer & Business Services | Warrant | Preferred Series G-3 | 68,187 | 204 | 445
Just Fabulous, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series B | 206,184 | 1,102 | 1,622
Lendio, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series D | 127,032 | 39 | 14
LogicSource | Internet Consumer & Business Services | Warrant | Preferred Series C | 79,625 | 30 | 122
Oportun (4) | Internet Consumer & Business Services | Warrant | Common Stock | 23,514 | 78 | 279
Postmates, Inc. | Internet Consumer & Business Services | Warrant | Common Stock | 189,865 | 317 | 83
RumbleON, Inc. (4) | Internet Consumer & Business Services | Warrant | Common Stock | 102,768 | 87 | 6
SeatGeek, Inc. | Internet Consumer & Business Services | Warrant | Common Stock | 689,880 | 662 | 596
ShareThis, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series C | 493,502 | 547 | —
Skyword, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series A | 444,444 | 83 | 43
Snagajob.com, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series A | 1,800,000 | 782 | 40
Internet Consumer & Business Services | Warrant | Preferred Series B | 1,211,537 | 62 | 15
Total Snagajob.com, Inc. | 3,011,537 | 844 | 55
Tapjoy, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series D | 748,670 | 316 | 2
The Faction Group LLC | Internet Consumer & Business Services | Warrant | Preferred Series AA | 8,076 | 234 | 395
Thumbtack, Inc. | Internet Consumer & Business Services | Warrant | Common Stock | 190,953 | 553 | 958
Xometry, Inc. | Internet Consumer & Business Services | Warrant | Preferred Series B | 87,784 | 47 | 180
Subtotal: Internet Consumer & Business Services (0.52%)* | 6,262 | 5,844
Media/Content/Info
Machine Zone, Inc. | Media/Content/Info | Warrant | Common Stock | 1,552,710 | 1,960 | 285
Napster | Media/Content/Info | Warrant | Common Stock | 715,755 | 384 | —
WP Technology, Inc. (Wattpad, Inc.) (5)(10) | Media/Content/Info | Warrant | Common Stock | 255,818 | 3 | —
Zoom Media Group, Inc. | Media/Content/Info | Warrant | Preferred Series A | 1,204 | 348 | —
Subtotal: Media/Content/Info (0.03%)* | 2,695 | 285
Medical Devices & Equipment

See notes to consolidated financial statements

28

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
Aspire Bariatrics, Inc. (15) | Medical Devices & Equipment | Warrant | Preferred Series B-1 | 112,858 | $ | 455 | $ | —
Flowonix Medical Incorporated | Medical Devices & Equipment | Warrant | Preferred Series AA | 155,325 | 362 | —
Medical Devices & Equipment | Warrant | Preferred Series BB | 725,806 | 351 | —
Total Flowonix Medical Incorporated | 881,131 | 713 | —
Gelesis, Inc. | Medical Devices & Equipment | Warrant | Preferred Series A-1 | 74,784 | 78 | 172
InspireMD, Inc. (4)(5)(10) | Medical Devices & Equipment | Warrant | Common Stock | 1,105 | — | —
Intuity Medical, Inc. (15) | Medical Devices & Equipment | Warrant | Preferred Series 5 | 1,819,078 | 294 | 338
Medrobotics Corporation (15) | Medical Devices & Equipment | Warrant | Preferred Series E | 455,539 | 370 | —
NinePoint Medical, Inc. | Medical Devices & Equipment | Warrant | Preferred Series A-1 | 587,840 | 170 | 38
Optiscan Biomedical, Corp. (6) | Medical Devices & Equipment | Warrant | Preferred Series E | 74,424 | 572 | 209
Outset Medical, Inc. | Medical Devices & Equipment | Warrant | Preferred Series A | 500,000 | 402 | 382
Sebacia, Inc. | Medical Devices & Equipment | Warrant | Preferred Series D | 778,301 | 133 | 4
SonaCare Medical, LLC | Medical Devices & Equipment | Warrant | Preferred Series A | 6,464 | 188 | —
Tela Bio, Inc. (4) | Medical Devices & Equipment | Warrant | Common Stock | 15,712 | 61 | 8
Subtotal: Medical Devices & Equipment (0.10%)* | 3,436 | 1,151
Semiconductors
Achronix Semiconductor Corporation | Semiconductors | Warrant | Preferred Series C | 360,000 | 160 | 6
Semiconductors | Warrant | Preferred Series D-2 | 750,000 | 99 | 330
Total Achronix Semiconductor Corporation | 1,110,000 | 259 | 336
Elenion Technologies Corporation | Semiconductors | Warrant | Preferred Series C | 225 | 8 | 6
Subtotal: Semiconductors (0.03%)* | 267 | 342
Software
Actifio, Inc. | Software | Warrant | Common Stock | 73,584 | 249 | 93
Software | Warrant | Preferred Series F | 31,673 | 343 | 91
Total Actifio, Inc. | 105,257 | 592 | 184
BryterCX, Inc. (p.k.a. ClickFox, Inc.) (15) | Software | Warrant | Preferred Series B | 492,877 | 152 | —
Software | Warrant | Preferred Series C | 592,019 | 730 | —
Software | Warrant | Preferred Series C-A | 2,218,214 | 230 | 1
Total BryterCX, Inc. (p.k.a. ClickFox, Inc.) | 3,303,110 | 1,112 | 1
CareCloud Corporation (15) | Software | Warrant | Common Stock | 13,499 | 258 | —
Cloudian, Inc. | Software | Warrant | Common Stock | 477,454 | 71 | 24
Couchbase, Inc. | Software | Warrant | Common Stock | 263,377 | 462 | 409
Dashlane, Inc. | Software | Warrant | Common Stock | 346,747 | 303 | 424
Delphix Corp. | Software | Warrant | Common Stock | 203,541 | 407 | 529
DNAnexus, Inc. | Software | Warrant | Preferred Series C | 909,091 | 97 | 68
Evernote Corporation | Software | Warrant | Common Stock | 62,500 | 106 | 67
Fuze, Inc. (15) | Software | Warrant | Preferred Series F | 256,158 | 89 | —
Lastline, Inc. | Software | Warrant | Common Stock | 363,636 | 133 | 136
Lightbend, Inc. (15) | Software | Warrant | Preferred Series C-1 | 854,787 | 130 | 122
Message Systems, Inc. (15) | Software | Warrant | Preferred Series C | 503,718 | 334 | 731
Nuvolo Technologies Corporation | Software | Warrant | Common Stock | 30,000 | 43 | 73
OneLogin, Inc. (15) | Software | Warrant | Common Stock | 381,620 | 305 | 602
Poplicus, Inc. | Software | Warrant | Common Stock | 132,168 | — | —
Quid, Inc. (15) | Software | Warrant | Preferred Series D | 71,576 | 1 | —
Software | Warrant | Preferred Series E | 40,261 | 1 | —
Total Quid, Inc. | 111,837 | 2 | —
RapidMiner, Inc. | Software | Warrant | Preferred Series C-1 | 4,982 | 24 | 20
RedSeal Inc. (15) | Software | Warrant | Preferred Series C-Prime | 640,603 | 66 | 2
Signpost, Inc. | Software | Warrant | Series Junior 1 Preferred | 474,019 | 314 | —
ZeroFox, Inc. | Software | Warrant | Preferred Series C-1 | 486,263 | 57 | 87
Subtotal: Software (0.31%)* | 4,905 | 3,479
Specialty Pharmaceuticals
Alimera Sciences, Inc. (4) | Specialty Pharmaceuticals | Warrant | Common Stock | 114,513 | 861 | 36
Subtotal: Specialty Pharmaceuticals (0.00%)* | 861 | 36
Surgical Devices
Gynesonics, Inc. (15) | Surgical Devices | Warrant | Preferred Series C | 180,480 | 74 | 4
Surgical Devices | Warrant | Preferred Series D | 1,575,965 | 320 | 13
Total Gynesonics, Inc. | 1,756,445 | 394 | 17
TransMedics Group, Inc. (p.k.a Transmedics, Inc.) (4) | Surgical Devices | Warrant | Common Stock | 64,441 | 139 | 444
Subtotal: Surgical Devices (0.04%)* | 533 | 461
Sustainable and Renewable Technology
Agrivida, Inc. | Sustainable and Renewable Technology | Warrant | Preferred Series D | 471,327 | 120 | —
Calera, Inc. | Sustainable and Renewable Technology | Warrant | Preferred Series C | 44,529 | 513 | —
Fulcrum Bioenergy, Inc. | Sustainable and Renewable Technology | Warrant | Preferred Series C-1 | 280,897 | 275 | 537
GreatPoint Energy, Inc. (15) | Sustainable and Renewable Technology | Warrant | Preferred Series D-1 | 393,212 | 548 | —
Kinestral Technologies, Inc. | Sustainable and Renewable Technology | Warrant | Preferred Series A | 325,000 | 155 | 168

See notes to consolidated financial statements

29

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2019

(unaudited)

(dollars in thousands)

Portfolio Company | Sub-Industry | Type of Investment (1) | Series | Shares | Cost (3) | Value (4)
Sustainable and Renewable Technology | Warrant | Preferred Series B | 131,883 | $ | 63 | $ | 52
Total Kinestral Technologies, Inc. | 456,883 | 218 | 220
NantEnergy, Inc. (p.k.a. Fluidic, Inc.) | Sustainable and Renewable Technology | Warrant | Preferred Series D | 61,804 | 102 | —
Polyera Corporation (15) | Sustainable and Renewable Technology | Warrant | Preferred Series C | 311,609 | 338 | —
Proterra, Inc. | Sustainable and Renewable Technology | Warrant | Common Stock | 36,630 | 1 | 4
Sustainable and Renewable Technology | Warrant | Preferred Series 4 | 477,517 | 41 | 252
Total Proterra, Inc. | 514,147 | 42 | 256
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) (6) | Sustainable and Renewable Technology | Warrant | Class A Units | 0.69 | — | —
TAS Energy, Inc. | Sustainable and Renewable Technology | Warrant | Preferred Series AA | 428,571 | 299 | —
Subtotal: Sustainable and Renewable Technology (0.09%)* | 2,455 | 1,013
Total: Warrant Investments (1.84%)* | 34,970 | 20,881
Total Investments in Securities (204.27%)* | $ | 2,402,032 | $ | 2,314,526
* | Value as a percent of net assets
(1) | Preferred and common stock, warrants, and equity interests are generally non-income producing.
(2) | Interest rate PRIME represents 4.75% at December 31, 2019. 1-month LIBOR, 3-month LIBOR, and 12-month LIBOR represent, 1.76%, 1.91%, and 2.00%, respectively, at December 31, 2019.
(3) | Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $70.3 million, $144.1 million, and $73.8 million, respectively. The tax cost of investments is $2.4 billion.
(4) | Except for warrants in 35 publicly traded companies and common stock in 25 publicly traded companies, all investments are restricted at December 31, 2019 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s board of directors (the “Board of Directors”). No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
(5) | Non-U.S. company or the company’s principal place of business is outside the United States.
(6) | Affiliate investment as defined under the Investment Company Act of 1940, as amended, (the “1940 Act”) in which Hercules owns at least 5% but generally less than 25% of the company’s voting securities.
(7) | Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.
(8) | Debt is on non-accrual status at December 31, 2019 and is therefore considered non-income producing. Note that only the PIK portion is on non-accrual for the Company’s debt investments in Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.), and Tectura Corporation.
(9) | Denotes that all or a portion of the debt investment is convertible debt.
(10) | Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.
(11) | Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitization (as defined in Note 4).
(12) | Denotes that all or a portion of the debt investment is pledged as collateral under the Wells Facility (as defined in Note 4).
(13) | Denotes that all or a portion of the debt investment is pledged as collateral under the Union Bank Facility (as defined in Note 4).
(14) | Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.
(15) | Denotes that all or a portion of the investment in this portfolio company is held by HT III, the Company’s wholly owned small business investment company, or SBIC, subsidiary.
(16) | Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total assets at December 31, 2019.
(17) | Denotes that there is an unfunded contractual commitment available at the request of this portfolio company at December 31, 2019. Refer to Note 10.
(18) | Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition.
(19) | Denotes second lien senior secured debt.

See notes to consolidated financial statements

30

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business and Basis of Presentation

Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. The Company sources its investments through its principal office located in Palo Alto, CA, as well as through its additional offices in Boston, MA, New York, NY, Bethesda, MD, Hartford, CT, and San Diego, CA. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.

The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was subject to tax as a corporation under Subchapter C of the Internal Revenue Code of 1986, as amended (the “Code”). Effective January 1, 2006, the Company elected to be treated for tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Code (see Note 5). As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946 (“Financial Services – Investment Companies”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”).

The Company does not currently use Commodity Futures Trading Commission (“CFTC”) derivatives, however, to the extent that it uses CFTC derivatives in the future, it intends to do so below prescribed levels and will not market itself as a “commodity pool” or a vehicle for trading such instruments. The Company has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”), pursuant to Rule 4.5 under the CEA. The Company is not, therefore, subject to registration or regulation as a “commodity pool operator” under the CEA.

Hercules Technology III, L.P. (“HT III”) and Hercules Technology IV, L.P. (“HT IV”) are Delaware limited partnerships that were formed in September 2009 and December 2010, respectively. On May 26, 2010, HT III was licensed to operate as a small business investment company (“SBIC”) under the authority of the Small Business Administration (“SBA”). Hercules Technology II, L.P. (“HT II”) was a Delaware limited partnership formed in January 2005 to operate as an SBIC. On July 13, 2018, the Company completed repayment of the remaining outstanding HT II debentures and subsequently surrendered the SBA license with respect to HT II and dissolved the entity.

As an SBIC, HT III is subject to a variety of regulations concerning, among other things, the size and nature of the companies in which it may invest and the structure of those investments. HT IV was formed in anticipation of receiving an additional SBIC license; however, the Company has not received such license, and HT IV currently has no material assets or liabilities. The Company also formed Hercules Technology SBIC Management, LLC (“HTM”), a limited liability company, in November 2003. HTM is a wholly owned subsidiary of the Company and serves as the limited partner and general partner of HT III (see Note 4 to the Company’s consolidated financial statements).

The Company also established wholly owned subsidiaries, all of which are structured as Delaware corporations or limited liability companies (“LLCs”), to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and the portfolio investments held by these subsidiaries are included in the Company’s consolidated financial statements and recorded at fair value. These taxable subsidiaries are not consolidated with Hercules for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments.

The consolidated financial statements include the accounts of the Company, its subsidiaries and its consolidated securitization VIEs. All significant inter-company accounts and transactions have been eliminated in consolidation. As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946.

The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6 and 10 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair presentation of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited

31

consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the period ended December 31, 2019. The year-end Consolidated Statements of Assets and L iabilities data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.

Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions could change in the future as more information becomes known, which could impact the amounts reported and disclosed herein.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company and its subsidiaries and all VIEs of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE.

To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE.

The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.

As of the date of this report, the VIEs consolidated by the Company are its securitization VIEs formed in conjunction with the issuance of the 2027 Asset-Backed Notes and the 2028 Asset-Backed Notes (as defined herein). See “Note 4 – Borrowings”.

Valuation of Investments

The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

At June 30, 2020, approximately 95.7% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820 (“Fair Value Measurements”). The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy approved by the Board of Directors in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by its Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

32

The Company intends to continue to engage one or more independent valuat ion firm(s) to provide management with assistance regarding the Company’s determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services . Specifically, on a quarter ly basis, the Company will identify portfolio investments with respect to which an independent valuation firm will assist in valuing. The Company selects these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discr etion of the Board of Directors. The Board of Directors are ultimately, and solely, responsible for determining the fair value of the Company’s investments in good faith.

ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company has categorized all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of June 30, 2020 and December 31, 2019.

(in thousands) | Balance June 30, | Quoted Prices In Active Markets For Identical Assets | Significant Other Observable Inputs | Significant Unobservable Inputs
Description | 2020 | (Level 1) | (Level 2) | (Level 3)
Senior Secured Debt | $ | 2,201,137 | $ | — | $ | — | $ | 2,201,137
Unsecured Debt | 15,215 | — | — | 15,215
Preferred Stock | 62,532 | — | — | 62,532
Common Stock | 63,161 | 23,948 | — | 39,213
Warrants | 21,476 | — | 6,993 | 14,483
Escrow Receivable | 972 | — | — | 972
Total | $ | 2,364,493 | $ | 23,948 | $ | 6,993 | $ | 2,333,552
(in thousands) | Balance December 31, | Quoted Prices In Active Markets For Identical Assets | Significant Other Observable Inputs | Significant Unobservable Inputs
Description | 2019 | (Level 1) | (Level 2) | (Level 3)
Senior Secured Debt | $ | 2,133,812 | $ | — | $ | — | $ | 2,133,812
Unsecured Debt | 14,780 | — | — | 14,780
Preferred Stock | 69,717 | — | — | 69,717
Common Stock | 75,336 | 41,789 | — | 33,547
Warrants | 20,881 | — | 7,159 | 13,722
Escrow Receivable | 955 | — | — | 955
Total | $ | 2,315,481 | $ | 41,789 | $ | 7,159 | $ | 2,266,533

33

The table below presents a reconciliation for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the six months ended June 30, 2020 an d the year ended December 31, 2019.

(in thousands) | Balance January 1, 2020 | Net Realized Gains (Losses) (1) | Net Change in Unrealized Appreciation (Depreciation) (2) | Purchases (5) | Sales | Repayments (6) | Gross Transfers into Level 3 (3) | Gross Transfers out of Level 3 (3) | Balance June 30, 2020
Senior Debt | $ | 2,133,812 | $ | — | $ | (41,019 | ) | $ | 378,935 | $ | — | $ | (270,591 | ) | $ | — | $ | — | $ | 2,201,137
Unsecured Debt | 14,780 | — | — | 435 | — | — | — | — | 15,215
Preferred Stock | 69,717 | — | (7,415 | ) | 230 | — | — | — | — | 62,532
Common Stock | 33,547 | 1,240 | 5,666 | — | (1,240 | ) | — | — | — | 39,213
Warrants | 13,722 | (2,868 | ) | 2,317 | 2,400 | (1,088 | ) | — | — | — | 14,483
Escrow Receivable | 955 | 91 | — | 1,415 | (1,489 | ) | — | — | — | 972
Total | $ | 2,266,533 | $ | (1,537 | ) | $ | (40,451 | ) | $ | 383,415 | $ | (3,817 | ) | $ | (270,591 | ) | $ | — | $ | — | $ | 2,333,552
(in thousands) | Balance January 1, 2019 | Net Realized Gains (Losses) (1) | Net Change in Unrealized Appreciation (Depreciation) (2) | Purchases (5) | Sales | Repayments (6) | Gross Transfers into Level 3 (4) | Gross Transfers out of Level 3 (4) | Balance December 31, 2019
Senior Debt | $ | 1,719,091 | $ | (5,513 | ) | $ | (2,424 | ) | $ | 1,031,832 | $ | — | $ | (609,174 | ) | $ | — | $ | — | $ | 2,133,812
Unsecured Debt | 14,401 | — | 329 | 50 | — | — | — | — | 14,780
Preferred Stock | 68,625 | (1,146 | ) | 12,566 | 4,638 | (16 | ) | — | — | (14,950 | ) | 69,717
Common Stock | 24,241 | (750 | ) | 4,962 | 5,094 | — | — | — | — | 33,547
Warrants | 22,673 | 6,270 | (7,922 | ) | 3,532 | (8,981 | ) | — | 3 | (1,853 | ) | 13,722
Escrow Receivable | 970 | (875 | ) | — | 897 | (37 | ) | — | — | — | 955
Total | $ | 1,850,001 | $ | (2,014 | ) | $ | 7,511 | $ | 1,046,043 | $ | (9,034 | ) | $ | (609,174 | ) | $ | 3 | $ | (16,803 | ) | $ | 2,266,533
(1) | Included in net realized gains or losses in the accompanying Consolidated Statements of Operations.
(2) | Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations.
(3) | There was no activity of transfers into or out of Level 3 during the six months ended June 30, 2020.
(4) | Transfers out of Level 3 during the year ended December 31, 2019 relate to the initial public offerings of Lightspeed POS, Inc., Lyft, Inc., Avedro, Inc., Stealth Bio Therapeutics Corp., X4 Pharmaceuticals, Inc., BridgeBio Pharma LLC, Pinterest, Inc., TransMedics Group, Inc., Fastly, Inc., Brickell Biotech, Inc., Oportun, and Tela Bio, Inc.. Transfers into Level 3 for the year ended December 31, 2019 relate to the delisting of Motif BioSciences Inc. common stock.
(5) | Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments.
(6) | Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.

For the six months ended June 30, 2020, approximately $7.4 million in net unrealized depreciation and $5.7 million in net unrealized appreciation were recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $41.7 million and $0.7 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

For the year ended December 31, 2019, approximately $11.6 million and $4.6 million in net unrealized appreciation was recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $5.9 million and $1.5 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

34

The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of June 30, 2020 and December 31, 2019. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologie s when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements.

The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.

Investment Type - Level Three Debt Investments | Fair Value at June 30, 2020 (in thousands) | Valuation Techniques/Methodologies | Unobservable Input (1) | Range | Weighted Average (2)
Pharmaceuticals | $ | 25,005 | Originated Within 4-6 Months | Origination Yield | 11.29% - 12.38% | 12.16%
645,689 | Market Comparable Companies | Hypothetical Market Yield | 9.32% - 14.31% | 11.16%
Premium/(Discount) | (0.50%) - 1.00%
— | Liquidation (3) | Probability weighting of alternative outcomes | 0.00% - 100.00%
Technology | 33,553 | Originated Within 4-6 Months | Origination Yield | 10.38% - 13.23% | 12.23%
990,275 | Market Comparable Companies | Hypothetical Market Yield | 9.44% - 18.29% | 12.88%
Premium/(Discount) | (0.50%) - 1.50%
22,747 | Liquidation (3) | Probability weighting of alternative outcomes | 25.00% - 80.00%
Sustainable and Renewable Technology | 15,585 | Market Comparable Companies | Hypothetical Market Yield | 10.11% - 10.53% | 10.22%
Premium/(Discount) | 0.00% - 0.00%
14,167 | Liquidation (3) | Probability weighting of alternative outcomes | 25.00% - 100.00%
Medical Devices | 408 | Originated Within 4-6 Months | Origination Yield | 8.00% | 8.00%
79,892 | Market Comparable Companies | Hypothetical Market Yield | 9.86% - 14.61% | 11.18%
Premium/(Discount) | (0.25%) - 0.75%
Lower Middle Market | 230,043 | Market Comparable Companies | Hypothetical Market Yield | 10.61% - 16.20% | 11.92%
Premium/(Discount) | (1.00%) - 0.75%
7,804 | Liquidation (3) | Probability weighting of alternative outcomes | 20.00% - 80.00%
Debt Investments Where Fair Value Approximates Cost
93,695 | Debt Investments originated within 3 months
- | Imminent Payoffs (4)
57,489 | Debt Investments Maturing in Less than One Year
$ | 2,216,352 | Total Level Three Debt Investments
(1) | The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:
• | Pharmaceuticals, above, is comprised of debt investments in the “Healthcare Services, Other” and “Drug Discovery & Development” industries in the Consolidated Schedule of Investments.
• | Technology, above, is comprised of debt investments in the “Software”, “Media/Content/Info”, “Internet Consumer & Business Services”, “Semiconductors”, “Communications & Networking”, “Medical Devices & Equipment”, and “Information Services” industries in the Consolidated Schedule of Investments.
• | Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology”, “Internet Consumer & Business Services”, and “Electronics & Computer Hardware” industries in the Consolidated Schedule of Investments.
• | Medical Devices, above, is comprised of debt investments in the “Drug Delivery” and “Medical Devices & Equipment” industries in the Consolidated Schedule of Investments.
• | Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Internet Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries in the Consolidated Schedule of Investments.
(2) | The weighted averages are calculated based on the fair market value of each investment.
(3) | The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.
( 4) | Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.

35

Investment Type - Level Three Debt Investments | Fair Value at December 31, 2019 (in thousands) | Valuation Techniques/Methodologies | Unobservable Input (1) | Range | Weighted Average (2)
Pharmaceuticals | $ | 34,898 | Originated Within 4-6 Months | Origination Yield | 10.87% - 12.01% | 11.38%
563,725 | Market Comparable Companies | Hypothetical Market Yield | 9.26% - 14.06% | 11.43%
Premium/(Discount) | (0.50%) - 0.50%
— | Liquidation (3) | Probability weighting of alternative outcomes | 0.00% - 100.00%
Technology | 21,365 | Originated Within 4-6 Months | Origination Yield | 9.40% - 13.04% | 12.33%
844,169 | Market Comparable Companies | Hypothetical Market Yield | 10.56% - 16.13% | 12.36%
Premium/(Discount) | (0.50%) - 0.50%
1,773 | Liquidation (3) | Probability weighting of alternative outcomes | 40.00% - 60.00%
Sustainable and Renewable Technology | 34,115 | Market Comparable Companies | Hypothetical Market Yield | 11.49% - 21.59% | 13.67%
Premium/(Discount) | (0.50%) - 3.00%
4,410 | Liquidation (3) | Probability weighting of alternative outcomes | 50.00%
Medical Devices | 101,349 | Market Comparable Companies | Hypothetical Market Yield | 9.13% - 14.74% | 12.07%
Premium/(Discount) | (0.50%) - 0.50%
Lower Middle Market | 34,822 | Originated Within 4-6 Months | Origination Yield | 13.24% | 13.24%
188,841 | Market Comparable Companies | Hypothetical Market Yield | 10.71% - 16.02% | 13.09%
Premium/(Discount) | (0.50%) - 0.00%
9,587 | Liquidation (3) | Probability weighting of alternative outcomes | 20.00% - 80.00%
Debt Investments Where Fair Value Approximates Cost
149,358 | Debt Investments originated within 3 months
78,052 | Imminent Payoffs (4)
82,128 | Debt Investments Maturing in Less than One Year
$ | 2,148,592 | Total Level Three Debt Investments
(1) | The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:
• | Pharmaceuticals, above, is comprised of debt investments in the “Healthcare Services, Other”, “Biotechnology Tools”, “Drug Delivery”, and “Drug Discovery & Development” industries in the Consolidated Schedule of Investments.
• | Technology, above, is comprised of debt investments in the “Software”, “Media/Content/Info”, “Internet Consumer & Business Services”, “Semiconductors”, “Diversified Financial Services”, and “Information Services” industries in the Consolidated Schedule of Investments.
• | Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology”, “Internet Consumer & Business Services”, and “Electronics & Computer Hardware” industries in the Consolidated Schedule of Investments.
• | Medical Devices, above, is comprised of debt investments in the “Drug Delivery”, and “Medical Devices & Equipment” industries in the Consolidated Schedule of Investments.
• | Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services, Other”, “Internet Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries in the Consolidated Schedule of Investments.
(2) | The weighted averages are calculated based on the fair market value of each investment.
(3) | The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.
(4) | Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.

36

Investment Type - Level Three Equity and Warrant Investments | Fair Value at June 30, 2020 (in thousands) | Valuation Techniques/ Methodologies | Unobservable Input (1) | Range | Weighted Average (6)
Equity Investments | $ | 41,339 | Market Comparable Companies | EBITDA Multiple (2) | 5.2x - 6.0x | 5.6x
Revenue Multiple (2) | 1.6x - 17.1x | 5.2x
Discount for Lack of Marketability (3) | 20.53% - 29.14% | 23.33%
Average Industry Volatility (4) | 73.87% - 125.1% | 97.28%
Risk-Free Interest Rate | 0.17% | 0.17%
Estimated Time to Exit (in months) | 10 | 10
8,104 | Market Adjusted OPM Backsolve | Market Equity Adjustment (5) | (94.52%) - 19.65% | (2.08%)
Average Industry Volatility (4) | 30.84% - 81.38% | 77.74%
Risk-Free Interest Rate | 0.18% - 2.65% | 0.75%
Estimated Time to Exit (in months) | 5 - 34 | 20
— | Liquidation | Revenue Multiple (2) | 1.7x - 2.6x | 2.2x
52,302 | Other (7)
Warrant Investments | 7,425 | Market Comparable Companies | EBITDA Multiple (2) | 5.2x - 13.0x | 12.9x
Revenue Multiple (2) | 0.3x - 6.9x | 4.5x
Discount for Lack of Marketability (3) | 20.53% - 31.00% | 25.06%
Average Industry Volatility (4) | 46.75% - 97.35% | 70.46%
Risk-Free Interest Rate | 0.16% - 0.24% | 0.18%
Estimated Time to Exit (in months) | 10 - 48 | 22
7,058 | Market Adjusted OPM Backsolve | Market Equity Adjustment (5) | (94.52%) - 40.05% | 1.93%
Average Industry Volatility (4) | 25.68% - 109.24% | 72.06%
Risk-Free Interest Rate | 0.18% - 2.65% | 0.73%
Estimated Time to Exit (in months) | 3 - 41 | 23
Total Level Three Warrant and Equity Investments | $ | 116,228
(1) | The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are revenue and/or EBITDA multiples, market equity adjustment factors, and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model (“OPM”) include industry volatility, risk free interest rate and estimated time to exit. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes.
(2) | Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
(3) | Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.
(4) | Represents the range of industry volatility used by market participants when pricing the investment.
(5) | Represents the range of changes in industry valuations since the portfolio company's last external valuation event.
(6) | Weighted averages are calculated based on the fair market value of each investment.
(7) | The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices and/or indicative offers.

37

Investment Type - Level Three Equity and Warrant Investments | Fair Value at December 31, 2019 (in thousands) | Valuation Techniques/ Methodologies | Unobservable Input (1) | Range | Weighted Average (6)
Equity Investments | $ | 45,205 | Market Comparable Companies | EBITDA Multiple (2) | 5.4x | 5.4x
Revenue Multiple (2) | 0.5x - 13.6x | 4.0x
Discount for Lack of Marketability (3) | 15.92% - 25.07% | 19.31%
Average Industry Volatility (4) | 54.15% - 106.47% | 74.87%
Risk-Free Interest Rate | 1.59% - 1.60% | 1.59%
Estimated Time to Exit (in months) | 11 - 31 | 11
14,910 | Market Adjusted OPM Backsolve | Market Equity Adjustment (5) | (19.78%) - 26.70% | 8.17%
Average Industry Volatility (4) | 32.48% - 90.07% | 79.18%
Risk-Free Interest Rate | 1.42% - 2.68% | 1.94%
Estimated Time to Exit (in months) | 11 - 40 | 16
— | Liquidation | Revenue Multiple (2) | 2.0x - 4.0x | 3.0x
43,149 | Other (7)
Warrant Investments | 9,074 | Market Comparable Companies | EBITDA Multiple (2) | 5.4x - 14.7x | 14.6x
Revenue Multiple (2) | 0.4x - 13.4x | 9.9x
Discount for Lack of Marketability (3) | 8.42% - 35.81% | 19.46%
Average Industry Volatility (4) | 35.81% - 97.06% | 57.26%
Risk-Free Interest Rate | 1.57% - 1.66% | 1.60%
Estimated Time to Exit (in months) | 4 - 48 | 21
4,648 | Market Adjusted OPM Backsolve | Market Equity Adjustment (5) | (42.45%) - 23.22% | 7.05%
Average Industry Volatility (4) | 26.31% - 98.99% | 62.78%
Risk-Free Interest Rate | 1.61% - 2.73% | 1.78%
Estimated Time to Exit (in months) | 7 - 39 | 18
Total Level Three Warrant and Equity Investments | $ | 116,986
(1) | The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are revenue and/or EBITDA multiples, market equity adjustment factors, and discounts for lack of marketability. Additional inputs used in the OPM include industry volatility, risk free interest rate and estimated time to exit. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.
(2) | Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
(3) | Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.
(4) | Represents the range of industry volatility used by market participants when pricing the investment.
(5) | Represents the range of changes in industry valuations since the portfolio company's last external valuation event.
(6) | Weighted averages are calculated based on the fair market value of each investment.
(7) | The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices.

Debt Investments

The Company follows the guidance set forth in ASC Topic 820 which establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy, which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. In addition, the Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives. These investments are considered Level 2 assets.

In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below.

The Company applies a procedure for debt investments that assumes the sale of each investment in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to

38

determine the change in market yields between inception of the debt investment and the measurement date. In dustry specific indices and other relevant market data are used to benchmark and assess market-based movements.

Under this process, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date.

The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values its syndicated debt investments using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost.

When originating a debt instrument, the Company generally receives warrants or other equity-related securities from the borrower. The Company determines the cost basis of the warrants or other equity-related securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity-related securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment.

Debt investments that are traded on a public exchange are valued at the prevailing market price as of the valuation date.

Equity-Related Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

The Company estimates the fair value of warrants using a Black Scholes OPM. At each reporting date, privately held warrant and equity-related securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition and general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity-related securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date.

Cash, Restricted Cash, and Cash Equivalents

Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. Restricted cash and cash equivalents include amounts that are collected and are held by trustees who have been appointed as custodians of the assets securing certain of the Company’s financing transactions.

Other Assets

Other assets generally consist of prepaid expenses, deferred financing costs net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow receivable.

Escrow Receivables

Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable

39

balances and the contractual maturity date. As of both June 30, 2020 and December 31, 2019, there were no material past due escrow receivables. The escrow receivable ba lance as of June 30, 2020 and December 31, 2019 was approximately $972,000 and $955,000, respectively, and was fair valued and held in accordance with ASC Topic 820.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 10 – Commitments and Contingencies”.

Portfolio Composition

As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments.

40

The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and six months ended June 30, 2020 and 2019.

(in thousands) | For the Three Months Ended June 30, 2020 | For the Six Months Ended June 30, 2020
Portfolio Company | Type | Fair Value at June 30, 2020 | Interest Income | Fee Income | Net Change in Unrealized (Depreciation)/ Appreciation | Realized Gain/ (Loss) | Interest Income | Fee Income | Net Change in Unrealized (Depreciation)/ Appreciation | Realized Gain/ (Loss)
Control Investments
Gibraltar Business Capital, LLC | Control | $ | 46,628 | $ | 559 | $ | 5 | $ | 3,370 | $ | — | $ | 1,118 | $ | 10 | $ | (3,560 | ) | $ | —
Tectura Corporation | Control | 7,803 | 172 | — | (728 | ) | — | 259 | — | (1,649 | ) | —
Total Control Investments | $ | 54,431 | $ | 731 | $ | 5 | $ | 2,642 | $ | — | $ | 1,377 | $ | 10 | $ | (5,209 | ) | $ | —
Affiliate Investments
Optiscan BioMedical, Corp. | Affiliate | $ | 1,010 | $ | 8 | $ | — | $ | (1,215 | ) | $ | — | $ | 13 | $ | — | $ | (8,590 | ) | $ | —
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) | Affiliate | 10,900 | 149 | — | 900 | — | 364 | — | (1,715 | ) | —
Total Affiliate Investments | $ | 11,910 | $ | 157 | $ | — | $ | (315 | ) | $ | — | $ | 377 | $ | — | $ | (10,305 | ) | $ | —
Total Control & Affiliate Investments | $ | 66,341 | $ | 888 | $ | 5 | $ | 2,327 | $ | — | $ | 1,754 | $ | 10 | $ | (15,514 | ) | $ | —
(in thousands) | For the Three Months Ended June 30, 2019 | For the Six Months Ended June 30, 2019
Portfolio Company | Type | Fair Value at June 30, 2019 | Interest Income | Fee Income | Net Change in Unrealized (Depreciation)/ Appreciation | Realized Gain/(Loss) | Interest Income | Fee Income | Net Change in Unrealized Appreciation/ (Depreciation) | Realized Gain/(Loss)
Control Investments
Gibraltar Business Capital, LLC | Control | $ | 46,224 | $ | 558 | $ | 4 | $ | 1,559 | $ | — | 1,109 | 8 | 6,709 | —
Tectura Corporation | Control | 9,670 | 482 | — | (751 | ) | — | 955 | — | (8,777 | ) | —
Total Control Investments | $ | 55,894 | $ | 1,040 | $ | 4 | $ | 808 | $ | — | $ | 2,064 | $ | 8 | $ | (2,068 | ) | $ | —
Affiliate Investments
Optiscan BioMedical, Corp. | Affiliate | $ | 8,372 | $ | — | $ | — | $ | (359 | ) | $ | — | $ | — | $ | — | $ | (236 | ) | $ | —
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) | Affiliate | 13,042 | 738 | 72 | (1,650 | ) | — | 1,247 | 160 | (2,990 | ) | —
Total Affiliate Investments | $ | 21,414 | $ | 738 | $ | 72 | $ | (2,009 | ) | $ | — | $ | 1,247 | $ | 160 | $ | (3,226 | ) | $ | —
Total Control & Affiliate Investments | $ | 77,308 | $ | 1,778 | $ | 76 | $ | (1,201 | ) | $ | — | $ | 3,311 | $ | 168 | $ | (5,294 | ) | $ | —

The following table shows the fair value of the Company’s portfolio of investments by asset class as of June 30, 2020 and December 31, 2019:

June 30, 2020 | December 31, 2019
(in thousands) | Investments at Fair Value | Percentage of Total Portfolio | Investments at Fair Value | Percentage of Total Portfolio
Senior Secured Debt | $ | 1,357,711 | 57.4 | % | $ | 1,348,468 | 58.3 | %
Senior Secured Debt with Warrants | 864,902 | 36.6 | % | 806,225 | 34.8 | %
Unsecured Debt | 15,215 | 0.6 | % | 14,780 | 0.6 | %
Preferred Stock | 62,532 | 2.7 | % | 69,717 | 3.0 | %
Common Stock | 63,161 | 2.7 | % | 75,336 | 3.3 | %
Total | $ | 2,363,521 | 100.0 | % | $ | 2,314,526 | 100.0 | %

The increase in senior secured debt and senior secured debt with warrants, as a percentage of the total portfolio, during the period is primarily due to an increase in new debt investments that include detachable equity enhancement features.

41

A summary of the Company’s investment portfolio, at value, by geographic location as of June 30, 2020 and December 31, 2019 is shown as follows:

June 30, 2020 | December 31, 2019
(in thousands) | Investments at Fair Value | Percentage of Total Portfolio | Investments at Fair Value | Percentage of Total Portfolio
United States | $ | 2,192,317 | 92.7 | % | $ | 2,039,900 | 88.2 | %
Australia | 52,295 | 2.2 | % | 51,547 | 2.2 | %
United Kingdom | 46,844 | 2.0 | % | 123,735 | 5.3 | %
Netherlands | 36,903 | 1.6 | % | 37,650 | 1.6 | %
Sweden | 13,177 | 0.6 | % | 4,410 | 0.2 | %
Cayman Islands | 12,086 | 0.5 | % | 17,503 | 0.8 | %
Ireland | 5,141 | 0.2 | % | 35,536 | 1.5 | %
Germany | 4,758 | 0.2 | % | 4,245 | 0.2 | %
Total | $ | 2,363,521 | 100.0 | % | $ | 2,314,526 | 100.0 | %

The following table shows the fair value of the Company’s portfolio by industry sector at June 30, 2020 and December 31, 2019:

June 30, 2020 | December 31, 2019
(in thousands) | Investments at Fair Value | Percentage of Total Portfolio | Investments at Fair Value | Percentage of Total Portfolio
Drug Discovery & Development | $ | 736,209 | 31.1 | % | $ | 747,955 | 32.2 | %
Software | 666,525 | 28.2 | % | 582,445 | 25.2 | %
Internet Consumer & Business Services | 521,164 | 22.1 | % | 495,132 | 21.4 | %
Healthcare Services, Other | 109,525 | 4.6 | % | 102,997 | 4.5 | %
Sustainable and Renewable Technology | 77,524 | 3.3 | % | 77,505 | 3.3 | %
Information Services | 53,208 | 2.3 | % | 60,094 | 2.6 | %
Diversified Financial Services | 46,628 | 2.0 | % | 78,933 | 3.4 | %
Drug Delivery | 45,333 | 1.9 | % | 46,218 | 2.0 | %
Medical Devices & Equipment | 43,461 | 1.8 | % | 73,341 | 3.2 | %
Semiconductors | 25,478 | 1.1 | % | 10,658 | 0.5 | %
Media/Content/Info | 20,846 | 0.9 | % | 21,071 | 0.9 | %
Communications & Networking | 9,674 | 0.4 | % | 3,962 | 0.2 | %
Surgical Devices | 3,956 | 0.2 | % | 4,120 | 0.2 | %
Electronics & Computer Hardware | 3,309 | 0.1 | % | 4,462 | 0.2 | %
Consumer & Business Products | 643 | 0.0 | % | 530 | 0.0 | %
Specialty Pharmaceuticals | 38 | 0.0 | % | 36 | 0.0 | %
Biotechnology Tools | — | 0.0 | % | 5,067 | 0.2 | %
Total | $ | 2,363,521 | 100.0 | % | $ | 2,314,526 | 100.0 | %

No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of June 30, 2020 and December 31, 2019.

Investment Collateral

In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. At June 30, 2020, approximately 83.5% of the Company’s debt investments were in a senior secured first lien position, with 43.0% secured by a first priority security in all of the assets of the portfolio company, including its intellectual property, 31.8% secured by a first priority security in all of the assets of the portfolio company other than intellectual property but the portfolio company was prohibited from pledging or encumbering its intellectual property, 0.7% of the Company’s debt investments were senior secured by the equipment of the portfolio company and 8.0% of the Company’s debt investments were in a first lien “last-out” senior secured position with security interest in all of the assets of the portfolio company, whereby the “last-out” loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, sale or other disposition. Another 15.8% of the Company’s debt investments were secured by a second priority security interest in the portfolio company’s assets, and 0.7% were unsecured.

42

Income Recognition

The Company records interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. OID initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. When a loan becomes 90 days or more past due, or if management otherwise does not expect that principal, interest, and other obligations due will be collected in full, the Company will generally place the loan on non-accrual status and cease recognizing interest income on that loan until all principal and interest due has been paid or the Company believes the portfolio company has demonstrated the ability to repay the Company’s current and future contractual obligations. Any uncollected interest related to prior periods is reversed from income in the period that collection of the interest receivable is determined to be doubtful. However, the Company may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection.

Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees. The Company had approximately $40.5 million of unamortized fees at June 30, 2020, of which approximately $34.1 million was included as an offset to the cost basis of the Company’s current debt investments and approximately $6.4 million was deferred contingent upon the occurrence of a funding or milestone. At December 31, 2019, the Company had approximately $42.0 million of unamortized fees, of which approximately $34.6 million was included as an offset to the cost basis of the Company’s current debt investments and approximately $7.4 million was deferred contingent upon the occurrence of a funding or milestone.

The Company recognizes nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fee income, including prepayment penalties, fees related to select covenant default, waiver fees and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. The Company recorded approximately $897,000 and $2.5 million in one-time fee income during the three months ended June 30, 2020 and 2019, respectively, and approximately $4.1 million and $3.2 million in one-time fee income during the six months ended June 30, 2020 and 2019, respectively.

In addition, the Company may also be entitled to an exit fee that is amortized into income over the life of the loan. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. At June 30, 2020, the Company had approximately $44.0 million in exit fees receivable, of which approximately $40.2 million was included as a component of the cost basis of the Company’s current debt investments and approximately $3.8 million was a deferred receivable related to expired commitments. At December 31, 2019, the Company had approximately $33.5 million in exit fees receivable, of which approximately $31.9 million was included as a component of the cost basis of its current debt investments and approximately $1.6 million was a deferred receivable related to expired commitments.

The Company has debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect the portfolio company to be able to pay all principal and interest due. The Company recorded approximately $2.1 million and $2.2 million in PIK income during the three months ended June 30, 2020 and 2019, respectively, and approximately $4.1 million and $4.4 million for six months ended June 30, 2020 and 2019, respectively.

To maintain the Company’s ability to be subject to tax as a RIC, PIK and exit fee income generally must be accrued and distributed to stockholders in the form of dividends for U.S. federal income tax purposes even though the cash has not yet been collected. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments.

In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the three and six months ended June 30, 2020 and 2019.

3. Fair Value of Financial Instruments

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. The

43

Company believes that the carrying amounts of its financial instruments, consisting of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The borrowings of the Company are recorded at amortized cost and not at fair value on the Conso lidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding borrowings is based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument.

Based on market quotations on or around June 30, 2020, the 2022 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, and 2022 Convertible Notes were quoted for 0.963, 1.000, 0.998, and 0.974 per dollar at par value, respectively. At June 30, 2020, the 2025 Notes and 2033 Notes were trading on the New York Stock Exchange (“NYSE”) at $24.95 and $25.05 per unit at par value, respectively. The par value at underwriting for the 2025 Notes and 2033 Notes was $25.00 per unit. Calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms, the fair values of the SBA debentures, July 2024 Notes, February 2025 Notes and June 2025 Notes were approximately $113.5 million, $112.4 million, $52.8 million, and $74.3 million, respectively, compared to the principal amounts of $110.3 million, $105.0 million, $50.0 million, and $70.0 million, respectively, as of June 30, 2020. The fair value of the outstanding borrowings under the Union Bank Facility and the Wells Facility is equal to their principal outstanding balances as of June 30, 2020.

See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in Note 2.

The following tables provide additional information about the fair value and level in the fair value hierarchy of the Company’s outstanding borrowings at June 30, 2020 and December 31, 2019:

(in thousands) | Identical Assets | Observable Inputs | Unobservable Inputs
Description | June 30, 2020 | (Level 1) | (Level 2) | (Level 3)
SBA Debentures | $ | 113,479 | $ | — | $ | — | $ | 113,479
2022 Notes | 144,510 | — | 144,510 | —
2025 Notes | 74,850 | — | 74,850 | —
2033 Notes | 40,080 | — | 40,080 | —
July 2024 Notes | 112,354 | — | — | 112,354
February 2025 Notes | 52,831 | — | — | 52,831
June 2025 Notes | 74,348 | — | — | 74,348
2027 Asset-Backed Notes | 200,000 | — | 200,000 | —
2028 Asset-Backed Notes | 249,609 | — | 249,609 | —
2022 Convertible Notes | 224,089 | — | 224,089 | —
Wells Facility | — | — | — | —
Union Bank Facility | — | — | — | —
Total | $ | 1,286,150 | $ | — | $ | 933,138 | $ | 353,012
(in thousands) | Identical Assets | Observable Inputs | Unobservable Inputs
Description | December 31, 2019 | (Level 1) | (Level 2) | (Level 3)
SBA Debentures | $ | 152,963 | $ | — | $ | — | $ | 152,963
2022 Notes | 151,215 | — | 151,215 | —
July 2024 Notes | 107,028 | — | — | 107,028
2025 Notes | 77,430 | — | 77,430 | —
2033 Notes | 42,160 | — | 42,160 | —
2027 Asset-Backed Notes | 200,750 | — | 200,750 | —
2028 Asset-Backed Notes | 251,094 | — | 251,094 | —
2022 Convertible Notes | 234,922 | — | 234,922 | —
Wells Facility | — | — | — | —
Union Bank Facility | 103,919 | — | — | 103,919
Total | $ | 1,321,481 | $ | — | $ | 957,571 | $ | 363,910

44

4. Borrowings

Outstanding Borrowings

At June 30, 2020 and December 31, 2019, the Company had the following available and outstanding borrowings:

June 30, 2020 | December 31, 2019
(in thousands) | Total Available | Principal | Carrying Value (1) | Total Available | Principal | Carrying Value (1)
SBA Debentures (2) | $ | 110,250 | $ | 110,250 | $ | 109,808 | $ | 149,000 | $ | 149,000 | $ | 148,165
2022 Notes | 150,000 | 150,000 | 148,776 | 150,000 | 150,000 | 148,514
2025 Notes | 75,000 | 75,000 | 73,161 | 75,000 | 75,000 | 72,970
2033 Notes | 40,000 | 40,000 | 38,555 | 40,000 | 40,000 | 38,501
July 2024 Notes | 105,000 | 105,000 | 103,795 | 105,000 | 105,000 | 103,685
February 2025 Notes | 50,000 | 50,000 | 49,465 | — | — | —
June 2025 Notes | 70,000 | 70,000 | 69,217 | — | — | —
2027 Asset-Backed Notes | 200,000 | 200,000 | 197,448 | 200,000 | 200,000 | 197,312
2028 Asset-Backed Notes | 250,000 | 250,000 | 247,511 | 250,000 | 250,000 | 247,395
2022 Convertible Notes | 230,000 | 230,000 | 227,395 | 230,000 | 230,000 | 226,614
Wells Facility (3) | 75,000 | — | — | 75,000 | — | —
Union Bank Facility (3) | 400,000 | — | — | 200,000 | 103,919 | 103,919
Total | $ | 1,755,250 | $ | 1,280,250 | $ | 1,265,131 | $ | 1,474,000 | $ | 1,302,919 | $ | 1,287,075
(1) | Except for the Wells Facility and Union Bank Facility, all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the loan as of the balance sheet date.
(2) | At June 30, 2020 and December 31, 2019, the total available borrowings under the SBA debentures were $110.3 million and $149.0 million, respectively.
(3) | Availability subject to the Company meeting the borrowing base requirements.

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30 (“Interest – Imputation of Interest”), debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements. Debt issuance costs, net of accumulated amortization, were as follows as of June 30, 2020 and December 31, 2019:

(in thousands) | June 30, 2020 | December 31, 2019
SBA Debentures | $ | 442 | $ | 835
2022 Notes | 840 | 1,020
2025 Notes | 1,839 | 2,030
2033 Notes | 1,445 | 1,499
July 2024 Notes | 1,205 | 1,315
February 2025 Notes | 535 | —
June 2025 Notes | 783 | —
2027 Asset-Backed Notes | 2,552 | 2,688
2028 Asset-Backed Notes | 2,489 | 2,605
2022 Convertible Notes | 1,486 | 1,932
Wells Facility (1) | 285 | 373
Union Bank Facility (1) | 3,123 | 1,497
Total | $ | 17,024 | $ | 15,794
(1) | As the Wells Facility and Union Bank Facility are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other Assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30.

Long-Term SBA Debentures

On May 26, 2010, HT III received a license to operate as an SBIC under the SBIC program in which HT III can borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. On March 1, 2020, the Company paid down $38.7 million of SBA debentures. With the Company’s net investment of $74.5 million in HT III as of June 30, 2020, HT III has the approved capacity to issue a total of $110.3 million of SBA guaranteed debentures, of which $110.3 million was outstanding as of June 3 0, 2020. As the Company is past its investment period for HT III, it will no longer make any future commitments to new

45

portfolio companies. The Company will only satisfy contractually agreed follow-on fundings to existing portfolio companies and may seek t o early pay-off a portion or all of the outstanding debentures as per the available liquidity in HT III.

As of June 30, 2020, HT III has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of June 30, 2020, the Company held investments in HT III in 34 companies with a fair value of approximately $176.1 million, accounting for approximately 7.5% of the Company’s total investment portfolio at June 30, 2020. HT III held approximately $200.0 million in tangible assets which accounted for approximately 8.1% of the Company’s total assets at June 30, 2020.

SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. SBICs are subject to a variety of regulations and oversight by the SBA concerning the size and nature of the companies in which they may invest as well as the structures of those investments.

HT III is periodically examined and audited by the SBA’s staff to determine its compliance with SBA regulations. HT III was in compliance with the terms of the SBIC’s leverage as of June 30, 2020 as a result of having sufficient capital as defined under the SBA regulations. The average amount of debentures outstanding for the three and six months ended June 30, 2020 for HT III were approximately $110.3 million and $123.4 million, respectively, with an average interest rate of approximately 3.17% and 2.97%, respectively.

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the SBA debentures were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 873 | $ | 1,273 | $ | 1,829 | $ | 2,533
Amortization of debt issuance cost (loan fees) | 83 | 128 | 392 | 255
Total interest expense and fees | $ | 956 | $ | 1,401 | $ | 2,221 | $ | 2,788
Cash paid for interest expense | $ | — | $ | — | $ | 2,533 | $ | 2,519

The Company reported the following SBA debentures outstanding principal balances as of June 30, 2020 and December 31, 2019:

(in thousands) Issuance/Pooling Date | Maturity Date | Interest Rate (1) | June 30, 2020 | December 31, 2019
September 22, 2010 | September 1, 2020 | 3.50% | $ | — | $ | 10,000
March 29, 2011 | March 1, 2021 | 4.37% | — | 28,750
September 21, 2011 | September 1, 2021 | 3.16% | 25,000 | 25,000
March 21, 2012 | March 1, 2022 | 3.28% | 25,000 | 25,000
March 21, 2012 | March 1, 2022 | 3.05% | 11,250 | 11,250
September 19, 2012 | September 1, 2022 | 3.05% | 24,250 | 24,250
March 27, 2013 | March 1, 2023 | 3.16% | 24,750 | 24,750
Total SBA Debentures | $ | 110,250 | $ | 149,000
(1) | Interest rate includes annual charge.

2022 Notes

On October 23, 2017, the Company issued $150.0 million in aggregate principal amount of 4.625% Notes due 2022 (the “2022 Notes”). The 2022 Notes were issued pursuant to the Fourth Supplemental Indenture to the Base Indenture, dated October 23, 2017 (the “2022 Notes Indenture”), between the Company and U.S. Bank, National Association, as trustee (the “2022 Trustee”). The sale of the 2022 Notes generated net proceeds of approximately $147.4 million, including a public offering discount of $826,500. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discounts and commissions of approximately $975,000, were approximately $1.8 million.

The 2022 Notes mature on October 23, 2022, unless previously repurchased in accordance with their terms. The 2022 Notes bear interest at a rate of 4.625% per year payable semiannually in arrears on April 23 and October 23 of each year, commencing on April 23, 2018.

46

The 2022 Notes are unsecured obligations of the Company that rank senior in right of payment to all of the Company ’s existing and future indebtedness that is expressly subordinated, or junior, in right of payment to the 2022 Notes. The 2022 Notes are not guaranteed by any of the Company’s current or future subsidiaries. The 2022 Notes rank pari passu, or equally, in r ight of payment with all of the Company’s existing and future liabilities that are not so subordinated, or junior. The 2022 Notes effectively rank subordinated, or junior, to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2022 Notes rank structurally subordinated, or junior, to all existing and future indebtedness (including trade payables) incurred by subsidiaries, financing vehicles or similar facilities of the Company.

The Company may redeem some or all of the 2022 Notes at any time, or from time to time, at the redemption price set forth under the terms of the indenture after September 23, 2022. No sinking fund is provided for the 2022 Notes. The 2022 Notes were issued in denominations of $2,000 and integral multiples of $1,000 thereof. As of June 30, 2020, the Company was in compliance with the terms of the 2022 Notes Indenture.

As of June 30, 2020 and December 31, 2019, the components of the carrying value of the 2022 Notes were as follows:

(in thousands) | June 30, 2020 | December 31, 2019
Principal amount of debt | $ | 150,000 | $ | 150,000
Unamortized debt issuance cost | (840 | ) | (1,020 | )
Original issue discount, net of accretion | (384 | ) | (466 | )
Carrying value of 2022 Notes | $ | 148,776 | $ | 148,514

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2022 Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 1,734 | $ | 1,735 | $ | 3,672 | $ | 3,468
Amortization of debt issuance cost (loan fees) | 90 | 90 | 180 | 180
Accretion of original issue discount | 41 | 41 | 82 | 82
Total interest expense and fees | $ | 1,865 | $ | 1,866 | $ | 3,934 | $ | 3,730
Cash paid for interest expense | $ | 3,469 | $ | 3,469 | $ | 3,469 | $ | 3,469

2024 Notes

On July 14, 2014, the Company and U.S. Bank, N.A. (the “2024 Trustee”), entered into the Third Supplemental Indenture (the “Third Supplemental Indenture”) to the Base Indenture between the Company and the 2024 Trustee, dated July 14, 2014, relating to the Company’s issuance, offer and sale of $100.0 million aggregate principal amount of 6.25% unsecured notes due 2024 (the “2024 Notes”).

On October 24, 2017, the Board of Directors approved a redemption of $75.0 million of outstanding aggregate principal amount of the 2024 Notes, which were redeemed on November 23, 2017. On February 9, 2018, the Board of Directors approved a redemption of $100.0 million of outstanding aggregate principal amount of the 2024 Notes, which were redeemed on April 2, 2018. Further, on December 7, 2018, the Board of Directors approved a full redemption, in two equal transactions, of $83.5 million of the outstanding aggregate principal amount of the 2024 Notes. The 2024 Notes were fully redeemed on January 14, 2019 and February 4, 2019.

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2024 Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | — | $ | — | $ | - | $ | 210
Amortization of debt issuance cost (loan fees) | — | — | — | 1,686
Amortization of original issue premium | — | — | 110
Total interest expense and fees | $ | — | $ | — | $ | - | $ | 2,006
Cash paid for interest expense | $ | — | $ | — | $ | — | $ | 1,305

47

July 2024 Notes

On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.77% notes due 2024 (the “July 2024 Notes”) to qualified institutional investors in a private placement pursuant to a note purchase agreement . The sale of the July 2024 Notes generated net proceeds of approximately $103.5 million. Aggregate estimated offering expenses in connection with the transaction, including fees and commissions, were approximately $1.5 million.

The July 2024 Notes have a fixed interest rate of 4.77% and are due on July 16, 2024, unless redeemed, purchased or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the July 2024 Notes is due semiannually and the July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

As of June 30, 2020 and December 31, 2019, the components of the carrying value of the July 2024 Notes were as follows:

(in thousands) | June 30, 2020 | December 31, 2019
Principal amount of debt | $ | 105,000 | $ | 105,000
Unamortized debt issuance cost | (1,205 | ) | (1,315 | )
Carrying value of July 2024 Notes | $ | 103,795 | $ | 103,685

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the July 2024 Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 1,252 | $ | — | $ | 2,504 | $ | —
Amortization of debt issuance cost (loan fees) | 74 | — | 147 | —
Total interest expense and fees | $ | 1,326 | $ | — | $ | 2,651 | $ | —
Cash paid for interest expense | $ | — | $ | — | $ | 2,504 | $ | —

As of June 30, 2020, the Company was in compliance with the terms of the note purchase agreement governing the July 2024 Notes.

February 2025 Notes

On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of senior unsecured notes due February 2025 (the “February 2025 Notes”) to qualified institutional investors in a private placement pursuant to a note purchase agreement (“ 2025 Note Purchase Agreement”). The sale of the February 2025 Notes generated net proceeds of approximately $49.4 million. Aggregate estimated offering expenses in connection with the transaction, including fees and commissions, were approximately $581,000.

The February 2025 Notes have a fixed interest rate of 4.28% and are due February 2025, unless redeemed, purchased or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the February 2025 Notes is due semiannually and the February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

The 2025 Note Purchase Agreement also provided for the issuance of an additional $70.0 million aggregate principal amount of senior unsecured notes due June 2025 with a fixed interest rate of 4.31% per year that were issued in June 2020 and is described below.

As of June 30, 2020 and December 31, 2019, the components of the carrying value of the February 2025 Notes were as follows:

(in thousands) | June 30, 2020 | December 31, 2019
Principal amount of debt | $ | 50,000 | $ | —
Unamortized debt issuance cost | (535 | ) | —
Carrying value of February 2025 Notes | $ | 49,465 | $ | —

48

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the February 2025 Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 535 | $ | — | $ | 868 | $ | —
Amortization of debt issuance cost (loan fees) | 28 | — | 46 | —
Total interest expense and fees | $ | 563 | $ | — | $ | 914 | $ | —
Cash paid for interest expense | $ | — | $ | — | $ | — | $ | —

As of June 30, 2020, the Company was in compliance with the terms of the 2025 Note Purchase Agreement.

June 2025 Notes

On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of senior unsecured notes due June 2025 (the “June 2025 Notes”) to qualified institutional investors in a private placement pursuant to the 2025 Note Purchase Agreement. The sale of the June 2025 Notes generated net proceeds of approximately $69.2 million. Aggregate estimated offering expenses in connection with the transaction, including fees and commissions, were approximately $796,000.

The June 2025 Notes have a fixed interest rate of 4.31% and are due June 2025, unless redeemed, purchased or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the June 2025 Notes is due semiannually and the June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

As of June 30, 2020 and December 31, 2019, the components of the carrying value of the June 2025 Notes were as follows:

(in thousands) | June 30, 2020 | December 31, 2019
Principal amount of debt | $ | 70,000 | $ | —
Unamortized debt issuance cost | (783 | ) | —
Carrying value of June 2025 Notes | $ | 69,217 | $ | —

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the June 2025 Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 235 | $ | — | $ | 235 | $ | —
Amortization of debt issuance cost (loan fees) | 12 | — | 12 | —
Total interest expense and fees | $ | 247 | $ | — | $ | 247 | $ | —
Cash paid for interest expense | $ | — | $ | — | $ | — | $ | —

As of June 30, 2020, the Company was in compliance with the terms of the 2025 Note Purchase Agreement.

2025 Notes

On April 26, 2018, the Company issued $75.0 million in aggregate principal amount of 5.25% notes due 2025 (the “2025 Notes”). The 2025 Notes were issued pursuant to the Fifth Supplemental Indenture to the Base Indenture, dated April 26, 2018 (the “2025 Notes Indenture”), between the Company and U.S. Bank, National Association, as trustee. The sale of the 2025 Notes generated net proceeds of approximately $72.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $2.6 million.

The 2025 Notes will mature on April 30, 2025, unless previously repurchased in accordance with their terms. The 2025 Notes bear interest at a rate of 5.25% per year payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year, commencing on July 30, 2018 and trade on the NYSE under the symbol “HCXZ”. The 2025 Notes are the Company’s direct unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

49

The Company may redeem some or all of the 2025 Notes at any time, or from time to time, at the redemption price set forth under the terms of the indenture after April 30, 2021 . No sinking fund is provided for the 2025 Notes. The 2025 Notes were issued in denominations of $25 and integral multiples of $25 thereof. As of June 30, 2020, the Company was in compliance with the terms of the 2025 Notes Indenture.

As of June 30, 2020 and December 31, 2019, the components of the carrying value of the 2025 Notes were as follows:

(in thousands) | June 30, 2020 | December 31, 2019
Principal amount of debt | $ | 75,000 | $ | 75,000
Unamortized debt issuance cost | (1,839 | ) | (2,030 | )
Carrying value of 2025 Notes | $ | 73,161 | $ | 72,970

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2025 Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 984 | $ | 984 | $ | 1,969 | $ | 1,969
Amortization of debt issuance cost (loan fees) | 95 | 95 | 190 | 190
Total interest expense and fees | $ | 1,079 | $ | 1,079 | $ | 2,159 | $ | 2,159
Cash paid for interest expense | $ | 984 | $ | 984 | $ | 1,969 | $ | 1,969

2033 Notes

On September 24, 2018, the Company issued $40.0 million in aggregate principal amount of 6.25% notes due 2033 (the “2033 Notes”). The 2033 Notes were issued pursuant to the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018 (the “2033 Notes Indenture”), between the Company and U.S. Bank, National Association, as trustee. The sale of the 2033 Notes generated net proceeds of approximately $38.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions were approximately $1.6 million.

The 2033 Notes will mature on October 30, 2033, unless previously repurchased in accordance with their terms. The 2033 Notes bear interest at a rate of 6.25% per year payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year, commencing on October 30, 2018 and trade on the NYSE under the symbol “HCXY.”

The 2033 Notes are the Company’s direct unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the indenture after October 30, 2023. No sinking fund is provided for the 2033 Notes. The 2033 Notes were issued in denominations of $25 and integral multiples of $25 thereof. As of June 30, 2020, the Company was in compliance with the terms of the 2033 Notes Indenture.

As of June 30, 2020 and December 31, 2019, the components of the carrying value of the 2033 Notes were as follows:

(in thousands) | June 30, 2020 | December 31, 2019
Principal amount of debt | $ | 40,000 | $ | 40,000
Unamortized debt issuance cost | (1,445 | ) | (1,499 | )
Carrying value of 2033 Notes | $ | 38,555 | $ | 38,501

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2033 Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 625 | $ | 625 | $ | 1,250 | $ | 1,250
Amortization of debt issuance cost (loan fees) | 27 | 27 | 54 | 54
Total interest expense and fees | $ | 652 | $ | 652 | $ | 1,304 | $ | 1,304
Cash paid for interest expense | $ | 625 | $ | 625 | $ | 1,250 | $ | 1,250

50

2027 Asset-Backed Notes

On November 1, 2018, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of $200.0 million in aggregate principal amount of fixed rate asset-backed notes (the “2027 Asset-Backed Notes”).

The 2027 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2018-1 (the “2018 Securitization Issuer”) pursuant to a note purchase agreement, dated as of October 25, 2018, by and among the Company, Hercules Capital Funding 2018-1 LLC, as trust depositor, the 2018 Securitization Issuer, and Guggenheim Securities, LLC, as initial purchaser, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. The securitization has a reinvestment period with a scheduled termination date of October 20, 2020 during which time principal collections may be reinvested into additional eligible loans. Interest on the 2027 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.605% per annum. The 2027 Asset-Backed Notes have a stated maturity of November 22, 2027.

At both June 30, 2020 and December 31, 2019, the 2027 Asset-Backed Notes had an outstanding principal balance of $200.0 million.

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2027 Asset-Backed Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 2,303 | $ | 2,303 | $ | 4,605 | $ | 4,605
Amortization of debt issuance cost (loan fees) | 71 | 69 | 136 | 138
Total interest expense and fees | $ | 2,374 | $ | 2,372 | $ | 4,741 | $ | 4,743
Cash paid for interest expense | $ | 2,303 | $ | 2,303 | $ | 4,605 | $ | 4,605

Under the terms of the 2027 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2027 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2027 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. At June 30, 2020 and December 31, 2019, there was approximately $11.9 million and $20.9 million, respectively, of funds segregated as restricted cash related to the 2027 Asset-Backed Notes.

As of June 30, 2020, the Company was in compliance with the terms of the note purchase agreement governing the 2027 Asset-Backed Notes.

2028 Asset-Backed Notes

On January 22, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of $250.0 million in aggregate principal amount of fixed rate asset-backed notes (the “2028 Asset-Backed Notes”).

The 2028 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2019-1 (the “2019 Securitization Issuer”) pursuant to a note purchase agreement, dated as of January 14, 2019, by and among the Company, Hercules Capital Funding 2019-1 LLC, as trust depositor, the 2019 Securitization Issuer, and Guggenheim Securities, LLC, as initial purchaser, MUFG Securities Americas Inc., as a co-manager, Wells Fargo Securities, LLC., as a co-manager, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. The securitization has a reinvestment period with a scheduled termination date of January 2021 during which time principal collections may be reinvested into additional eligible loans. Interest on the 2028 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.703% per annum. The 2028 Asset-Backed Notes have a stated maturity of February 22, 2028.

At both June 30, 2020 and December 31, 2019, the 2028 Asset-Backed Notes had an outstanding principal balance of $250.0 million.

51

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2028 Asset-Backed Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 2,939 | $ | 2,939 | $ | 5,879 | $ | 5,193
Amortization of debt issuance cost (loan fees) | 67 | 67 | 121 | 117
Total interest expense and fees | $ | 3,006 | $ | 3,006 | $ | 6,000 | $ | 5,310
Cash paid for interest expense | $ | 2,939 | $ | 2,939 | $ | 5,879 | $ | 4,866

Under the terms of the 2028 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2028 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2028 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. At June 30, 2020 and December 31, 2019, there was approximately $21.7 million and $29.7 million, respectively, of funds segregated as restricted cash related to the 2028 Asset-Backed Notes.

As of June 30, 2020, the Company was in compliance with the terms of the note purchase agreement governing the 2028 Asset-Backed Notes.

Convertible Notes

2022 Convertible Notes

On January 25, 2017, the Company issued $230.0 million in aggregate principal amount of 4.375% Convertible Notes due 2022 (the “2022 Convertible Notes”), which amount includes the additional $30.0 million aggregate principal amount of 2022 Convertible Notes issued pursuant to the initial purchaser’s exercise in full of its overallotment option. The 2022 Convertible Notes were issued pursuant to an Indenture, dated January 25, 2017 (the “2022 Convertible Notes Indenture”), between the Company and U.S. Bank, National Association, as trustee (the “2022 Trustee”). The sale of the 2022 Convertible Notes generated net proceeds of approximately $225.5 million, including $4.5 million of debt issuance costs.

The 2022 Convertible Notes mature on February 1, 2022, unless previously converted or repurchased in accordance with their terms. The 2022 Convertible Notes bear interest at a rate of 4.375% per year payable semiannually in arrears on February 1, and August 1 of each year, commencing on August 1, 2017.

The 2022 Convertible Notes are unsecured obligations of the Company and rank senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the 2022 Convertible Notes; equal in right of payment to the Company’s existing and future indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries, financing vehicles or similar facilities.

Prior to the close of business on the business day immediately preceding August 1, 2021, holders may convert their 2022 Convertible Notes only under certain circumstances set forth in the 2022 Convertible Notes Indenture. On or after August 1, 2021 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their 2022 Convertible Notes at any time. Upon conversion, the Company will pay or deliver, as the case may be, at its election, cash, shares of its common stock or a combination of cash and shares of its common stock. The conversion rate is initially 60.9366 shares of common stock per $1,000 principal amount of 2022 Convertible Notes (equivalent to an initial conversion price of approximately $16.41 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its 2022 Convertible Notes in connection with such a corporate event in certain circumstances. As of June 30, 2020, the conversion rate was 60.9366 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an adjusted conversion price of approximately $16.41 per share of common stock).

The Company may not redeem the 2022 Convertible Notes at its option prior to maturity. No sinking fund is provided for the 2022 Convertible Notes. In addition, if certain corporate events occur, holders of the 2022 Convertible Notes may require the Company to repurchase for cash all or part of their 2022 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2022 Convertible Notes to be repurchased, plus accrued and unpaid interest through, but excluding, the required repurchase date.

52

The 2022 Convertible Notes are accounted for in accordance with ASC Subt opic 470-20 (“Debt Instruments with Conversion and Other Options”). In accounting for the 2022 Convertible Notes, the Company estimated at the time of issuance that the values of the debt and the embedded conversion feature of the 2022 Convertible Notes we re approximately 98.5% and 1.5%, respectively. The OID of 1.5% or $3.4 million, attributable to the conversion feature of the 2022 Convertible Notes was recorded in “capital in excess of par value” in the Consolidated Statements of Assets and Liabilities. As a result, the Company records interest expense comprised of both stated interest expense as well as accretion of the OID resulting in an estimated effective interest rate of approximately 4.76%.

As of June 30, 2020 and December 31, 2019, the components of the carrying value of the 2022 Convertible Notes were as follows:

(in thousands) | June 30, 2020 | December 31, 2019
Principal amount of debt | $ | 230,000 | $ | 230,000
Unamortized debt issuance cost | (1,486 | ) | (1,932 | )
Original issue discount, net of accretion | (1,119 | ) | (1,454 | )
Carrying value of 2022 Convertible Notes | $ | 227,395 | $ | 226,614

For the three and six months ended June 30, 2020 and 2019, the components of interest expense, fees and cash paid for interest expense for the 2022 Convertible Notes were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 2,516 | $ | 2,516 | $ | 5,031 | $ | 5,031
Amortization of debt issuance cost (loan fees) | 223 | 223 | 446 | 446
Accretion of original issue discount | 168 | 168 | 336 | 336
Total interest expense and fees | $ | 2,907 | $ | 2,907 | $ | 5,813 | $ | 5,813
Cash paid for interest expense | $ | — | $ | — | $ | 5,031 | $ | 5,031

As of June 30, 2020, the Company was in compliance with the terms of the indentures governing the 2022 Convertible Notes.

Credit Facilities

As of June 30, 2020 and December 31, 2019, the Company has two available credit facilities, the Wells Facility and the Union Bank Facility (together, the “Credit Facilities”).

Wells Facility

On June 29, 2015, the Company, through a special purpose wholly owned subsidiary, Hercules Funding II LLC (“Hercules Funding II”), entered into an Amended and Restated Loan and Security Agreement (the “Wells Facility”) with Wells Fargo Capital Finance, LLC, as a lender and as the arranger and the administrative agent, and the lenders party thereto from time to time.

On January 11, 2019, Hercules Funding II entered into the Seventh Amendment to the Wells Facility, (the “Wells Facility Seventh Amendment”). The Wells Facility Seventh Amendment, among other things, amends certain key provisions of the Wells Facility to reduce the current interest rate to LIBOR plus 3.00% with an interest rate floor of 3.00%. The Wells Facility Seventh Amendment also extends the maturity date to January 2023, unless terminated earlier in accordance with its terms. In addition, Wells Fargo Capital Finance, LLC has committed $75.0 million in credit capacity with an accordion feature, in which the Company can increase the credit line up to an aggregate of $125.0 million, funded by additional lenders and with the agreement of Wells Fargo and subject to other customary conditions. The Wells Facility has an advance rate of 55% against eligible debt investments, and it is secured by all of the assets of Hercules Funding II. The Wells Facility requires payment of a non-use fee of up to 0.375% depending on the average monthly outstanding balance under the facility relative to the maximum amount of commitments at such time.

The Wells Facility also includes various financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding II, including covenants relating to certain changes of control of the Company and Hercules Funding II. Among other things, these covenants also require the Company to maintain certain financial ratios, including a maximum debt to worth ratio, minimum interest coverage ratio, and a minimum tangible net worth ratio.

On July 2, 2019, Hercules Funding II entered into the Eighth Amendment to the Wells Facility (the “Wells Facility Eighth Amendment”). The Wells Facility Eighth Amendment amends certain provisions of the Wells Facility to, among other things, revise certain provisions thereof to further permit a third party special servicer to act as servicer after an event of default instead of the

53

Company with respect to split-funded notes receivable owned by Hercules Funding II and an affiliate thereof (including Hercules Funding IV LLC).

The Wells Facility provides for customary events of default, including, without limitation, with respect to payment defaults, breach of representations and covenants, certain key person provisions, cross acceleration provisions to certain other debt, lien, and judgment limitations, and bankruptcy.

As of both June 30, 2020 and December 31, 2019, the Company had no borrowings outstanding under the Wells Facility.

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the Wells Facility were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | — | $ | 226 | $ | 25 | $ | 394
Amortization of debt issuance cost (loan fees) | 44 | 167 | 88 | 244
Total interest expense and fees | $ | 44 | $ | 393 | $ | 113 | $ | 638
Cash paid for interest expense | $ | — | $ | 210 | $ | 25 | $ | 335

As of June 30, 2020, the Company was in compliance with the terms of the Wells Facility.

Union Bank Facility

On February 20, 2020, the Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into the credit facility (the “Union Bank Facility”) with MUFG Union Bank, as the arranger and administrative agent, and the lenders party to the Union Bank Facility from time to time. The Union Bank Facility replaced the Company’s credit facility (the “2019 Union Bank Facility”) entered into on February 20, 2019 with MUFG Union Bank, as the arranger and administrative agent, and the lenders party thereto. The 2019 Union Bank Facility replaced the Company’s credit facility (the “Prior Union Bank Facility”) entered into on May 5, 2016 with MUFG Union Bank, as the arranger and administrative agent, and the lenders party thereto. Any references to amounts related to the Union Bank Facility prior to February 20, 2020 were incurred and relate to the Prior Union Bank Facility or the 2019 Union Bank Facility, as applicable.

Under the Union Bank Facility, the lenders have made commitments of $400.0 million. The Union Bank Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $200.0 million, funded by existing or additional lenders and with the agreement of MUFG Union Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility to increase available borrowings. Borrowings under the Union Bank Facility generally bear interest at a rate per annum equal to LIBOR plus 2.50%. The Union Bank Facility matures on February 22, 2023 plus a 12-month amortization period, unless sooner terminated in accordance with its terms . The Union Bank Facility is secured by all of the assets of Hercules Funding IV.

The Union Bank Facility requires payment of a non-use fee during the revolving credit availability period as follows: (i) 0.50% if less than or equal to 50% utilization; (ii) 0.375% if more than 50% utilization but less than or equal to 80% utilization; and (iii) 0.20% if more than 80% is utilized.

The Union Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants also require the Company to maintain certain financial ratios, including a minimum interest coverage ratio with respect to Hercules Funding IV and a minimum tangible net worth in an amount that is in excess of $723.0 million.

The Union Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy.

As of June 30, 2020, the Company had no borrowings outstanding on the Union Bank Facility. The Company had borrowings outstanding of $103.9 million on the Union Bank Facility at December 31, 2019.

54

For the three and six months ended June 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the previous and current Union Bank Facility were as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Interest expense | $ | 871 | $ | 705 | $ | 1,322 | $ | 889
Amortization of debt issuance cost (loan fees) | 343 | 438 | 628 | 768
Total interest expense and fees | $ | 1,214 | $ | 1,143 | $ | 1,950 | $ | 1,657
Cash paid for interest expense | $ | 951 | $ | 487 | $ | 1,496 | $ | 635

As of June 30, 2020, the Company was in compliance with the terms of the Union Bank Facility.

5. Income Taxes

The Company intends to operate so as to qualify to be subject to tax as a RIC under Subchapter M of the Code and, as such, will not be subject to U.S. federal income tax on the portion of taxable income (including gains) distributed as dividends for U.S. federal income tax purposes to stockholders. Taxable income includes the Company’s taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net realized securities gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized.

To qualify and be subject to tax as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing dividends of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions paid, to its stockholders. The amount to be paid out as a distribution is determined by the Board of Directors each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company’s earnings fall below the amount of dividend distributions declared, however, a portion of the total amount of the Company’s distributions for the fiscal year may be deemed a return of capital for tax purposes to the Company’s stockholders.

During the three and six months ended June 30, 2020, the Company declared and paid distributions of $0.32 per share and $0.72 per share, respectively. The determination of the tax attributes of the Company’s distributions is made annually as of the end of the Company’s taxable year generally based upon its taxable income for the full taxable year and distributions paid for the full taxable year. As a result, a determination made on a quarterly basis may not be representative of the actual tax attributes of the Company’s distributions for a full taxable year. If the Company had determined the tax attributes of our distributions taxable year-to-date as of June 30, 2020, 100% would be from our current and accumulated earnings and profits. However, there can be no certainty to stockholders that this determination is representative of what the actual tax attributes of the Company’s fiscal year of 2020 distributions to stockholders will be.

As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of our ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of our capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years, or the excise tax avoidance requirement. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net capital gains).

Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.

The Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable subsidiaries are included in the Company’s

55

consolidated financial statements and are recorded at fair value. These taxable subsidiaries ar e not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by these taxable subsidiaries generally would be subject to tax at normal corporate tax rates based on its taxable income.

Taxable income for the six months ended June 30, 2020 was approximately $75.6 million or $0.69 per share. Taxable net realized gains for the same period were $9.9 million or approximately $0.09 per share. Taxable income for the six months ended June 30, 2019 was approximately $71.4 million or $0.73 per share. Taxable net realized gains for the same period were $9.4 million or approximately $0.10 per share.

For the six months ended June 30, 2020, the Company paid approximately $2.5 million of income tax, including excise tax, and had $801,000 accrued but unpaid tax expense, as of the balance sheet date. For the six months ended June 30, 2019, the Company paid approximately $1.4 million of income tax, including excise tax, and had $320,000 accrued but unpaid tax expense as of the balance sheet date.

The Company intends to timely distribute to its stockholders substantially all of its annual taxable income for each year, except that it may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

6. Stockholders’ Equity

On September 7, 2017, the Company entered into an At-The-Market, (“ATM”) equity distribution agreement (the “Prior Equity Distribution Agreement”), with JMP Securities LLC (“JMP”). The Prior Equity Distribution Agreement, provided that the Company may offer and sell up to 12.0 million shares of its common stock from time to time through JMP, as its sales agent.

On May 6, 2019, the Company terminated the Prior Equity Distribution Agreement and entered into a new ATM equity distribution agreement (the “Equity Distribution Agreement”). As a result, the remaining shares that were available under the Prior Equity Distribution agreement are no longer available for issuance. The Equity Distribution Agreement provides that the Company may offer and sell up to 12.0 million shares of its common stock from time to time through JMP, as its sales agent. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three and six months ended June 30, 2020, the Company sold approximately 3.6 million shares and 6.0 million shares, respectively, of common stock under the Equity Distribution Agreement. For the same periods, the Company received total accumulated net proceeds of approximately $38.7 million and $73.9 million, respectively, including offering expenses of $352,000 and $714,000, respectively, from these sales. During both three and six months ended June 30, 2019, the Company sold approximately 2.0 million shares of common stock, of which 679,000 shares and 1.3 million shares were issued under the Prior Equity Distribution Agreement and the Equity Distribution Agreement, respectively. For the same periods, the Company received total accumulated net proceeds of approximately $25.1 million, including $311,000 of offering expenses, from these sales, of which $8.5 million, including offering expense of $146,000, was received under the Prior Equity Distribution Agreement and $16.6 million, including offering expense of $165,000, was received under the Equity Distribution Agreement.

The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of June 30, 2020, approximately 2.1 million shares remain available for issuance and sale under the Equity Distribution Agreement.

On June 17, 2019, the Company closed its underwritten public offering of 5.8 million shares of common stock, including an over-allotment option to purchase an additional 750,000 shares of common stock (“June 2019 Equity Offering”). The offering generated net proceeds, before expenses, of $70.5 million, including the underwriting discount and commissions of $2.2 million.

The Company has issued stock options for common stock subject to future issuance, of which 464,208 and 449,116 were outstanding at June 30, 2020 and December 31, 2019, respectively.

On July 2, 2020, the Company terminated the Equity Distribution Agreement and entered into a new ATM equity distribution agreement with JMP. See “Note 12 – Subsequent Events.”

56

7. Equity Incentive Plans

The Company and its stockholders authorized and adopted the 2004 Equity Incentive Plan (the “2004 Plan”) for purposes of attracting and retaining the services of its executive officers and key employees. The Company and its stockholders have authorized and adopted the 2006 Non-Employee Director Plan (the “2006 Plan”) for purposes of attracting and retaining the services of its Board of Directors. On June 21, 2017, the 2006 Plan expired in accordance with its terms and no additional awards may be granted under the 2006 Plan.

On May 13, 2018, the Board of Directors further amended and restated the 2004 Plan and renamed it the Hercules Capital, Inc. Amended and Restated 2018 Equity Incentive Plan (the “2018 Equity Incentive Plan”). Under the 2004 Plan, prior to the amendment and restatement, the Company was authorized to issue 12.0 million shares of common stock. The 2018 Equity Incentive Plan, among other things, increased the number of shares available for issuance to eligible participants by an additional 6.7 million shares. Unless earlier terminated by the Board of Directors, the 2018 Equity Incentive Plan will terminate on May 12, 2028. On May 13, 2018, the Board of Directors adopted the Hercules Capital, Inc. 2018 Non-employee Director Plan (the “Director Plan”). The Director Plan provides equity compensation in the form of restricted stock to the Company’s non-employee directors. Subject to certain adjustments, the maximum aggregate number of shares of stock that may be authorized for issuance as restricted stock awards granted under the Director Plan is 300,000 shares. Unless earlier terminated by the Board of Directors, the Director Plan will terminate on May 12, 2028. The 2018 Equity Incentive Plan and the Director Plan were each approved by stockholders on June 28, 2018. Except for the Retention PSUs (as described below), these employees awards generally vest 33% one year after the date of grant and ratably over the succeeding 24 months.

On May 29, 2018, the Company filed an exemptive application with the Securities and Exchange Commission (the “SEC”) and an amendment to the application on September 27, 2018, with respect to the 2018 Equity Incentive Plan and the Director Plan for exemptive relief from certain provisions of the 1940 Act. On January 30, 2019, the Company received approval from the SEC on its request for exemptive relief that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Equity Incentive Plan. The exemptive order also allows participants in the Director Plan and the 2018 Equity Incentive Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time of option exercise or vesting on restricted stock.

The following table summarizes the common stock options activities for the six months ended June 30, 2020 and 2019:

Six Months Ended June 30,
2020 | 2019
Common Stock Options | Weighted Average Exercise Price | Common Stock Options | Weighted Average Exercise Price
Outstanding at December 31, | 449,116 | $ | 13.32 | 481,032 | $ | 13.40
Granted | 54,000 | $ | 12.48 | 55,000 | $ | 12.64
Exercised | (29,267 | ) | $ | 12.36 | (14,113 | ) | $ | 11.39
Forfeited | (8,779 | ) | $ | 13.82 | (1,613 | ) | $ | 12.16
Expired | (862 | ) | $ | 11.79 | (52,665 | ) | $ | 14.82
Outstanding at June 30, | 464,208 | $ | 13.27 | 467,641 | $ | 13.21
Shares Expected to Vest at June 30, | 159,592 | $ | 13.52 | 167,238 | $ | 13.46

All options may be exercised for a period ending seven to ten years after the date of grant. At June 30, 2020, options for approximately 464,208 shares were outstanding at a weighted average exercise price of approximately $13.27 per share with weighted average of remaining contractual term of 4.43 years and $5,000 aggregate intrinsic value. At June 30, 2020, options for approximately 304,616 shares were exercisable at a weighted average exercise price of approximately $13.52 per share with weighted average of remaining contractual term of 3.53 years and zero aggregate intrinsic value.

The Company determined that the fair value of options granted under the 2018 Equity Incentive Plan during the six months ended June 30, 2020 and 2019 was approximately $7,000 and $21,000, respectively. During the six months ended June 30, 2020 and 2019, approximately $17,000 and $23,000 of share-based cost due to stock option grants was expensed, respectively. As of June 30, 2020, there was approximately $42,000 of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average period of 1.73 years.

The Company follows ASC Topic 718 to account for stock options granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the

57

vesting period. Determining the appropriate fair value model and calculating the fai r value of stock-based awards at the grant date requires judgment, including estimating stock price volatility, forfeiture rate and expected option life. The fair value of options granted is based upon a Black Scholes option pricing model using the assumpt ions in the following table for each of the six months ended June 30, 2020 and 2019 is as follows:

Six Months Ended June 30,
2020 | 2019
Expected Volatility | 15.71% | 18.40%
Expected Dividends | 10% | 10%
Expected term (in years) | 4.5 | 4.5
Risk-free rate | 0.26% - 1.66% | 1.72% - 2.62%

During the six months ended June 30, 2020 and 2019, the Company granted 688,885 shares and 57,324 shares, respectively, of restricted stock awards pursuant to the 2018 Equity Incentive Plan and the Director Plan. The Company determined that the fair values, based on grant date close price, of restricted stock awards granted under the 2018 Equity Incentive Plan and the Director Plan during the six months ended June 30, 2020 and 2019 were approximately $9.7 million and $716,526, respectively. As of June 30, 2020, there were approximately $9.4 million of total unrecognized compensation costs related to restricted stock awards. These costs are expected to be recognized over a weighted average period of 2.42 years.

The following table summarizes the activities for the Company’s unvested restricted stock awards for the six months ended June 30, 2020 and 2019:

Six Months Ended June 30,
2020 | 2019
Restricted Stock Awards | Weighted Average Grant Date Fair Value | Restricted Stock Awards | Weighted Average Grant Date Fair Value
Unvested at December 31, | 178,509 | $ | 12.88 | 380,870 | $ | 12.95
Granted | 688,885 | $ | 14.10 | 57,324 | $ | 12.50
Vested | (39,825 | ) | $ | 12.81 | (180,779 | ) | $ | 12.83
Forfeited | (13,427 | ) | $ | 14.15 | — | $ | —
Unvested at June 30, | 814,142 | $ | 13.89 | 257,415 | $ | 12.94

During the six months ended June 30, 2020, the Company did not grant restricted stock units pursuant to the 2018 Equity Incentive Plan. The Company granted approximately 1,022,144 shares of restricted stock units during the six months ended June 30, 2019. The Company also granted approximately 47,033 shares and 100,544 shares, respectively, of distribution equivalent units pursuant to the 2018 Equity Incentive Plan. The Company determined that the fair values, based on grant date close price, of restricted stock units granted under the 2018 Equity Incentive Plan during the six months ended June 30, 2020 and 2019, were approximately $631,000 and $14.8 million, respectively. As of June 30, 2020, there were approximately $3.4 million of total unrecognized compensation costs related to restricted stock units. These costs are expected to be recognized over a weighted average period of 1.52 years.

The following table summarizes the activities for the Company’s unvested restricted stock units for the six months ended June 30, 2020 and 2019:

Six Months Ended June 30,
2020 | 2019
Restricted Stock Units | Weighted Average Grant Date Fair Value | Restricted Stock Units | Weighted Average Grant Date Fair Value
Unvested at December 31, | 603,837 | $ | 13.13 | 732,533 | $ | 13.50
Granted | — | $ | — | 1,022,144 | $ | 13.11
Distribution Equivalent Unit Granted | 47,033 | $ | — | 100,544 | $ | —
Vested (1) | (283,547 | ) | $ | 13.23 | (300,710 | ) | $ | 13.50
Forfeited | (8,294 | ) | $ | 13.00 | (1,222 | ) | $ | 13.62
Unvested at June 30, | 359,029 | $ | 13.06 | 1,553,289 | $ | 13.24
(1) | With respect to restricted stock units granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock units will be deferred for four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock units will not be issued as common stock upon vesting until the completion of the deferral period.

58

During the six months ended June 30, 2020, the Company expensed approximately $3.3 million of compensation expense related to restricted stock awards and restricted stock units. The Company had approximately $4.8 million in compensation expense related to restricted stock awards and restricted stock units during the si x months ended June 30, 2019.

On May 2, 2018, the Company granted long-term Retention Performance Stock Unit awards (the “Retention PSUs”) under the 2004 Plan and separate cash bonus awards with similar terms (the “Cash Awards”) to senior personnel. The awards are designed to provide incentives that increase along with the total shareholder return (“TSR”). On May 2, 2018, the target number of Retention PSUs granted to senior personnel was 1,299,757 in the aggregate and the target amount of the Cash Awards granted to senior personnel was $4.0 million in the aggregate. As of June 30, 2020, there were 487,409 Retention PSUs outstanding at target and the target amount of the Cash Awards was $3.0 million in the aggregate. During the six months ended June 30, 2020, no Retention PSUs at target were forfeited. The Retention PSUs and Cash Awards do not vest until the fourth anniversary “cliff vest” of the grant date (or a change in control of the Company, if earlier) and the Retention PSUs must generally be held and not disposed of until the fifth anniversary of the grant date, except in the event of death, disability or a change in control (the “Performance Period”). Distribution equivalent units will accrue in respect only of the Retention PSUs in the form of additional Retention PSUs, but will not be paid unless the Retention PSUs to which such distribution equivalent units relate actually vest. The Cash Awards are not eligible to accrue distribution equivalent units.

The Company follows ASC Topic 718 (“Compensation – Stock Compensation”) to account for the Retention PSUs and Cash Awards granted. Under ASC Topic 718, compensation cost associated with Retention PSUs is measured at the grant date based on the fair value of the award and is recognized over the Performance Period. As the Cash Awards are settled in cash, the award is expensed as a liability, and will be re-measured at each reporting period until the Performance Period is complete. The compensation expense for these awards is based on the per unit grant date valuation using a Monte-Carlo simulation multiplied by the target payout level. The payout level is calculated based the Company’s TSR relative to specified BDCs during the performance period.

As of June 30, 2020, all outstanding Retention PSUs and Cash Awards were unvested and there were approximately $3.1 million of total unrecognized compensation costs related to the Retention PSUs. These costs are expected to be recognized over a weighted average remaining vesting period of 1.84 years. As of June 30, 2020, there was approximately $2.1 million of accumulated compensation expense related to the Cash Awards. The accumulated expense related to the Cash Awards is included within the Consolidated Statements of Assets and Liabilities.

8. Earnings Per Share

Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands, except per share data) | 2020 | 2019 | 2020 | 2019
Numerator
Net increase (decrease) in net assets resulting from operations | $ | 61,765 | $ | 48,131 | $ | 33,042 | $ | 109,716
Less: Distributions declared-common and restricted shares | (36,002 | ) | (32,151 | ) | (80,225 | ) | (62,051 | )
Undistributed earnings (loss) | 25,763 | 15,980 | (47,183 | ) | 47,665
Undistributed earnings (loss)-common shares | 25,577 | 15,940 | (47,183 | ) | 47,549
Add: Distributions declared-common shares | 35,743 | 32,069 | 79,627 | 61,898
Numerator for basic and diluted change in net assets per common share | $ | 61,320 | $ | 48,009 | $ | 32,444 | $ | 109,447
Denominator
Basic weighted average common shares outstanding | 111,558 | 98,223 | 110,256 | 97,226
Common shares issuable | 171 | 514 | 248 | 404
Weighted average common shares outstanding assuming dilution | 111,729 | 98,737 | 110,504 | 97,630
Change in net assets per common share
Basic | $ | 0.55 | $ | 0.49 | $ | 0.29 | $ | 1.13
Diluted | $ | 0.55 | $ | 0.49 | $ | 0.29 | $ | 1.12

In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per share.

For the three and six months ended June 30, 2020 and 2019, the effect of the 2022 Convertible Notes under the treasury stock method was anti-dilutive and, accordingly, was excluded from the calculation of diluted earnings per share.

59

The calculation of change in net assets resulting from operations per common share—assuming dilution, excludes all anti-dilutive shares. For the three months ended June 30, 2020, the numbe r of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, consisted of 8.6 million shares of 2022 Convertible Notes, 146,342 shares of unvested common stock options, 13,738 shares of unvested restricted stock units, 163,481 shares of unvested restricted stock awards, and no shares of unvested Retention PSUs. For the six months ended June 30, 2020, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the period, consisted of 5.8 million shares of 2022 Convertible Notes, 75,796 shares of unvested common stock options, no shares of unvested restricted stock units, 87,553 shares of unvested restricted stock awards, and no shares of unvested Retention PSUs. For the three and six months ended June 30, 2019, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, consisted of 3.7 millio n and 3.9 million shares, respectively, related to 2022 Convertible Notes, 27,228 shares and 32,810 shares, respectively, of unvested common stock options, no shares of unvested restricted stock units, and no shares of unvested Retention PSUs.

At both June 30, 2020 and December 31, 2019, the Company was authorized to issue 200.0 million shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote.

9. Financial Highlights

Following is a schedule of financial highlights for the six months ended June 30, 2020 and 2019:

Six Months Ended June 30,
2020 | 2019
Per share data (1) :
Net asset value at beginning of period | $ | 10.55 | $ | 9.90
Net investment income | 0.69 | 0.66
Net realized gain (loss) on investments | 0.06 | 0.09
Net unrealized appreciation (depreciation) on investments | (0.46 | ) | 0.38
Total from investment operations | 0.29 | 1.13
Net increase (decrease) in net assets from capital share transactions (1) | 0.02 | 0.16
Distributions of net investment income (6) | (0.72 | ) | (0.64 | )
Distributions of capital gains (6) | — | -
Stock-based compensation expense included in investment income (2) | 0.05 | 0.04
Net asset value at end of period | $ | 10.19 | $ | 10.59
Ratios and supplemental data:
Per share market value at end of period | $ | 10.47 | $ | 12.82
Total return (3) | (20.90 | %) | 21.57 | %
Shares outstanding at end of period | 114,230 | 104,282
Weighted average number of common shares outstanding | 110,256 | 97,226
Net assets at end of period | $ | 1,164,030 | $ | 1,104,684
Ratio of total expense to average net assets (4) | 11.48 | % | 12.92 | %
Ratio of net investment income before investment gains and losses to average net assets (4) | 13.41 | % | 13.03 | %
Portfolio turnover rate (5) | 13.40 | % | 14.72 | %
Weighted average debt outstanding | $ | 1,306,433 | $ | 1,119,440
Weighted average debt per common share | $ | 11.85 | $ | 11.51
(1) | All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date.
(2) | Stock option expense is a non-cash expense that has no effect on net asset value. Pursuant to ASC Topic 718, net investment income includes the expense associated with the granting of stock options which is offset by a corresponding increase in paid-in capital.
(3) | The total return for the six months ended June 30, 2020 and 2019 equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors.
(4) | The ratios are calculated based on weighted average net assets for the relevant period and are annualized.
(5) | The portfolio turnover rate for the six months ended June 30, 2020 and 2019 equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized.
(6) | Includes distributions on unvested restricted stock awards.

60

10. Commitments and Contingencies

The Company’s commitments and contingencies consist primarily of unused commitments to extend credit in the form of loans to the Company’s portfolio companies. A portion of these unfunded contractual commitments as of June 30, 2020 are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company’s credit agreements contain customary lending provisions which allow the Company relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the Company. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones.

At June 30, 2020, the Company had approximately $165.1 million of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by milestones.

The Company also had approximately $30.0 million of non-binding term sheets outstanding at June 30, 2020. Non-binding outstanding term sheets are subject to completion of the Company’s due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.

As of June 30, 2020, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows:

(in thousands)
Portfolio Company | Unfunded Commitments (1)
The Wing | $ | 30,000
memsql, Inc. | 25,000
Codiak Biosciences, Inc. | 15,000
Chemocentryx, Inc. | 15,000
Eidos Therapeutics, Inc. | 11,250
Antares Pharma Inc. | 10,000
G1 Therapeutics, Inc. | 10,000
Dashlane, Inc. | 8,000
Businessolver.com, Inc. | 6,375
Clarabridge, Inc. | 5,154
3GTMS, LLC. | 5,036
Reltio, Inc. | 5,000
Albireo Pharma, Inc. | 5,000
Nextroll, Inc. | 5,000
Campaign Monitor Limited | 2,979
Integral Health Holdings, LLC | 2,500
Ikon Science Limited | 1,050
The CM Group LLC | 750
Khoros (p.k.a Lithium Technologies) | 534
Yipit, LLC | 425
Mobile Solutions Services | 367
Cytracom Holdings LLC | 250
ePayPolicy Holdings, LLC | 250
Greenphire, Inc. | 200
Total | $ | 165,120
(1) | Amount represents unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones.

61

The Company’s contractual obligations as of June 30, 2020 include:

Payments due by period (in thousands)
Contractual Obligations (1) | Total | Less than 1 year | 1 - 3 years | 3 - 5 years | After 5 years
Borrowings (2)(3) | $ | 1,280,250 | $ | — | $ | 490,250 | $ | 300,000 | $ | 490,000
Lease and License Obligations (4) | 11,745 | 3,032 | 5,892 | 2,043 | 778
Total | $ | 1,291,995 | $ | 3,032 | $ | 496,142 | $ | 302,043 | $ | 490,778
(1) | Excludes commitments to extend credit to the Company’s portfolio companies.
(2) | Includes $110.3 million in principal outstanding under the SBA debentures, $150.0 million of the 2022 Notes, $105.0 million of the July 2024 Notes, $50.0 million of the February 2025 Notes, $70.0 million of the June 2025 Notes, $75.0 million of the 2025 Notes, $40.0 million of the 2033 Notes, $200.0 million of the 2027 Asset-Backed Notes, $250.0 million of the 2028 Asset-Backed Notes, and $230.0 million of the 2022 Convertible Notes. There were no outstanding borrowings under the Wells Facility or Union Bank Credit Facility as of June 30, 2020.
(3) | Amounts represent future principal repayments and not the carrying value of each liability. See Note 4 to the Company’s consolidated financial statements.
(4) | Facility leases and licenses including short-term leases.

Certain premises are leased or licensed under agreements which expire at various dates through June 2027. Total rent expense, including short-term leases, amounted to approximately $761,000 and $1.5 million during the three and six months ended June 30, 2020. Total rent expense amounted to approximately $623,000 and $1.2 million during the three and six months ended June 30, 2019. The Company recognizes an operating lease liability and a ROU asset for all leases, with the exception of short-term leases. The lease payments on short-term leases are recognized as rent expense on a straight-line basis. The discount rate applied to measure each ROU asset and lease liability is based on the Company’s weighted average cost of debt. The Company considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is appropriate to the intended use of the underlying lease. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset.

The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of June 30, 2020:

(in thousands) | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2020
Total operating lease cost | $ | 735 | $ | 1,470
Cash paid for amounts included in the measurement of lease liabilities | $ | 1,111 | $ | 1,661
ROU assets obtained in exchange for lease liabilities | $ | — | $ | —
As of June 30, 2020
Weighted-average remaining lease term (in years) | 4.47
Weighted-average discount rate | 5.46 | %

The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of June 30, 2020:

(in thousands)
Remainder of 2020 | $ | 1,683
2021 | 2,903
2022 | 3,002
2023 | 2,293
2024 | 693
Thereafter | 1,512
Total lease payments | 12,086
Less: imputed interest | (1,908 | )
Total operating lease liability | $ | 10,178

62

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of it s portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; ho wever, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

11. Recent Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to Disclosure Requirements for Fair Value Measurement”, which is intended to improve the effectiveness of fair value measurement disclosures. The amendment, among other things, affects certain disclosure requirements related to transfers between level 1 and level 2 of the fair value hierarchy, and level 3 fair value measurements as they relate to valuation process, unrealized gains and losses, measurement uncertainty, and significant unobservable inputs. The new guidance is effective for interim and annual periods beginning after December 15, 2019. The Company partially adopted the standard effective July 1, 2019 and fully adopted this standard effective January 1, 2020, which did not have a material impact, on its consolidated financial statements and related disclosures for the periods presented.

In August 2018, the SEC issued Final Rule Release No. 33-10532 - “Disclosure Update and Simplification.” This rule amends various SEC disclosure requirements that have been determined to be redundant, duplicative, overlapping, outdated, or superseded. The changes are generally expected to reduce or eliminate certain disclosures; however, the amendments did expand interim period disclosure requirements related to changes in stockholders' equity. This final rule is effective on November 5, 2018. The Company has adopted these amendments as currently required and these are reflected in its consolidated financial statements and related disclosures. Certain prior year information has been adjusted to conform with these amendments.

In March 2020, the FASB issued ASU 2020-04, “ Reference rate reform (Topic 848) - Facilitation of the effects of reference rate reform on financial reporting. ” The amendments in this update provide optional expedients and exceptions for applying U.S. GAAP to certain contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform and became effective upon issuance for all entities. The Company has agreements that have LIBOR as a reference rate with certain portfolio companies and also with certain lenders. These agreements include language for choosing an alternative successor rate if LIBOR reference is no longer considered to be appropriate. Such contract modifications are required to be evaluated in determining whether the modifications result in the establishment of new contracts or the continuation of existing contracts. The Company adopted this amendment as of March 12, 2020 and plans to apply the amendments in this update to account for contract modifications due to changes in reference rates. This update did not have a material impact on the Company’s consolidated financial statements and disclosures for the periods presented.

In May 2020, the SEC adopted rule amendments that will impact the requirement of investment companies, including BDCs, to disclose the financial statements of certain of their portfolio companies or acquired funds (the “Final Rules”). The Final adopted a new definition of “significant subsidiary” set forth in Rule 1-02(w)(2) of Regulation S-X under the Securities Act. Rules 3-09 and 4-08(g) of Regulation S-X require investment companies to include separate financial statements or summary financial information, respectively, in such investment company’s periodic reports for any portfolio company that meets the definition of “significant subsidiary.” The Final Rules amend the definition of “significant subsidiary” in a manner that is intended to more accurately capture those portfolio companies that are more likely to materially impact the financial condition of an investment company. The Final Rules will be effective on January 1, 2021, but voluntary compliance is permitted in advance of the effective date. The Company has elected to comply with the Final Rules effective June 30, 2020 which is expected to require the Company to provide separate audited financial statements and summarized financial information for fewer of its controlled portfolio companies going forward.

12. Subsequent Events

On July 2, 2020, the Company terminated the Equity Distribution Agreement and entered into a new ATM equity distribution agreement with JMP (the “2020 Equity Distribution Agreement”). As a result, the remaining shares that were available under the Equity Distribution Agreement are no longer available for issuance. The 2020 Equity Distribution Agreement provides that the Company may offer and sell up to 16.5 million shares of its common stock from time to time through JMP, as its sales agent. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

63

Subsequent to June 30, 2020 and as of July 29, 2020, the Company did not sell any shares of its common stock under the 2 020 Equity Distribution Agreement. As of July 29, 2020, 16.5 million shares remain available for issuance and sale under the 2020 Equity Distribution Agreement.

On July 22, 2020, the Board of Directors declared a cash distribution of $0.32 per share to be paid on August 17, 2020 to stockholders of record as of August 10, 2020.

COVID-19

The Company continues to closely monitor the COVID-19 pandemic, its broader impact on the global economy and the more recent impacts on the U.S. economy. As of July 30, 2020, there is no indication of a reportable subsequent event impacting the Company’s financial statements for the three and six months ended June 30, 2020. The Company continues to observe and respond, if necessary, to the evolving COVID-19 environment and its potential impact on areas across its business.

64

ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

The matters discussed in this report, as well as in future oral and written statements by management of Hercules Capital, Inc., that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:

• | the effect and consequences of the novel coronavirus (“COVID-19”) public health crisis on matters including global, U.S. and local economies, our business operations and continuity, potential disruption to our portfolio companies, tightened availability to capital and financing, the health and productivity of our employees, the ability of third-party providers to continue uninterrupted service, and the regulatory environment in which we operate;
• | our current and future management structure;
• | our future operating results;
• | our business prospects and the prospects of our prospective portfolio companies;
• | the impact of investments that we expect to make;
• | our informal relationships with third parties including in the venture capital industry;
• | the expected market for venture capital investments and our addressable market;
• | the dependence of our future success on the general economy and its impact on the industries in which we invest;
• | our ability to access debt markets and equity markets;
• | the ability of our portfolio companies to achieve their objectives;
• | our expected financings and investments;
• | our regulatory structure and tax status;
• | our ability to operate as a BDC, a SBIC and a RIC;
• | the adequacy of our cash resources and working capital;
• | the timing of cash flows, if any, from the operations of our portfolio companies;
• | the timing, form and amount of any distributions;
• | the impact of fluctuations in interest rates on our business;
• | the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and
• | our ability to recover unrealized losses.

You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this report.

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this report. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under Item 1A— “Risk Factors” of Part II of this quarterly report on Form 10-Q, Item 1A— “Risk Factors” of our annual report on Form 10-K filed with the SEC on February 20, 2020 and under “Forward-Looking Statements” of this Item 2.

65

COVID-19 Developments

We are continuing to closely monitor the impact of the outbreak of COVID-19 on all aspects of our business, including how it impacts our portfolio companies, employees, due diligence and underwriting processes, and financial markets. While COVID-19 had a negative impact on our net income for the six months ended June 30, 2020, other key financial components such as total investment income and net investment income increased as compared to previous periods. Given the fluidity of the situation, we cannot estimate the long-term impact of COVID-19 on our business, future results of operations, financial position or cash flows at this time. The extent to which our operations may be impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted, including new information which may emerge concerning the severity of the outbreak, the uncertainty surrounding its resurgence and actions by government authorities to contain the outbreak or treat its impact. Furthermore, the impacts of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.

Overview

We are a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industrie s. We source our investments through our principal office located in Palo Alto, CA, as well as through our additional offices in Boston, MA, New York, NY, Bethesda, MD, Hartford, CT, and San Diego, CA.

Our goal is to be the leading structured debt financing provider for venture capital-backed companies in technology-related industries requiring sophisticated and customized financing solutions. Our strategy is to evaluate and invest in a broad range of technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology and to offer a full suite of growth capital products. We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We invest primarily in private companies but also have investments in public companies.

We use the term “structured debt with warrants” to refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or other rights to purchase or convert into common or preferred stock. Our structured debt with warrants investments typically are secured by some or all of the assets of the portfolio company. We also provide “unitranche” loans, which are loans that combine both senior and mezzanine debt, generally in a first lien position.

Our investment objective is to maximize our portfolio total return by generating current income from our debt investments and capital appreciation from our warrant and equity-related investments. Our primary business objectives are to increase our net income, net operating income, and net asset value (“NAV”) by investing in structured debt with warrants and equity of venture capital-backed companies in technology-related industries with attractive current yields and the potential for equity appreciation and realized gains. Our equity ownership in our portfolio companies may exceed 25% of the voting securities of such companies, which represents a controlling interest under the 1940 Act. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide directly to venture capital-backed companies in technology-related industries is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations.

We also make investments in qualifying small businesses through HT III, which is our wholly owned SBIC. HT III holds approximately $200.0 million in tangible assets which accounted for approximately 8.1% of our total assets at June 30, 2020.

We have qualified as and have elected to be treated for tax purposes as a RIC under Subchapter M of the Code. Pursuant to this election, we generally will not be subject to corporate-level taxes on any income and gains that we distribute as dividends for federal income tax purposes to our stockholders. However, our qualification and election to be treated as a RIC requires that we comply with provisions contained in Subchapter M of the Code. For example, as a RIC we must earn 90% or more of our gross income during each taxable year from qualified sources, typically referred to as “good income,” as well as satisfy certain quarterly asset diversification and annual income distribution requirements.

We are an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a BDC under the 1940 Act. As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes securities of private U.S. companies, cash, cash equivalents and high-quality debt investments that mature in one year or less.

Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology related companies at various stages of their development. Consistent with requirements under the 1940 Act, we invest primarily in United-States based companies and to a lesser extent in foreign companies.

66

We regularly engage in discus sions with third parties with respect to various potential transactions. We may acquire an investment or a portfolio of investments or an entire company or sell a portion of our portfolio on an opportunistic basis. We, our subsidiaries or our affiliates ma y also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will be subject to completion of due d iligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions including, without limitation, the approval of our board of directors and req uired regulatory or third party consents and, in certain cases, the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management r esources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.

Portfolio and Investment Activity

The total fair value of our investment portfolio was approximately $2.4 billion and $2.3 billion at June 30, 2020 and December 31, 2019, respectively. The fair value of our debt investment portfolio at June 30, 2020 was approximately $2.2 billion, compared to a fair value of approximately $2.1 billion at December 31, 2019. The fair value of the equity portfolio at June 30, 2020 was approximately $125.7 million, compared to a fair value of approximately $145.0 million at December 31, 2019. The fair value of the warrant portfolio at June 30, 2020 was approximately $21.5 million, compared to a fair value of approximately $20.9 million at December 31, 2019.

Portfolio Activity

Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. From time to time, unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company, which is expected to affect our funding levels. These commitments are subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the two succeeding quarters from close. Not all debt commitments represent future cash requirements. Similarly, unfunded contractual commitments may expire without being drawn and thus do not represent future cash requirements.

Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days f rom signing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

Our portfolio activity for the six months ended June 30, 2020 and the year ended December 31, 2019 was comprised of the following:

(in millions) | June 30, 2020 | December 31, 2019
Debt Commitments (1)
New portfolio company | $ | 312.0 | $ | 1,101.3
Existing portfolio company | 210.0 | 355.8
Total | $ | 522.0 | $ | 1,457.1
Funded and Restructured Debt Investments (2)
New portfolio company | $ | 146.8 | $ | 640.6
Existing portfolio company | 218.1 | 367.3
Total | $ | 364.9 | $ | 1,007.9
Funded Equity Investments
New portfolio company | $ | — | $ | 6.1
Existing portfolio company | 1.0 | 11.7
Total | $ | 1.0 | $ | 17.8
Unfunded Contractual Commitments (3)
Total | $ | 165.1 | $ | 133.7
Non-Binding Term Sheets
New portfolio company | $ | 20.0 | $ | 50.0
Existing portfolio company | 10.0 | 144.0
Total | $ | 30.0 | $ | 194.0

67

(1) | Includes restructured loans and renewals in addition to new commitments.
(2) | Funded amounts include borrowings on revolving facilities.
(3) | Amount represents unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones.

We receive principal payments on our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to period. During the six months ended June 30, 2020, we received approximately $269.2 million in aggregate principal repayments. Of the approximately $269.2 million of aggregate principal repayments, approximately $33.3 million were scheduled principal payments and approximately $235.9 million were early principal repayments related to 17 portfolio companies. Of the approximately $235.9 million early principal repayments, approximately $76.0 million were early repayments due to merger and acquisition transactions for four portfolio companies.

Total portfolio investment activity (inclusive of unearned income and excluding activity related to taxes payable, and escrow receivables) as of and for the six months ended June 30, 2020 and the year ended December 31, 2019 was as follows:

(in millions) | June 30, 2020 | December 31, 2019
Beginning portfolio | $ | 2,314.5 | $ | 1,880.4
New fundings and restructures | 365.9 | 1,025.7
Warrants not related to current period fundings | (0.3 | ) | 0.8
Principal payments received on investments | (33.3 | ) | (73.4 | )
Early payoffs | (235.9 | ) | (526.8 | )
Accretion of loan discounts and paid-in-kind principal | 22.0 | 43.3
Net acceleration of loan discounts and loan fees due to early payoff or restructure | (1.4 | ) | (9.7 | )
New loan fees | (5.0 | ) | (15.3 | )
Sale of investments | (19.7 | ) | (29.1 | )
Gain (loss) on investments due to sales or write offs | 7.1 | 6.0
Net change in unrealized appreciation (depreciation) | (50.4 | ) | 12.6
Ending portfolio | $ | 2,363.5 | $ | 2,314.5

As of June 30, 2020, we held debt, warrants, or equity positions in four companies that have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings. All four companies filed confidentially under the Jumpstart Our Business Startups Act. Subsequent to June 30, 2020, we held debt, warrants, or equity positions in five companies that have filed registration statements, of which four are confidential, on Form S-1 with the SEC in contemplation of potential initial public offerings. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely manner or at all.

Changes in Portfolio

We generate revenue in the form of interest income, primarily from our investments in debt securities, and commitment and facility fees. Interest income is recognized in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate revenue in the form of capital gains, if any, on warrants or other equity-related securities that we acquire from our portfolio companies. Our investments generally range from $15.0 million to $40.0 million, although we may make investments in amounts above or below that range. As of June 30, 2020, our debt investments generally have a term of between two and five years and typically bear interest at a rate ranging from approximately 6.9% to approximately 11.5%. In addition to the cash yields received on our debt investments, in some instances, our debt investments may also include any of the following: exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt.

Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the investment. In addition, our loans may include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.

Loan origination and commitment fees received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. We had approximately $40.5 million of unamortized fees at June 30, 2020, of which approximately $34.1 million was included as an offset to the cost basis of our current debt

68

investments and approximately $6.4 million was de ferred contingent upon the occurrence of a funding or milestone. At December 31, 2019, we had approximately $42.0 million of unamortized fees, of which approximately $34.6 million was included as an offset to the cost basis of our current debt investments and approximately $7.4 million was deferred contingent upon the occurrence of a funding or milestone.

Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. At June 30, 2020, we had approximately $44.0 million in exit fees receivable, of which approximately $40.2 million was included as a component of the cost basis of our current debt investments and approximately $3.8 million was a deferred receivable related to expired commitments. At December 31, 2019, we had approximately $33.5 million in exit fees receivable, of which approximately $31.9 million was included as a component of the cost basis of our current debt investments and approximately $1.6 million was a deferred receivable related to expired commitments.

We have debt investments in our portfolio that contain a PIK provision. The PIK interest, computed at the contractual rate specified in each loan agreement, is recorded as interest income and added to the principal balance of the loan on specified capitalization dates. To maintain our ability to be subject to tax as a RIC, this non-cash source of income must be distributed to stockholders with other sources of income in the form of dividend distributions even though we have not yet collected the cash. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments. We recorded approximately $2.1 million and $2.2 million in PIK income during the three months ended June 30, 2020 and 2019, respectively. We recorded approximately $4.1 million and $4.4 million in PIK income during the six months ended June 30, 2020 and 2019, respectively.

The core yield on our debt investments, which excludes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications and other one-time events and includes income from expired commitments, was 11.5% and 12.7% during the three months ended June 30, 2020 and 2019, respectively. The effective yield on our debt investments, which includes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications and other one-time events, was 12.2% and 14.3% for the three months ended June 30, 2020 and 2019, respectively. The effective yield is derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the quarter, excluding non-interest earning assets such as warrants and equity investments. Both the core yield and effective yield may be higher than what our common stockholders may realize as the core yield and effective yield do not reflect our expenses and any sales load paid by our common stockholders. The total yield on our investment portfolio was 12.2% and 12.7% during the three months ended June 30, 2020 and 2019, respectively. The total yield is derived by dividing total investment income by the weighted average investment portfolio assets outstanding during the quarter, including non-interest earning assets such as warrants and equity investments at amortized cost.

The total return for our investors was approximately (20.9%) and 21.6% during the six months ended June 30, 2020 and 2019, respectively. The total return equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. The total return does not reflect any sales load that must be paid by investors. See “Note 9 – Financial Highlights” included in the notes to our consolidated financial statements appearing elsewhere in this report.

Portfolio Composition

Our portfolio companies are primarily privately held companies and public companies which are active in sectors characterized by high margins, high growth rates, consolidation and product and market extension opportunities. As of June 30, 2020, approximately 89.3% of the fair value of our portfolio was composed of investments in five industries: 31.1% was composed of investments in the "Drug Discovery & Development" industry, 28.2% was composed of investments in the "Software" industry, 22.1% was composed of investments in the "Internet Consumer & Business Services" industry, 4.6% was composed of investments in the "Healthcare Services, Other" industry, and 3.3% was composed of investments in the "Sustainable and Renewable Technology" industry.

Industry and sector concentrations vary as new loans are recorded and loans pay off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrants or other equity-related interests, can fluctuate materially when a loan is paid off or a warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated in several portfolio companies.

69

For the six months ended June 30, 2020 and the year ended December 31, 2019, our ten largest portfolio companies represented approximately 29.4% and 27.8% of the total fair value of our investments in portfolio companies, respectively. At June 30, 2020 and December 31, 2019, we had eight and six investments, respectively, that represented 5% or more of our net assets. At June 30, 2020, we had seven equity investments representing app roximately 72.4% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. At December 31, 2019, we had six equity investments which represented approximately 63.3% of the total fa ir value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. No single portfolio investment represents more than 10% of the fair value of our total investments as of June 30, 2020 and December 31, 2 019.

As of June 30, 2020, approximately 97.9% of the debt investment portfolio was priced at floating interest rates or floating interest rates with a Prime or LIBOR-based interest rate floor. Changes in interest rates, including Prime and LIBOR rates, may affect the interest income and the value of our investment portfolio for portfolio investments with floating rates. We believe we are well positioned to benefit should market interest rates rise in the future.

Our investments in senior secured debt with warrants have detachable equity enhancement features, typically in the form of warrants or other equity-related securities designed to provide us with an opportunity for capital appreciation. These features are treated as OID and are accreted into interest income over the term of the loan as a yield enhancement. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing round. As of June 30, 2020, we held warrants in 103 portfolio companies, with a fair value of approximately $21.5 million. The fair value of our warrant portfolio increased by approximately $595,000, as compared to a fair value of $20.9 million at December 31, 2019 primarily related to the increase in fair value of portfolio companies.

Our existing warrant holdings would require us to invest approximately $70.3 million to exercise such warrants as of June 30, 2020. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. Accordingly, we may experience losses from our warrant portfolio.

Portfolio Grading

We use an investment grading system, which grades each debt investment on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. The following table shows the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of June 30, 2020 and December 31, 2019, respectively:

(in thousands) | June 30, 2020 | December 31, 2019
Investment Grading | Number of Companies | Debt Investments at Fair Value | Percentage of Total Portfolio | Number of Companies | Debt Investments at Fair Value | Percentage of Total Portfolio
1 | 14 | $ | 443,640 | 20.1 | % | 14 | $ | 387,327 | 18.0 | %
2 | 41 | 877,919 | 39.6 | % | 52 | 1,180,536 | 55.0 | %
3 | 39 | 849,667 | 38.3 | % | 23 | 509,940 | 23.7 | %
4 | 4 | 25,029 | 1.1 | % | 6 | 69,016 | 3.2 | %
5 | 4 | 20,097 | 0.9 | % | 2 | 1,773 | 0.1 | %
102 | $ | 2,216,352 | 100.0 | % | 97 | $ | 2,148,592 | 100.0 | %

As of June 30, 2020 and December 31, 2019, our debt investments had a weighted average investment grading of 2.30 and 2.15 on a cost basis, respectively. Our policy is to lower the grading on our portfolio companies as they approach the point in time when they will require additional equity capital. Additionally, we may downgrade our portfolio companies if they are not meeting our financing criteria or are underperforming relative to their respective business plans. Various companies in our portfolio will require additional funding in the near term or have not met their business plans and therefore have been downgraded until their funding is complete or their operations improve.

As the COVID-19 situation continues to evolve, we are maintaining close communications with our portfolio companies to proactively assess and manage potential risks across our debt investment portfolio. We have also increased oversight and analysis of credits in vulnerable industries in an attempt to improve loan performance and reduce credit risk.

70

Results of Operations

Comparison of the three and six months ended June 30, 2020 and 2019

Investment Income

Interest Income

Total investment income for the three months ended June 30, 2020 was approximately $68.0 million as compared to approximately $69.3 million for the three months ended June 30, 2019. Total investment income for the six months ended June 30, 2020 was approximately $141.6 million as compared to approximately $128.1 million for the six months ended June 30, 2019.

Interest income for the three months ended June 30, 2020 totaled approximately $63.6 million as compared to approximately $61.7 million for the three months ended June 30, 2019. Interest income for the six months ended June 30, 2020 totaled approximately $129.8 million as compared to approximately $117.2 million for the six months ended June 30, 2019. The increase in interest income for the three and six months ended June 30, 2020 as compared to the same period ended June 30, 2019 is primarily attributable to an increase in recurring interest income caused by an increase in the weighted average principal outstanding of loans, and an increase in the acceleration of interest income due to early loan repayments.

Of the $63.6 million in interest income for the three months ended June 30, 2020, approximately $61.3 million represents recurring income from the contractual servicing of our loan portfolio and approximately $2.3 million represents income related to the acceleration of income due to early loan repayments and other one-time events during the period. Income from recurring interest and the acceleration of interest income due to early loan repayments represented approximately $58.9 million and $2.8 million, respectively, of the $61.7 million interest income for the three months ended June 30, 2019.

Of the $129.8 million in interest income for the six months ended June 30, 2020, approximately $122.1 million represents recurring income from the contractual servicing of our loan portfolio and approximately $7.7 million represents income related to the acceleration of income due to early loan repayments and other one-time events during the period. Income from recurring interest and the acceleration of interest income due to early loan repayments represented $114.0 million and $3.2 million, respectively, of the $117.2 million interest income for the six months ended June 30, 2019.

The following table shows the PIK-related activity for the six months ended June 30, 2020 and 2019, at cost:

Six Months Ended June 30,
(in thousands) | 2020 | 2019
Beginning PIK interest receivable balance | $ | 14,498 | $ | 12,717
PIK interest income during the period | 4,147 | 4,364
PIK accrued (capitalized) to principal but not recorded as income during the period | (5,684 | ) | —
Payments received from PIK loans | (1,107 | ) | (2,309 | )
Realized gain (loss) | — | —
Ending PIK interest receivable balance | $ | 11,854 | $ | 14,772

The slight decrease in PIK interest income during the six months ended June 30, 2020 as compared to the six months ended June 30, 2019 is due to a decrease in the weighted average principal outstanding for loans on accrual which bear PIK interest.

Fee Income

Fee income from commitment, facility and loan related fees for the three months ended June 30, 2020 totaled approximately $4.4 million as compared to approximately $7.6 million for the three months ended June 30, 2019. Fee income from commitment, facility and loan related fees for the six months ended June 30, 2020 totaled approximately $11.8 million as compared to approximately $10.9 million for the six months ended June 30, 2019. The decrease in fee income for the three months ended June 30, 2020 is primarily due to a decrease in early payoffs. The increase in fee income for the six months ended June 30, 2020 is primarily due to an increase in the facilities fees and one-time fees due to early repayments.

Of the $4.4 million in fee income for the three months ended June 30, 2020, approximately $2.9 million represents income from recurring fee amortization and approximately $1.5 million represents income related to the acceleration of unamortized fees due to early repayments, including one-time fees of $897,000 for the period. Income from recurring fee amortization and the acceleration of

71

unamortized fees due to early loan repaymen ts represented $2.6 million and $5.0 million, respectively, of the $7.6 million in income for the three months ended June 30, 2019.

Of the $11.8 million in fee income for the six months ended June 30, 2020, approximately $5.8 million represents income from recurring fee amortization and approximately $6.0 million represents income related to the acceleration of unamortized fees due to early repayments, including one-time fees of $4.1 million for the period. Income from recurring fee amortization and the acceleration of unamortized fees due to early loan repayments represented $4.7 million and $6.2 million, respectively, of the $10.9 million in income for the six months ended June 30, 2019.

In certain investment transactions, we may earn income from advisory services; however, we had no income from advisory services in the three and six months ended June 30, 2020 or 2019.

Operating Expenses

Our operating expenses are comprised of interest and fees on our borrowings, general and administrative expenses and employee compensation and benefits. Our operating expenses totaled approximately $32.3 million and $34.0 million during the three months ended June 30, 2020 and 2019, respectively. Our operating expenses totaled approximately $65.3 million and $63.8 million during the six months ended June 30, 2020 and 2019, respectively.

Interest and Fees on our Borrowings

Interest and fees on our borrowings totaled approximately $16.7 million and $15.2 million for the three months ended June 30, 2020 and 2019, respectively, and approximately $33.1 million and $30.7 million during the six months ended June 30, 2020 and 2019, respectively. Interest and fee expense during the three and six months ended June 30, 2020, as compared to the same periods ended June 30, 2019, increased due to the issuance of our July 2024 Notes in July 2019, the issuance of our February 2025 Notes in February 2020 and the issuance of our June 2025 Notes in June 2020.

We had a weighted average cost of debt, comprised of interest and fees, of approximately 5.0% and 5.2% for the three months ended June 30, 2020 and 2019, respectively, and a weighted average cost of debt of approximately 5.1% and 5.5% for the six months ended June 30, 2020 and 2019, respectively. The decrease in the weighted average cost of debt for both of the three and six months ended June 30, 2020, as compared to the same periods ended June 30, 2019, is primarily driven by a reduction in the weighted average principal outstanding on our higher yielding debt instruments compared to the prior period.

General and Administrative Expenses

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, taxes, rent, expenses associated with the workout of underperforming investments and various other expenses. Our general and administrative expenses increased to $5.9 million from $5.8 million for the three months ended June 30, 2020 and 2019, respectively. Our general and administrative expenses increased to $11.9 million from $9.9 million for the six months ended June 30, 2020 and 2019, respectively. The increase in general and administrative expenses for the three and six months ended June 30, 2020 is mainly due to an increase in income taxes, termination, and marketing related expenses.

Employee Compensation

Employee compensation and benefits totaled $7.2 million for the three months ended June 30, 2020 as compared to $9.2 million for the three months ended June 30, 2019, and $15.4 million for the six months ended June 30, 2020 as compared to $15.8 million for the six months ended June 30, 2019. The decrease between both of the three and six months ended June 30, 2020 and 2019 was primarily due to decreased variable compensation and payroll related expenses.

Employee stock-based compensation totaled $2.5 million for the three months ended June 30, 2020 as compared to $3.9 million for the three months ended June 30, 2019, and $5.0 million for the six months ended June 30, 2020 as compared to $7.3 million for the six months ended June 30, 2019. The decreases between the three and six months ended June 30, 2020 and 2019 was primarily due to a settlement with our former Chairman and Chief Executive Officer, and elimination of associated stock-based compensation expense.

Net Investment Realized Gains and Losses and Net Unrealized Appreciation and Depreciation

Realized gains or losses are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off

72

during the period, net of recoveries. Net change in unrealized appreciation or depreciation primarily reflects the change in portfolio investment values during the repo rting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

A summary of realized gains and losses for the three and six months ended June 30, 2020 and 2019 is as follows:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Realized gains | $ | 2,531 | $ | 6,104 | $ | 14,719 | $ | 14,942
Realized losses | (2,390 | ) | (1,833 | ) | (7,611 | ) | (6,116 | )
Net realized gains (losses) | $ | 141 | $ | 4,271 | $ | 7,108 | $ | 8,826

During the three and six months ended June 30, 2020, we recognized net realized gains of $141,000 and $7.1 million, respectively, on the portfolio. During the three months ended June 30, 2020, we recorded gross realized gains of $2.5 million primarily from the sale of our public equity holdings. These gains were partially offset by gross realized losses of $2.4 million primarily from the liquidation or write-off of our equity or warrant positions during the period.

During the six months ended June 30, 2020, we recorded gross realized gains of $14.7 million primarily from the sale of public equity positions and sale of our holdings due to merger and acquisition transactions. These gains were offset by gross realized losses of $7.6 million primarily from the liquidation or write-off of our equity or warrant positions during the period.

During the three and six months ended June 30, 2019, we recognized net realized gains of $4.3 million and $8.8 million, respectively, on the portfolio. During the three months ended June 30, 2019, we recorded gross realized gains of $6.1 million primarily from the sale of our public equity holdings. These gains were offset by gross realized losses of $1.8 million primarily from the liquidation or write-off of our debt, equity, and warrant positions during the period.

During the six months ended June 30, 2019, we recorded gross realized gains of $14.9 million primarily from the sale of public equity positions and sale of our holdings due to merger and acquisition transactions. These gains were offset by gross realized losses of $6.1 million primarily from the liquidation or write-off of our debt, equity, or warrant positions during the period.

The net unrealized appreciation and depreciation of our investments is based on the fair value of each investment determined in good faith by our Board of Directors. The following table summarizes the change in net unrealized appreciation or depreciation of investments for the three and six months ended June 30, 2020 and 2019:

Three Months Ended June 30, | Six Months Ended June 30,
(in thousands) | 2020 | 2019 | 2020 | 2019
Gross unrealized appreciation on portfolio investments | $ | 56,712 | $ | 37,656 | $ | 71,032 | $ | 88,486
Gross unrealized depreciation on portfolio investments | (33,365 | ) | (24,912 | ) | (119,888 | ) | (45,931 | )
Reversal of prior period net unrealized appreciation (depreciation) upon a realization event | 2,593 | (4,187 | ) | (1,474 | ) | (6,067 | )
Net unrealized appreciation (depreciation) on debt, equity, and warrant investments | 25,940 | 8,557 | (50,330 | ) | 36,488
Other net unrealized appreciation (depreciation) | — | 36 | — | 102
Total net unrealized appreciation (depreciation) on investments | $ | 25,940 | $ | 8,593 | $ | (50,330 | ) | $ | 36,590

During the three months ended June 30, 2020, we recorded $25.9 million of net unrealized appreciation, all of which was net unrealized appreciation from our debt, equity and warrant investments. We recorded $15.3 million of net unrealized depreciation on our debt investments which was primarily related to $15.9 million of net unrealized depreciation on the debt portfolio partially offset by $686,000 of unrealized appreciation due to the reversal of unrealized depreciation upon pay-off of our portfolio companies.

We recorded $29.8 million of net unrealized appreciation on our equity investments and $11.4 million of net unrealized appreciation on our warrant investments during the three months ended June 30, 2020. This net unrealized appreciation of $41.2 million was primarily attributable to $39.3 million of unrealized appreciation on the equity and warrant portfolio and $1.9 million of unrealized appreciation due to the reversal of unrealized depreciation upon acquisition or liquidation of our equity and warrant investments.

During the six months ended June 30, 2020, we recorded $50.3 million of net unrealized depreciation, all of which was net unrealized depreciation from our debt, equity and warrant investments. We recorded $41.0 million of net unrealized depreciation on

73

our debt investments which was primarily related to $42.4 million of unrealized depr eciation on the debt portfolio offset by $1.4 million of unrealized appreciation due to the reversal of unrealized depreciation upon pay-off of our debt investments.

We recorded $14.1 million of net unrealized depreciation on our equity investments and $4.8 million of net unrealized appreciation on our warrant investments during the six months ended June 30, 2020. This net unrealized depreciation of $9.3 million was primarily attributable to $6.5 million of unrealized depreciation on the equity and warrant portfolio and the $2.8 million of unrealized depreciation due to the reversal of unrealized appreciation upon acquisition or liquidation of our equity and warrant investments.

During the three months ended June 30, 2019, we recorded $8.6 million of net unrealized appreciation, all of which was primarily net unrealized appreciation from our debt, equity and warrant investments. We recorded $659,000 of net unrealized appreciation on our debt investments which was primarily related to $918,000 of net unrealized appreciation on the debt portfolio partially offset by $259,000 of unrealized depreciation due to the reversal of unrealized appreciation upon pay-off or write-off of our portfolio companies.

We recorded $9.9 million of net unrealized appreciation on our equity investments and $2.0 million of net unrealized depreciation on our warrant investments during the three months ended June 30, 2019. This net unrealized appreciation of $7.9 million was primarily attributable to $11.8 million of unrealized appreciation on the equity and warrant portfolio partially offset by $3.9 million of unrealized depreciation due to the reversal of unrealized appreciation upon acquisition or liquidation of our equity and warrant investments.

During the six months ended June 30, 2019, we recorded $36.6 million of net unrealized appreciation, of which $36.5 million was net unrealized appreciation from our debt, equity and warrant investments. We recorded $3.8 million of net unrealized appreciation on our debt investments which was primarily related to $2.3 million of unrealized appreciation primarily due to the reversal of unrealized depreciation upon write-off and $1.5 million of unrealized appreciation on the debt portfolio.

We recorded $33.0 million of net unrealized appreciation on our equity investments and $347,000 of net unrealized depreciation on our warrant investments during the six months ended June 30, 2019. This net unrealized appreciation of $32.7 million was primarily attributable to $41.1 million of unrealized appreciation on the equity and warrant portfolio partially offset by the $8.4 million of unrealized depreciation due to the reversal of unrealized appreciation upon acquisition or liquidation of our equity and warrant investments.

Income and Excise Taxes

We account for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differen ces between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

Because federal income tax regulations differ from accounting principles generally accepted in the United States, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.

Net Change in Net Assets Resulting from Operations and Earnings Per Share

For the three months ended June 30, 2020, we had a net increase in net assets resulting from operations of approximately $61.8 million and for the three months ended June 30, 2019, we had a net increase in net assets resulting from operations of approximately $48.1 million. For the six months ended June 30, 2020, we had a net increase in net assets resulting from operations of approximately $33.0 million and for the six months ended June 30, 2019, we had a net increase in net assets resulting from operations of approximately $109.7 million.

74

Both the basic and fully diluted net change in net assets per common share were $0.55 per share and $0.29 per share for the three and six months ended June 30, 2020. Both the basic and fully diluted net change in net assets per common share were $0.49 per share for the three months ended June 30, 2019. The basic and fully diluted net change in net asset s per common share was $1.13 per share and $1.12 per share, respectively, for the six months ended June 30, 2019.

For the purpose of calculating diluted earnings per share for three and six months ended June 30, 2020, the dilutive effect of the 2022 Convertible Notes, outstanding options, restricted stock units and awards and Retention PSUs under the treasury stock method was considered. The effect of the 2022 Convertible Notes was excluded from these calculations for the three and six months ended June 30, 2019 as our share price was less than the conversion price in effect which results in anti-dilution.

Financial Condition, Liquidity, and Capital Resources

Our liquidity and capital resources are derived from our SBA debentures, 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, 2025 Notes, 2033 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, 2022 Convertible Notes, Credit Facilities and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our borrowings and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. We may also raise additional equity or debt capital through registered offerings off a shelf registration, ATM, and private offerings of securities, by securitizing a portion of our investments, or by borrowing from the SBA through our SBIC subsidiaries.

SBA debentures

On July 13, 2018, we completed repayment of the remaining outstanding HT II debentures and subsequently surrendered the SBA license with respect to HT II.

On March 1, 2020, we paid down $38.7 million of SBA debentures.

2022 Notes

On October 23, 2017, we issued $150.0 million in aggregate principal amount of the 2022 Notes pursuant to the 2022 Notes Indenture. The sale of the 2022 Notes generated net proceeds of approximately $147.4 million, including a public offering discount of $826,500. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions of approximately $975,000, were approximately $1.8 million.

July 2024 Notes

On July 16, 2019, we issued $105.0 million in aggregate principal amount of July 2024 Notes. The sale of the July 2024 Notes generated net proceeds of approximately $103.5 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $1.5 million.

February 2025 Notes

On February 5, 2020, we issued $50.0 million in aggregate principal amount of February 2025 Notes pursuant to the 2025 Note Purchase Agreement. The sale of the February 2025 Notes generated net proceeds of approximately $49.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $581,000.

June 2025 Notes

On June 3, 2020, we issued $70.0 million in aggregate principal amount of June 2025 Notes pursuant to the 2025 Note Purchase Agreement. The sale of the June 2025 Notes generated net proceeds of approximately $69.2 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $796,000.

2025 Notes

On April 26, 2018, we issued $75.0 million in aggregate principal amount of the 2025 Notes pursuant to the 2025 Notes Indenture. The sale of the 2025 Notes generated net proceeds of approximately $72.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions were approximately $2.6 million.

75

2033 Notes

On September 20, 2018, we issued $40.0 million in aggregate principal amount of the 2033 Notes pursuant to the 2033 Notes Indenture. The sale of the 2033 Notes generated net proceeds of approximately $38.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions were approximately $1.6 million.

2027 Asset-Backed Notes

On November 1, 2018, we issued $200.0 million in aggregate principal amount of the 2027 Asset-Backed Notes. The sale of the 2027 Asset-Backed Notes generated net proceeds of approximately $197.0 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions were approximately $3.0 million.

2028 Asset-Backed Notes

On January 22, 2019, we issued $250.0 million in aggregate principal amount of the 2028 Asset-Backed Notes. The sale of the 2028 Asset-Backed Notes generated net proceeds of approximately $247.1 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions were approximately $2.9 million.

Fully Redeemed Notes

O n December 7, 2018, our Board of Directors approved a full redemption, in two equal transactions, of $83.5 million of the outstanding aggregate principal amount of the 2024 Notes. The 2024 Notes were fully redeemed on January 14, 2019 and February 4, 2019.

2022 Convertible Notes

On January 25, 2017, we issued $230.0 million in aggregate principal amount of 2022 Convertible Notes, which amount includes the additional $30.0 million aggregate principal amount issued pursuant to the initial purchaser’s exercise in full of its overallotment option. The sale generated net proceeds of approximately $225.5 million, including $4.5 million of debt issuance costs. Aggregate issuances costs include the initial purchaser’s discount of approximately $5.2 million, offset by the reimbursement of $1.2 million by the initial purchaser.

Credit Facilities

Wells Facility

On January 11, 2019, Hercules Funding II entered into the Wells Facility Seventh Amendment. The Wells Facility Seventh Amendment, among other things, amends certain key provisions of the Wells Facility to reduce the current interest rate to LIBOR plus 3.00% with an interest rate floor of 3.00% and extends the maturity date to January 2023. In addition, the Wells Fargo Capital Finance, LLC has committed $75.0 million in credit capacity under a $125.0 million accordion credit facility, subject to borrowing base, leverage and other restrictions.

Union Bank Facility

On February 20, 2019, we, through a special purpose wholly owned subsidiary, Hercules Funding IV, as borrower, entered the 2019 Union Bank Facility. The 2019 Union Bank Facility replaced the Prior Union Bank Facility. Any references to amounts related to the 2019 Union Bank Facility prior to February 20, 2019 were incurred and relate to the Prior Union Bank Facility. Under the 2019 Union Bank Facility, the lenders have made commitments of $200.0 million.

On June 28, 2019, Hercules Funding IV entered into the Union Bank Facility Amendment to the 2019 Union Bank Facility. The Union Bank Facility Amendment amends certain provisions of the 2019 Union Bank Facility to, among other things, (i) delete the financial covenant with respect to maintaining minimum portfolio funding liquidity, (ii) add a covenant prohibiting Hercules Funding IV from acquiring or owning unfunded commitments to makers of certain notes receivable, and (iii) revise certain provisions thereof to further permit a third party special servicer to act as servicer after an event of default instead of us with respect to split-funded notes receivable owned by Hercules Funding IV and an affiliate thereof (including Hercules Funding II).

On February 20, 2020, we, through a special purpose wholly owned subsidiary, Hercules Funding IV, as borrower, entered the Union Bank Facility. The Union Bank Facility replaced the 2019 Union Bank Facility. Any references to amounts related to the Union

76

Bank Facility from February 20, 2019 to February 20, 2020 were incurred and relate to the 2019 Union Bank Facility. Under the Union Bank Facility, the lenders have made commitments of $400.0 million.

Equity Distribution Agreement

On May 6, 2019, we entered into the Equity Distribution Agreement. The Equity Distribution Agreement provides that we may offer and sell up to 12.0 million shares of our common stock from time to time through JMP, as our sales agent. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three and six months ended June 30, 2020, we sold 3.5 million and 6.0 million shares of common stock, respectively, under the Equity Distribution Agreement. As of June 30, 2020, approximately 2.1 million shares remain available for issuance and sale under the Equity Distribution Agreement.

On July 2, 2020, we terminated the Equity Distribution Agreement and entered into a new ATM equity distribution agreement with JMP. See Item 2. Subsequent Events below.

Equity Offerings

On June 17, 2019, we closed the June 2019 Equity Offering. The offering generated net proceeds, before expenses, of $70.5 million, including the underwriting discount and commissions of $2.2 million.

Stock Repurchase

We may from time to time seek to retire or repurchase our common stock through cash purchases, as well as retire, cancel or purchase our outstanding debt through cash purchases and/or exchanges, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual and regulatory restrictions and other factors. The amounts involved may be material.

On December 17, 2018, our Board of Directors authorized a stock repurchase plan permitting us to repurchase up to $25.0 million of our common stock until June 18, 2019, after which the plan expired. We had no common stock repurchases during 2019.

Available liquidity and capital resources as of June 30, 2020

At June 30, 2020, we had $110.3 million of SBA debentures, $150.0 million of 2022 Notes, $105.0 million of July 2024 Notes, $50.0 million of February 2025 Notes, $70.0 million of June 2025 Notes, $75.0 million of 2025 Notes, $40.0 million of 2033 Notes, $200.0 million of 2027 Asset-Backed Notes, $250.0 million of 2028 Asset-Backed Notes, and $230.0 million of 2022 Convertible Notes payable, along with no outstanding borrowings on both the Wells Facility and the Union Bank Facility.

At June 30, 2020, we had $510.9 million in available liquidity, including $35.9 million in cash and cash equivalents. We had available borrowing capacity of $75.0 million under the Wells Facility and $400.0 million under the Union Bank Facility, both subject to existing terms, borrowing base, advance rates and regulatory requirements. We primarily invest cash on hand in interest bearing deposit accounts.

At June 30, 2020, we had $74.5 million of capital outstanding in restricted accounts related to our SBIC. With our net investment of $74.5 million in HT III, we have the approved capacity to issue a total of $110.3 million of SBA guaranteed debentures. At June 30, 2020, we have issued $110.3 million in SBA guaranteed debentures in our SBIC subsidiaries. As we are past our investment period for HT III, we will no longer make any future commitments to new portfolio companies. We will only satisfy contractually agreed follow-on fundings to existing portfolio companies and may seek to early pay-off a portion or all of the outstanding debentures as per the available liquidity in HT III.

At June 30, 2020, we had approximately $33.6 million of restricted cash, which consists of collections of interest and principal payments on assets that are securitized. In accordance with the terms of the related securitized 2027 Asset-Backed Notes and 2028 Asset-Backed Notes, based on current characteristics of the securitized debt investment portfolios, the restricted funds may be used to pay monthly interest and principal on the securitized debt with any excess distributed to us or available for our general operations.

During the six months ended June 30, 2020, we principally funded our operations from (i) cash receipts from interest, dividend and fee income from our investment portfolio and (ii) cash proceeds from the realization of portfolio investments through the

77

repayments of debt investments and the sale of debt and equity investments, (iii) debt offerings along with borrowings on our credit facilities, and (iv) equity of ferings.

During the six months ended June 30, 2020, our operating activities used $12.8 million of cash and cash equivalents, compared to $251.5 million used during the six months ended June 30, 2019. This $238.8 million decrease in cash used in operating activities is primarily related to a decrease of $242.0 million in purchase of investments.

During the six months ended June 30, 2020, our investing activities used approximately $67,000 of cash, compared to $241,000 used during the six months ended June 30, 2019. The $174,000 decrease in cash used in investing activities was due to a decrease in purchase of capital equipment.

During the six months ended June 30, 2020, our financing activities used $32.7 million of cash, compared to $234.5 million provided by financing activities during the six months ended June 30, 2019. The $267.2 million decrease in cash provided by financing activities was primarily due to a $209.9 million decrease in borrowings from new note issuances and credit facilities for the six months ended June 30, 2020, compared to the six months ended June 30, 2019.

As of June 30, 2020, our net assets totaled $1.2 billion, with a NAV per share of $10.19. We intend to continue to operate in order to generate cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.

As described above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe we have ample liquidity to support our near-term capital requirements. As the impact of the COVID-19 continues to unfold, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the current circumstances.

The SBCAA, which was signed into law in March 2018, decreased the minimum asset coverage ratio in Section 61(a) of the 1940 Act for BDCs from 200% to 150% (subject to either stockholder approval or approval of both a majority of the board of directors and a majority of directors who are not interested persons). On September 4, 2018 and December 6, 2018, our Board of Directors, including a “required majority” (as such term is defined in Section 57(o) of the 1940 Act) and our stockholders, respectively, approved the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act. As a result, effective December 7, 2018, the asset coverage ratio under the 1940 Act applicable to us decreased from 200% to 150%, permitting us to incur additional leverage. As of June 30, 2020, our asset coverage ratio under our regulatory requirements as a BDC was 199.5% excluding our SBA debentures as a result of our exemptive order from the SEC that allows us to exclude all SBA leverage from our asset coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 150%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total asset coverage when including our SBA debentures was 190.9% at June 30, 2020.

Refer to “Note 4 – Borrowings” included in the notes to our consolidated financial statements appearing elsewhere in this report for a discussion of our borrowings.

Commitments

In the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet. Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. As such, our disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones.

At June 30, 2020, we had approximately $165.1 million of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by milestones. We intend to use cash flow from normal and early principal repayments, and proceeds from borrowings and notes to fund these commitments.

78

We also had approximately $30.0 million of non-binding term sheets outstanding to one new company and one existing company, which generally convert to contractual commitments within approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as th e negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

The fair value of our unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.

Contractual Obligations

The following table shows our contractual obligations as of June 30, 2020:

Payments due by period (in thousands)
Contractual Obligations (1) | Total | Less than 1 year | 1 - 3 years | 3 - 5 years | After 5 years
Borrowings (2)(3) | $ | 1,280,250 | $ | — | $ | 490,250 | $ | 300,000 | $ | 490,000
Lease and License Obligations (4) | 11,745 | 3,032 | 5,892 | 2,043 | 778
Total | $ | 1,291,995 | $ | 3,032 | $ | 496,142 | $ | 302,043 | $ | 490,778
(1) | Excludes commitments to extend credit to our portfolio companies.
(2) | Includes $110.3 million principal outstanding under the SBA debentures, $150.0 million of the 2022 Notes, $105.0 million of the July 2024 Notes, $50.0 million of February 2025 Notes, $70.0 million of the June 2025 Notes, $75.0 million of the 2025 Notes, $40.0 million of the 2033 Notes, $200.0 million of the 2027 Asset-Backed Notes, $250.0 million of the 2028 Asset-Backed Notes, and $230.0 million of the 2022 Convertible Notes. There were no outstanding borrowings under the Union Bank Credit Facility or the Wells Facility as of June 30, 2020.
(3) | Amounts represent future principal repayments and not the carrying value of each liability. See Note 4 to the Company’s consolidated financial statements.
(4) | Facility leases and licenses including short-term leases.

Certain premises are leased or licensed under agreements which expire at various dates through June 2027. Total rent expense, including short-term leases, amounted to approximately $761,000 and $1.5 million, respectively, during the three and six months ended June 30, 2020 and approximately $623,000 and $1.2 million, respectively, during the three and six months ended June 30, 2019.

Indemnification Agreements

We have entered into indemnification agreements with our directors and executive officers. The indemnification agreements are intended to provide our directors and executive officers the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that we shall indemnify the director or executive officer who is a party to the agreement, or an “Indemnitee,” including the advancement of legal expenses, if, by reason of his or her corporate status, the Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted by Maryland law and the 1940 Act.

We and our executives and directors are covered by Directors and Officers Insurance, with the directors and officers being indemnified by us to the maximum extent permitted by Maryland law subject to the restrictions in the 1940 Act.

Distributions

Our Board of Directors maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90% - 100% of our taxable quarterly income or potential annual income for a particular taxable year. In addition, our Board of Directors may choose to pay additional special distributions, so that we may distribute approximately all of our annual taxable income in the taxable year in which it was earned, or may elect to maintain the option to spill over our excess taxable income into the following taxable year as part of any future distribution payments.

79

Distributions from our taxable income (including gains) to a stockholder generally will be treated as a dividend for U.S. federal income tax purposes to the extent of such stockholder’s allocable share of our current or accumulated earnings and profits. Distributions in excess of our current and accumulated earnings and profits would generally b e treated first as a return of capital to the extent of a stockholder’s tax basis in our shares, and any remaining distributions would be treated as a capital gain. The determination of the tax attributes of our distributions is made annually as of the end of our taxable year based upon our taxable income for the full taxable year and distributions paid for the full taxable year. As a result, any determination of the tax attributes of our distributions made on a quarterly basis may not be representative of the actual tax attributes of our distributions for a full taxable year. Of the distributions declared during the year ended December 31, 2019, 100% were distributions derived from our current and accumulated earnings and profits. There can be no certainty to stockholders that this determination is representative of what the tax attributes of our 2020 distributions to stockholders will actually be.

We maintain an “opt out” dividend reinvestment plan that provides for reinvestment of our distribution on behalf of our stockholders, unless a stockholder elects to receive cash. As a result, if our Board of Directors authorizes, and we declare a cash distribution, then our stockholders who have not “opted out” of our dividend reinvestment plan will have their cash distribution automatically reinvested in additional shares of our common stock, rather than receiving the cash distributions.

Shortly after the close of each calendar year information identifying the source of the distribution (i.e., paid from ordinary income, paid from net capital gains on the sale of securities, and/or a return of paid-in-capital surplus which is a nontaxable distribution, if any) will be provided to our stockholders subject to information reporting. To the extent our taxable earnings fall below the total amount of our distributions for any taxable year, a portion of those distributions may be deemed a tax return of capital to our stockholders.

We expect to qualify to be subject to tax as a RIC under Subchapter M of the Code. In order to be subject to tax as a RIC, we are required to satisfy certain annual gross income and quarterly asset composition tests, as well as make distributions to our stockholders each taxable year treated as dividends for federal income tax purposes of an amount at least equal to 90% of the sum of our investment company taxable income, determined without regard to any deduction for dividends paid, plus our net tax-exempt income, if any. Upon being eligible to be subject to tax as a RIC, we would be entitled to deduct such distributions we pay to our stockholders in determining the overall components of our “taxable income.” Components of our taxable income include our taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net realized securities gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses and generally excludes net unrealized appreciation or depreciation as such gains or losses are not included in taxable income until they are realized. In connection with maintaining our ability to be subject to tax as a RIC, among other things, we have made and intend to continue to make the requisite distributions to our stockholders each taxable year, which generally should relieve us from corporate-level U.S. federal income taxes.

As a RIC, we will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income and gains unless we make distributions treated as dividends for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year of an amount at least equal to the excise tax avoidance requirement. We will not be subject to this excise tax on any amount on which we incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net capital gains).

Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year distributions treated as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over taxable income into the next taxable year, distributions declared and paid by us in a taxable year may differ from our taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.

We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, if we issue senior securities, we will be prohibited from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the 1940 Act or if distributions are limited by the terms of any of our borrowings. Our ability to make distributions will be limited by the asset coverage requirements under the 1940 Act.

We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

80

Critical Accounting Policies

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.

Valuation of Investments

The most significant estimate inherent in the preparation of our consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

At June 30, 2020, approximately 95.7% of our total assets represented investments in portfolio companies whose fair value is determined in good faith by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. Our investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. Our debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of our investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, we value substantially all of our investments at fair value as determined in good faith pursuant to a consistent valuation policy by our Board of Directors in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of our investments determined in good faith by our Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

We intend to continue to engage one or more independent valuation firm(s) to provide us with valuation assistance regarding our determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. Specifically, on a quarterly basis, we will identify portfolio investments with respect to which an independent valuation firm will assist in valuing. We select these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of the services rendered by an independent valuation firm is at the discretion of the Board of Directors. Our Board of Directors is ultimately, and solely, responsible for determining the fair value of our investments in good faith.

Refer to “Note 2 – Summary of Significant Accounting Policies” included in the notes to our consolidated financial statements appearing elsewhere in this report for a discussion of our valuation policies for the three and six months ended June 30, 2020.

Income Recognition

See “— Changes in Portfolio” for a discussion of our income recognition policies and results during the three and six months ended June 30, 2020. See “— Results of Operations” for a comparison of investment income for the three and six months ended June 30, 2020 and 2019.

Stock Based Compensation

We have issued and may, from time to time, issue stock options and restricted stock to employees under the 2018 Equity Incentive Plan and the Director Plan. We follow the guidelines set forth under ASC Topic 718 to account for stock options granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment, including estimating stock price volatility, forfeiture rate and expected option life.

81

Subsequent Events

On July 2, 2020, we terminated the Equity Distribution Agreement and entered into a new ATM equity distribution agreement, or the 2020 Equity Distribution Agreement. As a result, the remaining shares that were available under the Equity Distribution Agreement are no longer available for issuance. The 2020 Equity Distribution Agreement provides that we may offer and sell up to 16.5 million shares of our common stock from time to time through JMP, as our sales agent. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

Subsequent to June 30, 2020 and as of July 29, 2020, we did not sell any shares of common stock under the 2020 Equity Distribution Agreement. As of July 29, 2020, 16.5 million shares remain available for issuance and sale under the 2020 Equity Distribution Agreement.

On July 22, 2020, the Board of Directors declared a cash distribution of $0.32 per share to be paid on August 17, 2020 to stockholders of record as of August 10, 2020.

COVID-19

We continue to closely monitor the COVID-19 pandemic, its broader impact on the global economy and the more recent impacts on the U.S. economy. As of July 30, 2020, there is no indication of a reportable subsequent event impacting our financial statements for the three and six months ended June 30, 2020. We continue to observe and respond, if necessary, to the evolving COVID-19 environment and its potential impact on areas across our business.

82

ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our investment income will be affected by changes in various interest rates, including LIBOR and Prime rates, to the extent our debt investments include variable interest rates. As of June 30, 2020, approximately 97.9% of the loans in our portfolio had variable rates based on floating Prime or LIBOR rates with a floor. Our borrowings under the Credit Facilities bear interest at a floating rate and the borrowings under our SBA debentures, 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, 2025 Notes, 2033 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, and 2022 Convertible Notes bear interest at a fixed rate. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.

Based on our Consolidated Statements of Assets and Liabilities as of June 30, 2020, the following table shows the approximate annualized increase (decrease) in components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and borrowings.

(in thousands) | Interest | Interest | Net
Basis Point Change | Income | Expense | Income | EPS
(75) | $ | (650 | ) | $ | (180 | ) | $ | (470 | ) | $ | -
(50) | $ | (492 | ) | $ | (120 | ) | $ | (372 | ) | $ | -
(25) | $ | (307 | ) | $ | (60 | ) | $ | (247 | ) | $ | -
25 | $ | 1,663 | $ | 60 | $ | 1,603 | $ | 0.01
50 | $ | 3,363 | $ | 120 | $ | 3,243 | $ | 0.03
75 | $ | 5,062 | $ | 180 | $ | 4,882 | $ | 0.04
100 | $ | 6,888 | $ | 240 | $ | 6,648 | $ | 0.06
200 | $ | 17,051 | $ | 479 | $ | 16,572 | $ | 0.15

We do not currently engage in any hedging activities. However, we may, in the future, hedge against interest rate fluctuations (and foreign currency) by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates (and foreign currency), they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the six months ended June 30, 2020, we did not engage in interest rate or foreign currency hedging activities.

Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including borrowings under our SBA debentures, 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, 2025 Notes, 2033 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, 2022 Convertible Notes and Credit Facilities that could affect the net increase in net assets resulting from operations, or net income. It also does not assume any repayments from borrowers. Accordingly, no assurances can be given that actual results would not differ materially from the statement above.

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio.

For additional information regarding the interest rate associated with each of our, SBA debentures, 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, 2025 Notes, 2033 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, 2022 Convertible Notes, and Credit Facilities, refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Financial Condition, Liquidity and Capital Resources - Outstanding Borrowings” in this quarterly report on Form 10-Q and “Note 4 – Borrowings” included in the notes to our consolidated financial statements appearing elsewhere in this report.

83

ITEM 4. | CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our chief executive and chief financial officers, under the supervision and with the participation of our management, conducted an evaluation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. As of the end of the period covered by this quarterly report on Form 10-Q, our chief executive and chief financial officers have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financing reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

84

PART II: OTHER INFORMATION

ITEM 1. | LEGAL PROCEEDINGS

We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.

ITEM 1A. | RISK FACTORS

In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 20, 2020 (the “Annual Report”).

The effects of the outbreak of COVID-19 have negatively affected the global economy and the United States economy, and may disrupt our operations, which could have an adverse effect on our business, financial condition and results of operations.

The ongoing COVID-19 global and national health emergency has caused significant disruption in the United States and global economies and financial markets. The spread of COVID-19 has caused quarantines, cancellation of events and travel, business and school shutdowns, reduction in business activity and financial transactions, labor shortages, supply chain interruptions and overall economic and financial market instability. The COVID-19 outbreak may disrupt our operations through its impact on our employees, our portfolio companies and their businesses, and certain industries in which our portfolio companies operate. Disruptions to our portfolio companies may impair their ability to fulfill their obligations to us and could result in increased risk of delinquencies, defaults, declining collateral values associated with our existing loans, and impairments or losses on our loans. Further, the spread of the COVID-19 outbreak has caused severe disruptions in the United States economy and may materially disrupt financial activity generally and in the areas in which we operate. This would likely result in a decline in demand for our loans which would negatively impact our liquidity position and our growth strategy. Any one or more of these developments could have a material adverse effect on our business, operations, consolidated financial condition, and consolidated results of operations. We are taking precautions to protect the safety and well-being of our employees. However, no assurance can be given that the steps being taken will be deemed to be adequate or appropriate, nor can we predict the level of disruption which will occur to our employees’ ability to service the portfolio.

The extent of the impact of the COVID-19 pandemic on our operational and financial performance, including our ability to execute our business strategies and initiatives in the expected time frame, will depend on future developments, including the duration and spread of the pandemic and related restrictions on travel and transportation, all of which are uncertain and cannot be predicted. An extended period of global supply chain and economic disruption could materially affect our business, results of operations, access to sources of liquidity and financial condition.

Our common stock price may be volatile or trade below its NAV per share, which may cause a decline in your investment or limit our ability to raise additional equity capital.

The stock markets have recently experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of shares of our common stock, regardless of our operating performance, and cause the value of your investment to decline.

If our common stock is trading below its NAV per share, we will generally not be able to issue additional shares of our common stock at its market price without first obtaining the approval for such issuance from our stockholders and our independent directors. We have received the approval from our stockholders to issue shares of our common stock at a price below its then current NAV per share, subject to certain limitations and with the approval of our independent directors. If our common stock trades below NAV, the higher cost of equity capital may result in it being unattractive to raise new equity, which may limit our ability to grow. The risk of trading below NAV is separate and distinct from the risk that our NAV per share may decline. We cannot predict whether shares of our common stock will trade above, at or below our NAV.

85

Additionally, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation or other derivative shareholder lawsuits. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business co ncerns, which could seriously harm our business regardless of the outcome.

If we sell common stock at a discount to our net asset value per share, stockholders who do not participate in such sale will experience immediate dilution in an amount that may be material.

We have received the approval from our stockholders to issue shares of our common stock at a price below its then current NAV per share, subject to certain limitations and with the approval of our independent directors. The issuance or sale by us of shares of our common stock at a price per share, after offering expenses and commission, that is a discount to net asset value poses a risk of dilution to our stockholders. In particular, stockholders who do not purchase additional shares at or below the discounted price in proportion to their current ownership will experience an immediate decrease in net asset value per share (as well as in the aggregate net asset value of their shares if they do not participate at all). These stockholders will also experience a disproportionately greater decrease in their participation in our earnings and assets and their voting power than the increase we experience in our assets, potential earning power and voting interests from such issuance or sale. In addition, such sales may adversely affect the price at which our common stock trades.

Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.

Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies at June 30, 2020 that represent greater than 5% of our net assets:

June 30, 2020
(in thousands) | Fair Value | Percentage of Net Assets
BridgeBio Pharma LLC | $ | 83,646 | 7.2 | %
Oak Street Health | 82,453 | 7.1 | %
EverFi, Inc. | 82,286 | 7.1 | %
Tricida, Inc. | 78,980 | 6.8 | %
Paratek Pharmaceuticals, Inc. | 73,106 | 6.3 | %
Businessolver.com, Inc. | 65,401 | 5.6 | %
Delphix Corp. | 59,637 | 5.1 | %
SeatGeek, Inc. | 58,532 | 5.0 | %
• | BridgeBio Pharma LLC is a clinical-stage biopharmaceutical company that discovers and develops drugs for patients with genetic diseases.
• | Oak Street Health operates primary care clinics and healthcare centers that provides healthcare facilities for Medicare eligible beneficiaries, and it serves patients in the United States.
• | EverFi, Inc. is a technology company that offers a web-based media platform to teach and certify students in the core concepts of financial literacy, from student loan defaults and sub-prime mortgages to credit card debt and rising bankruptcy rates.
• | Tricida, Inc. is a biopharmaceutical company that focuses on the discovery and clinical development of novel therapeutics to address renal, metabolic, and cardiovascular diseases.
• | Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.
• | Businessolver.com, Inc. is a technology company that provides a cloud-based SaaS platform for employee benefit administration designed to manage and monitor enrollment and payroll dashboards with real-time data.
• | Delphix Corp. is a technology company that develops database virtualization software solutions.
• | SeatGeek, Inc. is a technology company that develops online ticket search engines for live entertainment such as sports, concerts, and other events.

Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

86

ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Dividend Reinvestment Plan

During the six months ended June 30, 2020, we issued 121,015 shares of common stock to stockholders in connection with the dividend reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act. The aggregate value of the shares of our common stock issued under our dividend reinvestment plan was approximately $1.5 million.

ITEM 3. | DEFAULTS UPON SENIOR SECURITIES

Not Applicable

ITEM 4. | MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5. | OTHER INFORMATION

Not Applicable

87

ITEM 6. | EXHIBITS
Exhibit Number | Description
10.1 | Equity Distribution Agreement, dated July 2, 2020, between Hercules Capital, Inc. and JMP Securities, LLC. (1)
31.1* | Chief Executive Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2* | Chief Financial Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1* | Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2* | Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
* | Filed herewith.
(1) | Previously filed as part of the Current Report on Form 8-K of the Company, as filed on July 2, 2020.

.

88

Schedule 12 – 14

HERCULES CAPITAL, INC.

SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

For the Six Months Ended June 30, 2020

(in thousands)

Portfolio Company | Investment (1) | Amount of Interest Credited to Income (2) | Realized Gain (Loss) | As of December 31, 2019 Fair Value | Gross Additions (3) | Gross Reductions (4) | Net Change in Unrealized Appreciation/ (Depreciation) | As of June 30, 2020 Fair Value
Control Investments
Majority Owned Control Investments
Gibraltar Business Capital, LLC (7) | Unsecured Debt | $ | 1,118 | $ | — | $ | 14,780 | $ | 28 | $ | — | $ | — | $ | 14,808
Preferred Stock | — | — | 33,000 | — | — | (3,321 | ) | 29,679
Common Stock | — | — | 2,380 | — | — | (239 | ) | 2,141
Total Majority Owned Control Investments | $ | 1,118 | $ | — | $ | 50,160 | $ | 28 | $ | — | $ | (3,560 | ) | $ | 46,628
Other Control Investments
Tectura Corporation (5) | Senior Debt | $ | 259 | $ | — | $ | 9,586 | $ | — | $ | (134 | ) | $ | (1,649 | ) | $ | 7,803
Preferred Stock | — | — | — | — | — | — | —
Common Stock | — | — | — | — | — | — | —
Total Other Control Investments | $ | 259 | $ | — | $ | 9,586 | $ | — | $ | (134 | ) | $ | (1,649 | ) | $ | 7,803
Total Control Investments | $ | 1,377 | $ | — | $ | 59,746 | $ | 28 | $ | (134 | ) | $ | (5,209 | ) | $ | 54,431
Affiliate Investments
Optiscan BioMedical, Corp. | Convertible Debt | $ | 13 | $ | — | $ | — | $ | 407 | $ | — | $ | — | $ | 407
Preferred Warrants | — | — | 209 | — | — | (208 | ) | 1
Preferred Stock | — | — | 8,984 | — | — | (8,382 | ) | 602
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) (6) | Senior Debt | 364 | — | 12,615 | — | — | (1,715 | ) | 10,900
Common Stock | — | — | — | — | — | — | —
Total Affiliate Investments | $ | 377 | $ | — | $ | 21,808 | $ | 407 | $ | — | $ | (10,305 | ) | $ | 11,910
Total Control and Affiliate Investments | $ | 1,754 | $ | — | $ | 81,554 | $ | 435 | $ | (134 | ) | $ | (15,514 | ) | $ | 66,341
(1) | Stock and warrants are generally non-income producing and restricted.
(2) | Represents the total amount of interest or dividends credited to income for the period an investment was an affiliate or control investment.
(3) | Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities.
(4) | Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period.
(5) | As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018.
(6) | As of September 30, 2017, the Company's investment in Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) became classified as an affiliate investment due to a reduction in equity ownership. Note that this investment was classified as a control investment as of June 30, 2017 after the Company obtained a controlling financial interest.
(7) | As of March 31, 2018, the Company's investment in Gibraltar Business Capital, LLC became classified as a control investment as a result of obtaining a controlling financial interest.

89

Schedule 12 – 14

HERCULES CAPITAL, INC.

SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

As of June 30, 2020

(in thousands)

Portfolio Company | Industry | Type of Investment (1) | Maturity Date | Interest Rate and Floor | Principal or Shares | Cost | Value (2)
Control Investments
Majority Owned Control Investments
Gibraltar Business Capital, LLC | Diversified Financial Services | Unsecured Debt | March 2023 | Interest rate FIXED 14.50% | $ | 15,000 | $ | 14,808 | $ | 14,808
Diversified Financial Services | Preferred Series A Equity | 10,602,752 | 26,122 | 29,679
Diversified Financial Services | Common Stock | 830,000 | 1,884 | 2,141
Total Gibraltar Business Capital, LLC | $ | 42,814 | $ | 46,628
Total Majority Owned Control Investments (4.01%)* | $ | 42,814 | $ | 46,628
Other Control Investments
Tectura Corporation | Internet Consumer & Business Services | Senior Secured Debt | June 2021 | PIK Interest 5.00% | $ | 10,680 | $ | 240 | $ | —
Internet Consumer & Business Services | Senior Secured Debt | June 2021 | Interest rate FIXED 8.25% | $ | 8,250 | 8,250 | 7,803
Internet Consumer & Business Services | Senior Secured Debt | June 2021 | PIK Interest 5.00% | $ | 13,023 | 13,023 | —
Internet Consumer & Business Services | Preferred Series BB Equity | 1,000,000 | — | —
Internet Consumer & Business Services | Common Stock | 414,994,863 | 900 | —
Total Tectura Corporation | $ | 22,413 | $ | 7,803
Total Other Control Investments (0.67%)* | $ | 22,413 | $ | 7,803
Total Control Investments (4.68%)* | $ | 65,227 | $ | 54,431
Affiliate Investments
Optiscan BioMedical, Corp. | Medical Devices & Equipment | Convertible Debt | July 2021 | Interest rate FIXED 8.00% | 408 | $ | 408 | $ | 407
Medical Devices & Equipment | Preferred Series B Equity | 61,855 | 3,000 | 3
Medical Devices & Equipment | Preferred Series C Equity | 19,273 | 655 | 1
Medical Devices & Equipment | Preferred Series D Equity | 551,038 | 5,257 | 50
Medical Devices & Equipment | Preferred Series E Equity | 507,103 | 4,240 | 548
Medical Devices & Equipment | Preferred Series E Warrants | 74,424 | 572 | 1
Total Optiscan BioMedical, Corp. | $ | 14,132 | $ | 1,010
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) | Sustainable and Renewable Technology | Senior Secured Debt | December 2020 | Interest rate FIXED 6.48%, PIK Interest 6.48%, 6.67% Exit Fee | $ | 10,000 | $ | 10,775 | $ | 9,408
Sustainable and Renewable Technology | Senior Secured Debt | December 2020 | PIK Interest 10.00% | $ | 683 | 683 | —
Sustainable and Renewable Technology | Senior Secured Debt | December 2020 | Interest rate FIXED 8.85%, PIK Interest 8.85% | $ | 1,492 | 1,492 | 1,492
Sustainable and Renewable Technology | Common Stock | 488 | 61,502 | —
Sustainable and Renewable Technology | Class A Warrants | 1 | — | —
Total Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) | $ | 74,452 | $ | 10,900
Total Affiliate Investments (1.02%)* | $ | 88,584 | $ | 11,910
Total Control and Affiliate Investments (5.70%)* | $ | 153,811 | $ | 66,341
* | Value as a percent of net assets
(1) | Stock and warrants are generally non-income producing and restricted.
(2) | All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

90

SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HERCULES CAPITAL, INC. (Registrant)
Dated: July 30, 2020 | /S/ SCOTT BLUESTEIN
Scott Bluestein
President, Chief Executive Officer, and Chief Investment Officer
Dated: July 30, 2020 | /S/ SETH H. MEYER
Seth H. Meyer
Chief Financial Officer, and Chief Accounting Officer

91

File and source

File

htgc-10q-20200630-htm_7215f687b65bbb23.html

Size

12,026,135 bytes

SHA-256

1b2b9d6cfce043d4b0836250ee37cce78a52656f102272c86d6268a4e010be05

Our copy

htgc-10q-20200630-htm_7215f687b65bbb23.html

Original

www.sec.gov